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Abstract
Abstract???
Mass spectrometry (MS) has emerged over the last two decades as the 
analytical technique of choice in systems-level protein studies, known as 
proteomics. Two are the MS-based approaches generally applied to 
proteomics: bottom-up (BU), which relies on the proteolytic digestion of 
proteins into short (~10 amino acids) peptides, and top-down (TD), where 
proteolysis is omitted, intact proteins are detected and fragmented in gas 
phase. Both methods present advantages as well as drawbacks. Here, we 
sought to establish a complete platform to put forward a third MS-based 
proteomic approach; middle-down (MD). It implies protein digestion as in BU, 
but aims to generate large peptides which size approaches the one of small 
intact proteins that are readily analyzed in TD. This novel domain aims to 
account for the shortcoming of both classical approaches. Until now, the main 
reasons behind the limited use of MD proteomics have been the lack of easy-
to-use cleaving agents capable of producing peptides in the desired 3-15 kDa 
mass range with high specificity, limitations in MS and allied instrumentation, 
and the absence of dedicated bioinformatics tools for processing of acquired 
data. The latter greatly impedes the next milestone in MD proteomics – large-
scale analysis. MD can potentially combine the analysis of large portions of 
proteins carrying set of biologically-relevant modifications – allowing exploring 
proteins of molecular weight or complexity incompatible with current TD 
capabilities – with the high-throughput hallmark of BU proteomics. Here, we 
first in silico evaluated the potential target amino acid residues to produce 
peptides in the MD mass range within the proteomes of different organisms. 
This bioinformatics work was followed by an experimental study based on 
synthetic MD-sized peptides, aimed at determining the optimal MS and 
tandem MS parameters for large peptide characterization. Next, we pursued 
two distinct ways of performing MD proteolysis: i) the use of an enzyme and 
ii) the use of a chemical reagent. We selected the protease Sap9 as a target 
enzyme for MD, which we fully characterized and successfully applied to the 
study of a mixture of monoclonal antibodies, where it showed an advantage 
over traditional BU in terms of reduced introduction of artifacts to the sample, 
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allowing the post-translational modification investigation and unambiguous 
antibody identification. The chemical cleavage way we addressed via judicious 
protocol optimization for hydrolysis at the N-terminal side of cysteine with 
NTCB reagent. We also advanced MD protocols by generation of large (~50 
kDa) subunits of monoclonal antibodies through the use of papain and 
another more specific novel protease, GingisKHAN, combined with new MS 
signal processing and data analysis capabilities. The developed workflow 
improved mapping of the connectivity of cysteines involved in inter- and intra-
molecular disulfide bridges in antibodies. To summarize, we demonstrated 
that MD approach to mass spectrometry and proteomics is a powerful, yet 
underdeveloped, complement to BU and TD. This work has benchmarked MD 
for targeted protein analysis. In the near future, with advancements of the 
field, we envision its growing use for large-scale complex proteome analysis. 
 
Keywords: mass spectrometry, MS; tandem mass spectrometry, MS/MS; 
middle-down, MD; Fourier transform mass spectrometry, FTMS; Orbitrap; 
protein; immunoglobulin G, IgG; chemical digestion; proteolysis. 
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Riassunto in italiano
Riassunto in italiano?
La spettrometria di massa (MS) è assurta nelle ultime due decadi al ruolo di 
tecnologia d’eccellenza in studi di proteine a livelli sistemici, noti come 
proteomica. Due sono gli approcci generalmente impiegati in proteomica: 
bottom-up (BU), che si basa sulla digestione delle proteine in peptidi più corti 
(~10 amminoacidi), e top-down (TD), in cui la proteolisi viene omessa, e le 
proteine sono analizzate e poi frammentate ancora intere in fase gassosa. 
Entrambi i metodi presentano sia vantaggi che limiti. Attraverso il lavoro di 
questa Tesi abbiamo cercato di definire in modo completo una piattaforma per 
avanzzare l’applicazione di una terzo approccio di proteomica basata su 
spettrometria di massa: il middle-down (MD). MD può concettualmente essere 
pensato come un ibrido delle due metodologie tradizionali, BU e TD. Esso, 
infatti, implica la digestione delle proteine come nel caso del BU, ma allo scopo 
di generare peptidi lunghi, la cui massa rasenti quella di piccole proteine 
intatte che sono quelle piu’ facilmente analizzabili nel TD. Questa nuova 
strategia ambisce a rispondere dei limiti di entrambi gli approcci classici. Le 
ragioni principali alla base della sinora ridotta diffusione della proteomica MD 
sono da ricercarsi nella mancanza di un agente per la digestione proteolitica 
di facile utilizzo e che fosse in grado di produrre con alevata specificità peptidi 
nell’intervallo di massa desiderato, tra 3 e 15 kDa, oltre a limiti nella 
strumentazione, tanto di MS che di tecnologie complementari, ed infine 
nell’assenza di strumenti bioinformatici dedicati all’analisi di dati MD. 
Quest’ultimo ostacolo tutt’ora impedisce in particolare il raggiungimento del 
prossimo traguardo nella proteomica MD, ossia la realizzazione di analisi su 
larga scala.L’MD può potenzialmente combinare l’analisi di ampie porzioni di 
proteina corredate da specifici gruppi di modifiche (genetiche o chimiche) di 
rilevanza biologica – acconsentendo dunque di esplorare proteine di peso 
molecolare o complessita’ incompatibili con l’attuale livello raggiunto dal TD – 
con le caratteristiche high-throughput del bottom-up. Pertanto, abbiamo 
dapprima effettuato una ricerca in silico sui potenziali target amminoacidici 
utili a produrre peptidi nell’intervallo di massa tipico dell’MD, considerando i 
proteomi di diversi organismi. Poi, a questa ricerca bioinformatica è seguito 
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uno studio sperimentale basato su peptide sintetici di dimensioni compatibili 
con l’MD, mirato a determinare i parametri ottimali di MS ed MS/MS da 
impiegare nella caratterizzazione di peptidi di grandi dimensioni. 
Successivamente abbiamo percorso due vie distinte per ottenere una proteolisi 
per l’MD: i) attraverso l’uso di un enzima, e ii) con un reagente chimico. 
Abbiamo scelto come enzima per l’MD la proteasi Sap9, che abbiamo 
caratterizzato in modo completo e utilizzato con successo nello studio di una 
miscela di anticorpi monoclonali, applicazione nella quale ha dimostrato un 
vantaggio rispetto al tradizionale BU in termini di ridotta introduzione di 
artefatti nel campione, acconsentendo contemporaneamente alla mappatura 
di modifiche post-traduzionali e alla identificazione inequivocabile dei singoli 
anticorpi.Parallelamente, abbiamo implementato la modalità di digestione 
chimica attraverso una attenta ottimizzazione del protocollo di idrolisi del 
legame peptidico al lato N-terminale della cisteina attraverso il reagente NTCB. 
Sono stati infine migliorati anche i protocolli per MD destinati alla produzione 
di grandi subunità (~50 kDa) di anticorpi monoclonali attraverso l’uso di 
papaina e di un’altra proteasi ancor più specifica, combinati con nuove 
evoluzioni nel signal processing e nella analisi dei dati derivati dall’MS. In 
conclusione, abbiamo dimostrato che l’approccio MD alla spettrometria di 
massa ed alla proteomica è un strumento potente, benchè non ancora 
sviluppato a pieno, complementare tanto al BU quanto al TD. Questo lavoro 
ha valutato l’MD nell’analisi mirata di singole proteine. In futuro, grazie agli 
sviluppi del settore, prevediamo invece la sua applicazione estensiva ad studi 
di proteomica su larga scala. 
Parole chiave: spettrometria di massa, MS; spettrometria di massa tandem, 
MS/MS; middle-down, MD; spettrometria di massa a trasformata di Fourier, 
FTMS; Orbitrap; proteina; immunoglobulina G, IgG; digestione chimica; 
proteolisi.  
?
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Introduction
1.1. Studying biology with analytical techniques, or coupling uncertainties??
The concept of uncertainty inevitably occupies a pivotal role in epistemology, 
the branch of philosophy discussing the limits of knowledge. Naturally, also 
scientific research, as a study of the nature of things, is widely interconnected 
with this subject, and some of the most famous and celebrated scientific 
discoveries and achievements are fully centered on this topic. A notable 
example is given by 1927 Heisenberg’s uncertainty principle, which postulates 
how there is a fundamental limit to the precision with which certain pairs of 
physical properties of a particle, such as position and momentum, can be 
known simultaneously [1]. This famous principle is valid in physics, 
specifically in quantum mechanics, but similar examples can be found in 
other scientific disciplines. In mathematical logic, for instance, Gödel’s 
incompleteness theorems, formulated in 1931, describe the intrinsic 
limitations of formal mathematical systems that, simply speaking, cannot be 
at the same time consistent and complete. The trait d’union of Heisenberg’s 
and Gödel’s works seems to be found, at least at a first glimpse, in the 
ontological impossibility of a fully complete scientific knowledge. 
It is needless to say that the epistemological consequences of such 
formulations are extremely sophisticated and would require a separate 
dissertation. This Thesis, however, will focus on the study of biological systems 
and entities through the application of analytical techniques: therefore, it is first 
important to acknowledge the existence of uncertainty principles also within 
life sciences. To this regard, a recent example is given by the work of Strippoli 
et al [2], demonstrating that the sequence of the genome of a living cell can be 
determined only with a level of uncertainty that is always greater than zero, 
and is determined as a function of mutation rate and size of the investigated 
genome.  
An in-depth analysis and extension of this last work can lead us to more 
effectively describe biological uncertainty as a combination of: (i) inherent 
characteristics of living systems, which are subject to variations (in the 
mentioned case, genetic mutation of DNA base pairs), and (ii) limitations of 
the analytical techniques used for their study. This scheme, despite its 
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extreme simplicity, can be related to the distinction between the notions of 
aleatoric (or statistical) and epistemic (or systematic) uncertainty, as defined 
by the field of uncertainty quantification. 
Applying this conclusion as guiding light, the following paragraphs of this 
Introduction and subsequent Chapters will introduce the object of my 
scientific investigation, the proteome, describing the biological reasons of its 
deep complexity, and later will present some key features of the analytical tool 
used for its study, known as mass spectrometry, and the conceptual 
differences – and limitations in terms of achievable information – of the 
different approaches through which such technique can be used for the 
proteome analysis. 
 
1.2. From genome to proteome - Era of proteomics 
The sequencing of the DNA content within human cells accomplished by the 
Human Genome project revealed presence of around 25’000 genes [3]. A large 
number, which nevertheless does not fully explain the complexity of human 
beings [4]. This is indeed illustrated by gene effectors, or proteins. From the 
initial «one gene-one enzyme» hypothesis by Beadle and Tatum (1941), in the 
last decades science obtained more realistic picture of the landscape of 
expressed proteins. Unlike the finite genome (i.e. the complete complement of 
genetic information in a cell), the proteome is constantly changing in response 
to internal and external stimuli. Number of proteins certainly exceed the 
number of coding genes because of genetic (i.e. alternative splicing) and 
chemical modifications (endogenous or introduced, referred to as post-
translational modifications, PTMs), which can influence structure and, 
subsequently, biological activity of proteins. It has been estimated how all 
these processes contribute to yield more than one million unique protein forms 
[5]. 
Proteomics, as counterpart of genomics, offers highly complementary 
information to genomics,?deeper insight into complex cell communication and 
reveals biologically important processes at protein level carried out through 
their interactions. It is the proteome (i.e. the entire set of proteins expressed 
?????????????????
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at a particular time in a cell) that ultimately determines cellular function and 
phenotype. While DNA and RNA sequencing data is used to predict gene 
products (e.g., protein sequences, Figure 1.1) and expression levels in cells, 
protein sequences and abundances can only be inferred based on genome and 
transcriptome data, and this is one of the major driving factors for the 
development of methods to directly analyze proteins.  
?
Amino Acid DNA codons 
Isoleucine ATT, ATC, ATA 
Leucine CTT, CTC, CTA, CTG, TTA, TTG 
Valine GTT, GTC, GTA, GTG 
Phenylalanine TTT, TTC 
Methionine ATG 
Cysteine TGT, TGC 
Alanine GCT, GCC, GCA, GCG 
Glycine GGT, GGC, GGA, GGG 
Proline CCT, CCC, CCA, CCG 
Threonine ACT, ACC, ACA, ACG 
Serine TCT, TCC, TCA, TCG, AGT, AGC 
Tyrosine TAT, TAC 
Tryptophan TGG 
Glutamine CAA, CAG 
Asparagine AAT, AAC 
Histidine CAT, CAC 
Glutamic acid GAA, GAG 
Aspartic acid GAT, GAC 
Lysine AAA, AAG 
Arginine CGT, CGC, CGA, CGG, AGA, AGG 
Stop codons TAA, TAG, TGA 
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Figure 1.1. List of twenty proteinogenic amino acids with their corresponding 
DNA codons representing each amino acid. All 64 possible 3-letter combinations 
of the DNA coding units T, C, A and G are used either to encode one of these 
amino acids or as one of the three stop codons that signals the end of a 
sequence. While DNA can be decoded unambiguously, it is not possible to 
predict a DNA sequence from its protein sequence. Because most amino acids 
have multiple codons, a number of possible DNA sequences might represent the 
same protein sequence. Adapted from http://www.hgvs.org/ 
?
This large-scale qualitative and quantitative study of proteins, particularly 
their structure and function is one of the cornerstone applications of mass 
spectrometry (MS) [6]. The applications of MS-based proteomics range from 
proteome profiling between healthy and diseased systems to recognizing point 
mutations and deletions in the protein sequence as well as identifying and 
localizing post-translational modifications. 
However, state-of-the-art instrumentation available nowadays in MS along 
with the development and improvement of methodology still does not enable 
routine, e.g., clinical, applications which are still restricted by the time-
consuming sample preparation as well as by sample complexity, e.g., the large 
dynamic range of proteins present [7]. 
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1.3. Mass spectrometry (MS): a magnifying glass into proteome complexity? 
Mass spectrometry (MS) is defined as an analytical technique for identifying 
and quantifying compounds by measuring their physical properties: the mass-
to-charge ratios (m/z) and abundances of charged particles (ions) in the gas 
phase. The m/z is expressed in Thomson unit (Th) [8] fundamentally defined 
as: 
1 Th = 1 Da/e = 1.036426 * 10-8 kg C-1 
Even though the first mass spectrometer was constructed by J. J. Thomson 
more than a hundred years ago (called parabola spectrograph [9], followed by 
Thomson’s discovery of first stable isotopes 20 and 22 of neon (Ne)), one of the 
first commercial instruments, called calutron, was designed forty years later 
by Ernest O. Lawrence during the Manhattan Project. The instrument was 
designed to separate the isotopes of uranium (U-235). Since then, MS 
underwent countless improvements, all up to the advent of entirely new 
generation of instruments. Nowadays, emphasis in development is put to meet 
the needs of 'omics' (proteomics, metabolomics, transcriptomics, etc.). Hence, 
the field of proteomics is discretely becoming synonymous with high-
throughput MS-based characterization of proteomes. As a result, mass 
spectrometry nowadays is established as one of the most versatile tools in 
protein structural analysis [10-12] and has become the method of choice for 
protein identification and quantification [13, 14], protein post-translational 
modifications (PTMs) mapping [15, 16] and the elucidation of protein-protein 
interactions [17]. 
The use of a sophisticated technique such as mass spectrometry is justified 
by the extreme complexity of proteomes, particularly of eukariota. Two distinct 
phenomena contribute to such complexity: (i) proteoform variability and (ii) 
protein dynamic range.  
?????????????????
Introduction
30
1.3.1. Proteome complexity: from gene to proteoform. 
The term proteoform, introduced recently by Smith, Kelleher, and Top-Down 
Proteomics Consortium [18], represents the attempt of filling the gap 
separating the realm of genomics, which focuses on a relatively stable entity, 
the genome, comprising a defined set of protein-encoding genes, and 
proteomics, which studies gene products. A gene product in its biologically 
active form is the result of potential modifications, occurring both at the 
genetic level (e.g., alternative splicing, polymorphisms like snips (SNPs), etc.) 
as well as the chemical level (with the so-called post-translational 
modifications, or PTMs). A proteoform is, therefore, a protein which includes 
a specific set of such modifications. 
To better understand the level of variability of the actual pool of proteoforms 
forming a proteome, compared to that of the set of genes originally responsible 
for protein transcription, we can consider that an eukariotic organism has a 
genome composed of a few thousands of protein-encoding genes (from the 
~6'600 of Saccharomyces cerevisiae [19] to the ~25'000 of Homo sapiens [20]). 
Currently, the number of known PTMs exceeds 200 [21] and it was estimated 
that ~80% of protein-encoding genes undergoes alternative splicing [22]. A 
final number of one million proteoforms seems, therefore, a realistic estimate 
for the human proteome. Notably, this «natural» variability can be further 
increased in an artificial fashion, as demonstrated by Zubarev and co-workers 
[23], due to the procedures required for proteoform extraction/purification 
and for eventually preparing them for proteomic experiments. 
1.3.2. The protein abundance dynamic range in cells and tissues. 
The different biological functions carried out by proteins require a 
differentiation in terms of their copy-per-cell number (considering only cellular 
proteins) or, more in general, of their expression level (if we include also 
secreted proteins). Proteomes of the most different organisms seem to all follow 
one rule, which probably reflects some indispensable requirements for life to 
be possible: a limited number of proteins is highly abundant, then a large 
portion of the proteome belongs to what can be considered a medium 
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abundant class and, finally, another limited pool of proteins is expressed in 
an extremely low number of copies (Figure 1.2.). The difference in the copy-
per-cell numbers between the most and least abundant proteins, also called 
protein dynamic range, is dramatically pronounced: referring to the previously 
mentioned examples of yeast and human, a combination of transcriptomic 
and proteomic techniques allowed to estimate that for these two organisms 
the range is of 6 [24] and 7 [25] orders of magnitude, respectively. 
Furthermore, specific tissues or fluids, oftentimes of common value for 
biological or clinical research, can reach even higher values: for instance, the 
dynamic range of human plasma spans up to 11-12 orders of magnitude, with 
the consequence that even accessing 6 orders of magnitude of this range 
(operation that is complicated by the extreme abundance of a restricted 
number of proteins, namely immunoglobulins and albumin) would still 
completely exclude from the proteomic analysis most of the biologically 
relevant proteins such as interleukins and signalling-cascade activation 
factors [26, 27].  
 
 
 
Figure 1.2. The distribution of protein abundances in a typical mammalian 
organism, Mus musculus, shows a bell-shaped distribution. Note, that the 
related mRNA distribution would have a similar shape, although shifted 
towards the left on the x-axis (data not shown). Figure adapted from references 
[28] and [29].  
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1.4. Classical MS approaches: bottom-up vs top-down 
Proteomic studies employ two main approaches, «bottom-up» and «top-down», 
for characterization of complex protein mixtures, e.g., proteomes, using mass 
spectrometry, Figure 1.3. Bottom-up proteomics (BUP) is currently the method 
of choice for large-scale identification and characterization of proteins present 
in complex samples, such as cell lysates, body fluids or tissues. This 
conventional approach relies on protein digestion of whole or sub-proteome 
into short (6-30 amino acid) peptides with enzyme of choice (usually trypsin) 
before on-line chromatographic separation and tandem mass spectrometry 
(MS/MS) analysis. These peptides can be efficiently fragmented and identified, 
but their sequences bring limited specificity at the protein level and they are 
oftentimes discarded as ambiguous hits. In a typical shotgun proteomic 
experiment ~100,000 peptides may be present in the sample and a large 
number of low-abundance peptides are never analyzed [30]. Thus, among the 
major drawbacks of BUP approach in case of using tryptic digestion is the 
large number of peptides present in the sample. As a result, most of the 
precursor ion isolation windows (typically 2 to 3 m/z units) contain co-eluted 
peptides. The fragmentation patterns of these peptides may overlap and, 
depending on the level of precursor ion fraction, a search engine may return 
wrong sequence candidates. Additionally, an inherent limitation of BUP is the 
so-called protein inference problem [31]: several of the proteolytic peptides 
analyzed during an MS-based shotgun experiment can be associated with 
multiple gene products (thus leading to ambiguous protein identifications) or, 
when related to a unique gene, are shared among different proteoforms, that 
cannot be individually defined. In other words, bottom-up proteomics can 
yield the identification of protein families or groups, not of specific proteoforms.  
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Figure 1.3. MS-based proteomic approaches. 
 
Top-down MS is at the other end of available strategies for proteome 
coverage. This approach omits proteolysis and intact proteins (primarily in 15-
50 kDa range) are fragmented in the gas phase [32, 33]. The major advantage 
of top-down proteomics (TDP) is the access to the entire protein sequence and 
information about possible genetic or post-translational modifications 
present, overcoming the protein inference problem [32]. However, technical 
challenges in MS methods, for what concerns both the detection of intact 
species as well as their fragmentation in the gas phase require the use of 
highly sophisticated instrumentation for TDP, which is currently efficient in 
the identification and characterization only of small proteins (typically below 
30 kDa). Additionally, the separation of intact proteins using adsorption 
chromatography (vide infra) is also limited to small size proteins with low level 
of diversity. Because of the above reasons, the implementation of TDP 
approach has been so far circumscribed to low complexity mixtures of proteins 
of relatively low molecular weights, although a top-down approach has been 
used for the targeted characterization of proteins and protein complexes up to 
150 kDa and above [34-36]. 
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1.5. Middle-down (MD) MS approach 
Middle-down proteomics (MDP) is an approach that aims to combine the 
benefits of bottom-up and top-down approaches, while minimizing their 
above-mentioned limitations. Here, similarly to bottom-up, proteins are 
digested, however, a restricted (less frequent) proteolysis is employed to 
increase the average size distribution of the resulting peptides. The target 
peptide distribution here is 30-150 residues or 3–15 kDa. The complexity of a 
mixture is reduced, allowing high resolution mass analysis on liquid 
chromatography (LC) separation timescale. In addition, the increased peptide 
length typically results in a larger number of charges per precursor ion thus 
increasing the efficiency of MS event [37]. 
 Specifically, efficient separation of these long peptides can be readily 
performed on commercial chromatographic columns, and the elution profile 
and LC peak capacities are comparable to those of the bottom-up approach. 
Although a longer acquisition time is necessary for recording of high resolution 
MS/MS spectra, this is achievable with modern instrumentation, such as the 
hybrid instruments (vide infra, Chapter 3). In addition, the long amino acid 
series enhance the uniqueness of the sequence and increase the probability 
for localization of covalent modifications such as PTMs and single-point 
mutations. Therefore, we consider this paradigm shift towards analysis of 
longer peptides to be the key for achieving increased dynamic range of protein 
concentrations and high-throughput identification of targeted proteoforms. 
Proof-of-principle preliminary experiments that attest the viability and 
importance of the MDP method have been conducted previously by prominent 
US-based research groups in the field of proteomics and mass spectrometry, 
namely undersigned by distinguished research investigators such as 
Catherine Fenselau (University of Maryland) and Scott McLuckey (Purdue 
University). Previous research efforts in MDP have been using proteolytic 
enzymes with well-established cleavage sites and optimized proteolysis 
conditions that cleave selectively at a single residue (AspN, LysC, and GluC) 
[38-42] as well as chemical cleavage such as microwave-assisted acid 
hydrolysis [37]. 
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1.6. Selected application: Analysis of Immunoglobulins G (IgGs)  
Immunoglobulins currently represent the fastest growing class of 
biotherapeutics in the pharmaceutical industry. Produced by B cells, these 
proteins recognize a target molecule (antigen) with both high specificity and 
selectivity (e.g., binding constant in the nano/picomolar range). 
Immunoglobulins are tetrameric glycoprotein complexes; their characteristic 
quaternary structure is composed of two identical light and two identical 
heavy chains, whose molecular weight (MW) is ~25 and 50 kDa each, 
respectively, for a total MW of ~150 kDa, Figure 1.4. 
 
Figure 1.4. Schematic representation of an immunoglobulin class G1 (isotype 
IgG1). Heavy chains are colored in blue, light chains in green. Glycosylation 
sites are highlighted in grey. The typical G0F glycan is indicated in circles. CDRs 
are located on variable domains, indicated with VL and VH for light and heavy 
chain, respectively. 
 
 According to the type of heavy chain (indicated by Greek letters ǂ, ǅ, ǆ, Ǆ 
and Ǎ), in mammals we distinguish five isotypes of immunoglobulins: IgA, IgD, 
IgE, IgG and IgM. Three of them are monomeric (IgD, IgE and IgG), whereas 
IgA are dimeric and IgMs are present in pentameric form. The most important 
isotype is that of IgG, which is divided into 4 subclasses (numbered from 1 to 
4). These subclasses differ essentially for one of the most important structural 
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features of immunoglobulins, which is the disulfide bond connectivity. Both 
the chains of IgGs are divided into globular domains, each of which includes 
an intramolecular disulfide bridge. Intermolecular disulfide bridges connect 
then each light chain with one heavy chain, and the heavy chains are 
connected together by a number of S-S bonds, variable according to the 
subclass, in the so-called hinge region.  
Most of therapeutical immunoglobulins are IgG of the subclass 1, IgG1, 
which is also the most abundant in humans. These are characterized by two 
intermolecular disulfide bridges at the hinge region as depicted in Figure 1.4. 
Immunoglobulins belonging to the same isotype share most of the sequence 
of their heavy chains (specifically, the central and C-terminal portion). 
Similarly, this is the case also for the two possible kinds of light chains, ǌ and 
ǋ. The highly conserved regions of immunoglobulins form the constant 
domains, whereas the N-terminal part of each chain is referred to as the 
variable domain. The latter includes, on both light and heavy chains, three 
regions exposed to the surface, and loops, called complementarity determining 
regions (CDRs). CDRs are responsible for the binding of a specific region 
(epitope) of the target antigen. Antigen binding is mediated by the variable 
domains, mainly by three loops connecting individual ǃ-strands in each 
domain (CDR). Like natural IgGs, all recombinant antibodies contain an -Asn-
X-Ser/Thr-Y- consensus sequence for N-glycosylation in their heavy chain 
CH2 constant domain where X and Y are amino acids different from proline.  
 
?? PTMs in IgG  
Among the post-translational modifications found on IgGs, the most important 
is surely represented by the N-glycosylation (+> 1000 Da) of the heavy chain 
(occurring at Asn297, following Kabat numbering (see Johnson [43] and 
references therein). The glycosylation profile of recombinant IgGs can change 
according to the host system. Further common PTMs include pyroglutamic 
acid formation, methionine oxidation, deamidation of glutamine and 
asparagine. Deamidation is a spontaneous phenomenon believed to target 
proteins for degradation [44], but it can also be enzymatically induced. 
?????????????????
Introduction
37
Deamidation converts Gln and Asn in glutamate and aspartate, respectively, 
with a mass shift of +0.984 Da. This implies that deamidation replaces a polar 
amino acid with a charged one, with potential structural consequences on the 
involved protein. Importantly, deamidation occurs via the formation of a cyclic 
intermediate, so that the final product can be a structural isomer (enantiomer) 
of Glu and Asp, like Ǆ-glutamic acid or ǃ-aspartic acid[45] (also known as iso-
Asp), respectively (Figure 1.5). 
 
 
Figure 1.5. Pathways leading to the formation of structural isomers of Asp and 
Glu as a consequence of deamidation of Asn and Gln, respectively. Left panel 
shows the formation of a succinimide intermediate with possible production of 
either ?-Asp or ?-Asp. Right panel illustrates the formation of ?-Glu or ?-Glu from 
a glutarimide intermediate. Schemes derived from references [46] and [47]. 
 
Mass spectrometry was shown to be a powerful tool in identification as well 
as quantitation of this PTM. Although enantiomer formation was first detected 
in MS-based studies applying collision-induced ion activation, electron-based 
activation methods rose as methods of choice for investigation of modifications 
involving structural isomers rearrangements. Here the distinction between 
amino acid isomers is achieved through the observation of specific reporter 
product ions that can be identified in the ECD/ETD tandem mass spectra only 
in presence of non-? amino acids. ETD was applied to the differentiation of ǂ-
Asp from ǃ-Asp [48]. Deamidation is of particular importance in?
biotherapeutics quality control, as it is known how the deamidation of Asn in 
the paratope region (CDR2 of IgG1) can lead to unsuccessful antigen binding 
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and affect its activity, hence, advancement of MS-based methods for its 
elucidation. Chapter 4 provides results relevant to this problematic by 
successful adaptation of novel extended bottom-up proteomics (eBUP) 
pipeline. Conceptual relevance of the obtained results is presented and 
summarized in the research article within Chapter 4 (Paper 4). 
?? MS-based structural analysis of IgGs and allied challenges  
IgGs offer vast variety of problematics, making it both a suitable molecule and 
at the same time a challenging test bed for method development. The role of 
mass spectrometry in the characterization of immunoglobulins is fundamental 
for different reasons. First, due to the non-widely studied PTMs occurrence, 
whose masses are always very small compared to the overall size of the intact 
protein. Furthermore, the size of these proteins complicates the analysis with 
other traditionally employed techniques such as gel electrophoresis. Last but 
not the least, given the high sequence homology between IgG classes, as well 
as within the class (IgG1), it is important to confirm the IgG sequence obtained 
by genomic data, particularly for the CDR domains, given the high variability 
of these sequences. Traditionally, detailed characterization of IgGs has been 
carried out primarily by bottom-up MS [49]. The combination of data derived 
from the digestion of the antibody by different proteases can effectively result 
in high sequence coverage (up to 100%) and facilitate the identification of both 
large (e.g., glycosylation) and small (e.g., deamidation) PTMs [50]. 
 Nevertheless, up to date, there is no universal MS approach that would 
suffice to yield successful analysis of all the underlined problematics relative 
to IgGs. However, in past decade, various approaches tackling different 
aspects of this protein were adopted, as depicted in Figure 1.6. 
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Figure 1.6. MS-based mainstream avenues adopted in structural analysis of 
IgGs. Figure adapted from references [35, 36, 51, 52] 
 
Within this thesis, particularly in Chapters 5-7 we will introduce alternative 
and complementary avenues developed for structural analysis of IgGs. 
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1.7. Aim of the thesis 
Comprehensive qualitative and quantitative description of biological systems 
requires further improvement of molecular structure analysis approaches. 
Current large-scale and targeted protein analysis based on bottom-up and 
top-down mass spectrometry cannot provide the required level of analytical 
characteristics. The common trait of the hereinafter presented research can 
be thus defined as advancing structure analysis of proteins constituting 
complex biological systems, e.g., proteomes and protein complexes, by 
developing and applying middle-down approaches on the ???????????????? 
mass spectrometry technology. The term state-of-the-art is not referred only 
to hardware or software features, but rather to the application of advanced 
instruments to extreme cases, finalized to obtain a proof-of-concept and to 
push the limits of technology by recognizing and addressing its current 
limitations. Project objectives to be achieved were defined by work in the 
following interdisciplinary research directions: (i) bioinformatics for rational 
design of proteome digestion strategies and tailored processing of middle-
down proteomics data; (ii) search for specific reagents, e.g., proteases, for 
middle-down proteomics; (iii) tandem mass spectrometry method and 
technique development, including optimization of radical chemistry-based ion 
activation and dissociation strategies; (iv) improved conditions for solution-
phase protein fractionation and separation; (v) validation and comparison of 
the method performances using sets of known proteins with equimolar and 
variable concentrations and (vi) targeted applications of middle-down 
proteomics, particularly including structural analysis of monoclonal 
antibodies. 
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1.8. Overview of Chapters 
In order to provide a fundamental understanding of herein applied technology 
and comprehensive explanation of results, this Thesis is structured as follows: 
Chapter 2 is aimed at clarifying in detail the basic mass spectrometry concepts 
and introducing the problematic of biological systems we aim to investigate, 
finally underlying the current limitations of the chosen approach, but at the 
same time the rationale supporting their choice. Chapter 3 is dedicated to in-
depth description of the instrumentation and techniques used in this Thesis. 
Chapters 4 to 7 report introductions and summaries of results achieved 
including pertaining research articles: for the elucidation of the effects of 
enzymatically-induced modifications on a peptide. Finally, Chapter 8 
summarizes the obtained results and outlines future research directions. 
  
?????????????????
Introduction

43
?
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2.1. MS fundamentals: what to understand and how to apply it in 
proteomics analysis 
 
2.1.1. Mass accuracy and mass resolution  
The capability of determining the nature of an analyte observed in a mass 
spectrum depends heavily on two parameters, mass resolution and mass 
accuracy. This statement becomes more important with the increased 
complexity of the sample under analysis and the size of the pool of potential 
candidates to match with the experimental data – which is a situation well 
represented by proteomic studies. 
Starting with mass resolution, this is a measure of the capability of the 
mass spectrometer of distinguishing two analytes represented by close signals 
in a mass spectrum (see Marshall and Hendricks [53] and references therein). 
Using a more precise formalism, mass resolution is defined as the minimum 
difference in mass, ?m=m2-m1 (with m1 and m2 being the masses of the two 
analytes, the first smaller than the second), between the signals of the two 
analytes such that the valley between the mentioned signals corresponds to a 
define percentage of the height of the the smaller peak. Traditionally, this 
percentage corresponds to 50%, and the relative mass resolution is indicated 
with ?m50%. The resolving power is defined as m/?m, and typically the 
resolution that is considered is ?m50%, therefore we usually talk of resolving 
power as full width at half maximum, or FWHM. 
On the other hand, mass accuracy corresponds to: 
???????? ? ?????? ? ???????????????? ???????????????? ? 
where m/zexp and m/ztheor are the experimentally determined and theoretical 
mass-to-charge values of a given analyte, respectively. Mass accuracy is 
usually expressed in parts-per-million (ppm). 
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Back to the introduction of this paragraph, it will be now apparent how 
mass resolution and accuracy are related to each other, as, for instance, 
higher mass resolution allows for reduced interference of neighboring peak in 
determining the final peak shape of the signal of a given analyte, thus 
improving the correct positioning of the peak apex and, finally, mass accuracy. 
If it is true that the mass calibration of an MS instrument is obtained by fitting 
the observed m/z values of calibrants of known molecular formula with their 
exact masses (i.e., the mass obtained by summing the isotopes of each element 
included in its molecular formula, vide infra), performing experiments on 
unknown analytes (as in any proteomic project) we try to match an observed 
m/z value (and, therefore, mass) with a possible chemical formula. Increasing 
the mass resolution by using more sophisticated instrumentation (see Chapter 
3) has dramatic beneficial effects in the reduction of the potential candidates: 
for instance, it has been estimated that for a tryptic peptide of Saccharomyces 
cerevisiae with a mass of ~2.36 kDa passing from a mass accuracy of 2 Da to 
0.5 Da (or from ~850 to ~ 200 ppm) reduces four-fold the number of potential 
candidates [54]. Furthermore, a more recent in silico simulation [55] showed 
how that if MS measurements are performed at 1 ppm mass accuracy on 
tryptic peptides, it is possible to exclude 99% of peptides having the same 
nominal mass (i.e., the mass calculated using the integer mass of the most 
abundant isotope of each element in the chemical formula) but different 
chemical formula and, hence, amino acid compositions. 
 
 
2.1.2. Isotopes and their role in mass spectrometry of polypeptides 
In nature, each chemical species can be associated to a chemical formula, 
which defines the type and number of atoms present in that given neutral 
molecule or ion. In the case of this Thesis, the object of our analytical 
investigation are polypeptides, which are built of a limited number of amino 
acids (see Chapter 1). These building blocks for peptides and proteins are in 
turn composed of a restricted group of elements: hydrogen, carbon, oxygen, 
nitrogen, and sulfur (in order of relative abundance in proteins). Considering 
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that each of this elements include different isotopes, it is apparent that, when 
analyzing a polypeptide we will be in the presence of not only a single species 
(a single ion, in the case of MS analysis), but of a group of isotopologues, or 
chemical species with the same chemical formula differing by the isotopic 
composition [56]. Although it is technically possible to isolate a single 
isotopologue, in practice an MS measurement usually detects isotopic 
envelopes (also known as isotopic distributions or isotopic clusters). In mass 
spectrometry the isotopologue ions of a single chemical species can allow the 
determination of the charge of the ion cluster itself – if the elemental 
composition is known, as it is the case for polypeptides. Specifically, we can 
approximate the mass difference between consecutive isotopologues in any 
envelope generated by peptide or protein ions as equal to the addition of a 13C: 
going from left to right in the isotopic cluster we are increasing the mass of 
the isotopologues of m13c-m12c~1.003 u (essentially, the mass of a neutron). 
This approximation can be applied as carbon is one of the most abundant 
elements in polypeptides and at the same time the one with the highest relative 
abundance of heavy isotopes (13C represents about 1% of the total carbon, 
whereas for instance 2H is only ~0.01%). Therefore, provided that sufficient 
mass resolution is used, so that the exact m/z values can be assigned to each 
isotopologue, the spacing between consecutive isotopologues will be equal to 
1.003/z, where z indicates the charge of the ion cluster. Obviously, knowing 
the charge z and the corresponding m/z value of an ion in a mass spectrum 
means to be in the position of determining its mass. To precisely determine 
the mass of the neutral molecule, also the ionization technique and/or the 
charge carrier has to be known (see Chapter 3.1). 
The presence of isotopes is also the reason of the existence of multiple 
possible definitions of mass for each polypeptide (or, more in general, for any 
molecule): in particular, the monoisotopic mass corresponds to the mass value 
calculated by considering only the most abundant isotopes of each element, 
which in the case of a polypeptide correspond also to the lightest isotopes. 
Conversely, the average mass is obtained by summing the average atomic 
masses of all of the elements present in a molecule. Notably, in the mass 
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spectrum representing a polypeptide, the monoisotopic peak, representing an 
ionized monoisotopic molecule, corresponds always to the isotopologue ion 
positioned at the extreme left of the isotopic cluster. Differently, the average 
mass is a pure mathematical estimate and does not physically correspond to 
any isotopologue ion in a cluster. Nevertheless, by increasing the size of the 
polypeptide the isotopic distribution assumes a progressively more 
pronounced Gaussian-like shape (Figure 2.1.), and the average mass becomes 
generally closer to the most abundant mass, which is the mass of the most 
abundant isotopologue. Indeed, the average mass can be also defined as the 
centroid of the isotopic distribution. 
 
Figure 2.1. Isotopic distributions of the singly-charged ions of model 
homopeptides H-Val10-OH and H-Val100-OH. The two examples show how the 
monoisotopic peak is also the most abundant isotopologue in the cluster for the 
shorter peptide, but becomes a relatively low-abundant isotopologue peak in the 
case of a larger peptide. 
Importantly, when the spectral mass resolution is not sufficient to 
distinguish the isotopologues present in an isotopic cluster (as, for example, 
in the case of particularly highly-charged ions), the charge state – and, 
therefore, the mass – of an ion can be still inferred if the analyte ionized 
producing several ion clusters of different charge state, as it is often the case 
for polypeptides. The sum of all the charge states referring to a single 
polypeptide is generally called charge state envelope or distribution. 
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Considering two consecutive charge states in the envelope, whose respective 
m/z values are indicated as X and Y (with X higher than Y), we will have that: 
? ? ??? ? ?? ? ?? ? ????????????????????? ?  
 and also: 
? ? ??? ?
? ? ?? ? ??
?? ?
? ? ??? ? ?? ? ??
?? ? ? ??????????????? ? 
Where z1 and z2 are the charge states of X and Y, respectively, and m is the 
average mass of the analyte. In the simple and common case that the charge 
carrier is a proton, for the sake of simplicity we can approximate its mass to 
1 u, and therefore the charge z1 can be calculated as: 
?? ?
? ? ?
? ? ??????????????????? ? 
Finally, the average mass of the polypeptide will be approximately equal to: 
? ? ?? ? ??? ? ?????????????????? ? 
 
 
2.1.3. Signal to noise ratio, spectral dynamic range  
In every analytical measurement, including mass spectrometric ones, it is 
possible to distinguish two main components: the signal of the desired 
analyte, and background noise. In general, the noise can cause distortions in 
the analyte signals, especially for low-abundant ones, and is detrimental for 
achieving high mass accuracy and resolution. For most mass spectrometers, 
including Fourier transform-based instruments discussed in the following 
Chapter of this Thesis, we can differentiate between two components in the 
spectral noise: chemical noise, which is the complex of signals originated from 
chemical components in the sample matrix other than the target analyte, and 
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thermal noise, generated by the electronic apparatus used for ion detection. 
Maximizing the so-called signal-to-noise ratio (S/N or SNR) improves both the 
limit of detection (LOD) as well as the limit of quantification (LOQ) for analyzed 
molecules. Different methods have been applied to estimate the noise level or 
intensity and, thus, SNR. Commonly, the “N sigma” rule is applied: considered 
the stochastic nature of noise, this will have an certain distribution, whose 
width can be described through its standard deviation, ?; a signal level equal 
to N? (with N positive number) is then defined as the threshold below which 
the signal of the analyte is not clearly distinguishable from noise and cannot 
be considered for confident assignment [57]. Effectively, this method aims at 
defining a “noise baseline” to discriminate between true positive and false 
positive signals. This concept is then extended to several softwares used in 
proteomics: for instance, the algorithm THRASH calculates this baseline by 
assuming that noise-rich areas of the spectrum are characterized by the 
highest point (i.e., recorded signal) density, and subsequently allows for “true 
positive signals”-filtering using a user-defined value of SNR calculated on the 
base of such noise baseline [58]. Finally, among the strategies aimed at 
improving SNR there is the averaging of mass spectra or, in the case of Fourier 
transform MS (vide infra), time-domain signal. In the latter case, this time-
consuming method produces an increase of SNR equal to ??, where N is the 
number of averaged time-domain signals (this depends on the fact that the 
signal amplitude increases linearly with N, whereas the noise amplitude with 
?) [59]. Closely related to the concept of SNR, the spectral dynamic range 
defines the ratio between the amplitude of the most over the least intense 
signal within a single mass spectrum. This parameter is essentially a function 
of the used hardware, more precisely of the mass analyzer (see Chapter 3). We 
can anticipate that in the case of the Orbitrap mass analyzer (vide infra), used 
for all the works presented in this Thesis, the spectral dynamic range has been 
estimated in 4 orders of magnitude in the best cases [60]. The effective 
dynamic range value that allows for accurate mass measurements, though, is 
reduced to about 5000. Under suboptimal experimental conditions, like in the 
case of particularly complex mass spectra (where the signal is spread through 
a multitude of different ions), this value can further decrease. This last 
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scenario is very common in proteomic experiments, were multiple polypeptide 
ions can be simultaneously analyzed. As described in the previous paragraph, 
polypeptides ionize forming isotopic clusters, which are composed of a number 
of isotopologue ions that increases with the length of the polypeptide chain. 
Therefore, mass spectra of MD and TD experiments are generally 
characterized by a smaller dynamic range compared to those of BUP (where 
shorter peptides are investigated), and the identification of the monoisotopic 
peak in further complicated by its relatively-low abundance within the isotopic 
cluster. Further considerations on SNR and its improvement in MD 
experiments are discussed in research articles, Paper VI and VII, enclosed in 
the Chapter 7.  
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2.2. Tandem mass spectrometry MS/MS 
In the previous section of this chapter the importance of mass accuracy and 
resolution is discussed, as a prerequisite for intact mass determination when 
elemental composition of the investigated protein/peptide is known. In such 
case accurate mass determination from the first mass measurement (referred 
to as MS1 or the survey scan) is sufficient for the identification of analyte of 
interest. However, when two peptides share the same intact mass, but differ 
in the order of amino acid residues they are composed of (e.g. isomers or 
isobaric peptides), additional information is needed. For this reason, as well 
as the need to elucidate the structure of unknown species, or to obtain 
quantitative measurements, in 1960s a two stage mass analysis experiments 
known as tandem mass spectrometry (MS/MS or MS2) were introduced [61, 
62]. Conceptually MS/MS consists of three processes: i) m/z selection of the 
target ion, ii) activation/fragmentation of the selected ion and iii) analysis of 
the resulting product ions. By convention, the targeted ion is referred to as 
the precursor, and the fragment one as the product ion, earlier called parent 
and daughter ion, respectively. Depending on the instrument employed, and 
the way steps are carried out, tandem mass spectrometry can be performed 
either in space or in time [63]. In the former, the precursor selection, 
fragmentation and fragment detection occur in different mass analyzers (e.g., 
as in triple quadrupole instruments, QQQ). On the other hand, when all the 
steps occur in the same mass analyzer in temporal sequence (e.g., linear ion 
traps, LIT) the MS/MS process is defined as in time. Ion activation and 
dissociation step ultimately allows elucidation of the peptide/protein via the 
cleavage of the polypeptide chain along the backbone, resulting in N- and/or 
C-terminal-containing product ions. Generally there are six main types of 
MS/MS product ions, depending on which of the three backbone bonds (N-C?, 
C?-C and C-N) is cleaved. Oftentimes other types of cleavages might occur, 
that lead to formation of internal fragments, or those that result in neutral 
losses (most commonly loss of H20, CO2, NH3, etc.) or even losses of an entire 
side-chain. The latter might aid in localizing introduced or endogenous 
modification on a primary sequence; however accessing this information 
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comes at the price of broad array of progeny ions present in the tandem mass 
spectra that are then challenging for deconvolution and characterization. The 
nomenclature for the polypeptide fragmentation pathways was originally 
proposed by Roepstorff and Fohlmann [64]. According to the currently 
accepted convention fragment ions have alphabetical assignments that denote 
type of the bond cleaved. Numerical denotation indicates the position of the 
cleavage site in the polypeptide chain. A graphical illustration of the above 
mentioned fragments nomenclature, as well as the activation methods that 
lead to their formation (which will be described in the following subsection) is 
shown in Figure 2.2.  
 
Figure 2.2. Scheme of MS/MS product ions and selection of ion activation 
methods that lead to their formation. Product ions that retain N-terminus are 
reffered to as a, b and c- ions, whereas those retaining C-terminus are x, y and 
z- ions. Complementary ion pairs a/x, b/y and c/z are yielded by the cleavage 
of C?-C , C-N and N-C?, respectively. Adapted from Zhurov et al.[65] 
 
Fragmentation of a polypeptide chain is accomplished by employing 
different activation/fragmentation methods some of which are introduced in 
Figure 2.2. and roughly categorized by the type of the product ions they yield. 
However, generation and entity of product ions is circumspect by different 
applied mechanisms under which the backbone cleavages occur. Thus, ion 
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activation methods are classified into two main groups that can be defined as: 
i) energy threshold-based activation and ii) radical-driven activation. We will 
further discuss their main concepts and list most widely used methods of each 
group. For the scope of this dissertation, only those employed for the research 
will be further described in subsections of this Chapter.  
 
 
2.3. Ion activation and dissociation: Energy threshold-based activation  
Tandem MS methods belonging to this group are considered as ‘ergodic’ 
process, which means that energy is impinged and randomized throughout all 
vibration modes before dissociation. Deposition of energy depends either on 
collisions with the neutral gas molecules; here we distinguish between 
collision-induced dissociation (CID) and higher-energy collision dissociation 
(HCD); or on ion-photon interactions. The latter can be further divided in 
interaction with low energy infrared photons used for infrared multiphoton 
dissociation (IRMPD) [66, 67] and high energy ultraviolet photons used for 
ultraviolet photodissociation (UVPD) [68, 69]. CID and IRMPD are ‘slow-
heating’ methods because they require multiple energy accumulation events, 
while HCD and UVPD are more energetic and require fewer 
collisions/absorptions. Dissociation occurs when energetic barrier of a 
chemical bond is surpassed, leading to the cleavage of the weakest bond in 
polypeptide. In addition to (and separate from) the backbone C-N bond, these 
bonds are also present at the side chains of amino acid residues.  
 
?? Collision Induced Dissociation  
CID or collision activated dissociation (CAD) [70-73] was the first ion activation 
employed and has an undeniable importance in overall tandem MS 
development. It is widely utilized and readily implemented in most of the mass 
spectrometers, still remaining the activation method of choice to which all 
other methods are measured up to for fragmentation of positively charged 
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peptides [74]. Strictly speaking it is a two-step process which involves 
heterolytic cleavage of the sigma (?) C-N bond ultimately resulting in 
dissociation of the precursor ion. In the case of a singly charged precursor 
dissociation will lead to the formation of a charged fragment ion and a neutral 
portion, while for a higher charge state precursor (2+ and above) two charged 
fragment ions could be produced. Historically, collision-induced ion excitation 
was developed in two variants: “soft” CID, performed through resonant 
excitation, and beam-type CID [75]. Hereinafter when using the acronym CID 
we will be referring uniquely to the former, whereas the latter will be identified 
through the name of one of its commercial implementations, HCD. 
In collision induced ion activation the dampening of the kinetic energy of 
the precursor ions is achieved by their multiple inelastic collisions with the 
molecules of an inert bath-gas (such as He or N). As a result, each collision 
deposits an increment of internal energy whose excess is then translated into 
the vibrational energy of the bonds in precursor ion, until the dissociation 
threshold is exceeded which in turn results in a bond cleavage. Traditionally, 
in low-energy CID yielded collisions are in range of 1-100 eV [75] whereas 
high-energy collisions are considered to be in order of several keV. In CID, 
multiple, low energy collisions are required for reaching the bond 
fragmentation threshold, whilst the more energetic beam-type activation 
requires fewer collision events.  
HCD is a beam-type collision induced activation (as the one implemented 
in QQQ) specific to Orbitrap-based instrument. Differently from CID, HCD 
does not suffer from a low mass cutoff from resonant excitation, so for example 
reporter ions from isobaric tagged peptides can be easily observed. Even 
though its name implies that dissociation occurs under high energy, this 
activation method is still in the regime of low energy (less than 100 eV) [76], 
however, the final applied energy is somewhat higher compared to the CID 
one, commonly used in bottom-up regime (30-35 eV). This derives from the 
fact that HCD is actually a charge dependent method for peptide 
fragmentation and the redistributed normalized collisional energy (NCE) is 
recalculated with respect to the precursor charge state and its m/z, for every 
precursor of the dependent scan in part, as given in the formula below: 
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??? ? ????? ????????       (2.6.) 
 
Where m/z refers to the precursor in question, 500 is reference m/z at 
charge state 1, and CF is a HCD correction factor for each charge state as 
follows (correction factor (charge state)): 1 (1.0); 0.90 (2); 0.85 (3); 0.80 (4) and 
0.75 (5). 
Similarly to CID, HCD is thought to produce complementary b- and y- ion 
series. Given the very energetic activation and thus often disruptive for the 
more unstable b- ions which then break into internal fragments and smaller 
b-ions, the returned HCD product ions are mostly y-series. The reduced yield 
of the b-ions could be considered one of the shortcomings of this method for 
data interpretation of MD range (and larger) peptides, and will be discussed 
as such in the following Chapters. 
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2.4. Ion activation and dissociation: Electron-based activation methods 
Differently from the previous group, electron-based methods could be 
classified as ‘non-ergodic’ process, given that dissociation is suggested to 
precede the energy randomization. These methods are based on interactions 
of a polypeptide cation or anion with an electron in the gas phase. As a result, 
a radical species within the peptide backbone is formed leading to the bond 
rupture. Two most commonly employed methods entailing attainment of an 
electron by a polyprotonated species are electron capture dissociation (ECD) 
and electron transfer dissociation (ETD). Due to the common traits between 
these methods (vide infra), and for the sake of simplicity hereinafter those will 
be also referred to as ExD (see Zhurov et al. [65] and references therein). For 
the past almost two decades, since the introduction of ECD in 1998 [77, 78] 
there is an ongoing debate about the underlying fragmentation mechanism, 
and various mechanistic approaches were proposed [79-82]. According to the 
‘Cornell mechanism’ ExD proceeds via electron capture/transfer at the site of 
ionizing proton (typically protonated nitrogen of the amine group at the N-
terminus or a side chain of basic amino acid residues Arg, Lys, His) inducing 
a backbone rupture through migration of hydrogen and formation of a radical 
aminoketyl group [77, 83]. Regardless of the differences on where electron is 
attained, and how fragmentation proceeds, mechanisms generally agree on 
non-ergodic dissociation which results in the random homolytic cleavage of N-
C? bonds along the backbone (see TureĀek et al [84] and references therein). 
However, recently, heterolytic cleavage was also put into consideration as an 
alternative pathway [85-87]  
 
?? Electron Transfer Dissociation 
ETD [88] is a radical-driven fragmentation technique based on an electron 
transfer from an electron-donor molecule, a radical anion, and a multiply-
charged cation. The characteristic ion-ion reaction upon ETD can be denoted 
as: 
?? ? ????? ? ??? ? ?? ? ?????????? ? ? ? ???????????????????????? ? 
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where "A" represents the electron donor molecule. The bond cleavage gives rise 
to the series of even-electron c'-ions and radical odd-electron z•-ions. ETD 
dependence on amino acid composition/sequence of the peptide/protein is 
generally weak. However, it is to be noted how the cleavage at the N-terminal 
side of proline cannot lead to product ion formation due to the structure of 
this amino acid. Due to the charge reduction proceeding the electron transfer 
it is obvious how only multiply charged (z>1) precursors can be subjected for 
a successful fragmentation outcome. However, it has been shown how ETD 
methods are mostly futile in dissociating doubly charged peptide cations [88, 
89]. Consequently, supplemental activations (such as IR photo activation or 
low energy collision activation) have been implemented for ExD to allow for 
more effective product ion generation [90-92]. For better understanding of 
ETD, one of important parameters to consider is charge density which 
indicates the total number of charges distributed in a peptide/protein (here 
we refer to the number of residues or simply mass). After electron transfer-
induced backbone cleavage, fragment ions are still bound in the [c'+ z•](n-1)+• 
complex by non-covalent interactions. Their separation depends upon the 
Coulombic repulsions and the nature of the amino acids around particular 
cleavage site. Ions with greater charge density (lower m/z) yield repulsions 
sufficient to overcome the interactions and separate now detectable individual 
fragment ions. Conversely, low charge density induces more compact cationic 
structure, which in turn prevents separation and subsequent fragments 
detection. Instead, only m/z values of charge-reduced species are detected. 
This phenomenon of partitioning from a direct dissociation is denoted as 
electron transfer without dissociation (ETnoD) [93]. As a consequence, ETD 
percent fragmentation (a number of observed c- and z- type ions over the 
theoretical number of product ions for a considered peptide sequence; e.g. a 
15 residue long primary peptide sequence has 14 cleavable backbone N-C? 
bonds that could give rise to a total of 28 c- and z- product ions) is linearly 
decreasing with the increase of the precursor m/z On the other hand, this 
dependence is much less pronounced in sequence coverage of peptides 
(defined as a number of backbone bonds cleaved versus the theoretical 
number of all backbone bonds of the same types) as shown by Good et al [92].  
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Two peculiar features distinguishing ExD from energy threshold-based ion 
activation methods are: i) the capability of retaining labile PTMs such as 
phosphorylation, methylation, acetylation and glycosylation [94-102] (this is 
true for systems with smaller molecular weight such as peptides, see Chapter 
4) and elucidating the enantiomere structure by generating diagnostic ions 
(e.g. deamidation of Asn to Asp/isoAsp)[46, 48, 103, 104] ii) the announced 
preference of cleaving disulfide bridges [79]. 
Practical aspects of above described fragmentation methods in respect to 
the instrument employed for this Thesis will be further considered in the 
Instrumentation Chapter. 
?
 
2.5. Where to cleave a protein? 
The definition of the MDP pipeline cannot disregard the key question of the 
ideal cleavage site on polypeptide chains. A protein is built using 20 different 
proteinogenic amino acids, differentiated by their side chains (Figure 2.3).  
 
Figure 2.3. The twenty proteinogenic amino acids ordered by the increased 
hydrophobicity (top left to bottom right) according to the Kyte-Doolittle scale 
[105]. Amino acids are indicated with the three letter code. 
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Our purpose is to generate proteolytic peptides of a length of about 30-100 
residues. Therefore, it will be important to consider two main aspects when 
selecting the best theoretical targets for protein cleavage: first, the frequency 
of occurrence of each of the 20 amino acids in the proteome of interest (and, 
eventually, of their combinations, in the case of protein digestion strategies 
based either on two consecutive cleavages or recognition of pairs of targets); 
second, the position of specific amino acid residues, such as the basic ones 
that can be protonated, within the sequence of the obtained peptide. The latter 
aspect, in combination with the average size of obtained polypeptides, is 
important as it might potentially affect the peptide fragmentation, potentially 
defining which ion activation technique is more suitable for this category of 
proteolytic peptide. 
This Thesis will present two distinct studies aimed at elucidating both of 
the above mentioned aspects: Paper I focuses on bioinformatics studies to 
define the set of residues to target for performing middle-down experiments in 
different model organism, from bacteria to human. Paper II, instead, discusses 
the effect of specific positioning of basic residues on the fragmentation of large 
(>20 amino acids) peptides. 
Cela va sans dire, the practical fulfillment of an MDP experiment means to 
identify a cleaving agent – either enzymatic or chemical – that can actually 
yield the proteolytic cleavage suggested by the observations and calculations 
illustrated in Paper I. The field of proteomics has already defined a large set of 
proteases capable of cleaving proteins with different specificities. Figure 2.4. 
compares commercially available proteases, generally employed in bottom-up 
experiments (with the sole exclusion of Glu-C, which can be used for MDP of 
restricted groups of proteins, such as histones, characterized by a peculiar 
amino acidic composition), with Sap9, a secreted aspartic protease at the 
center of several pilot studies presented in this Thesis (see Papers III and IV 
on Chapter 5). 
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?
Figure 2.4. Scale of pH and relative range of activity of most common proteases 
used in proteomics. Sap9, which is objet of this research work, is highlighted in 
red. 
?
 
2.6. High-throughput vs targeted analysis in proteomics 
Going from general to particular according to the deductive method, it is 
apparent that the development of new ways of studying complex objects 
requires a targeted investigation. Large scale studies would indeed introduce 
issues in the interpretation of results. Specifically, in this thesis method 
development and validation of proposed pipelines was initially focused on a 
smaller sample pool of proteins whose complexity arises from the large size, 
the presence of multiple modifications whose biological relevance, and/or 
connectivity between such cannot be readily addressed by a currently adopted 
single methodology, either because proteins exceed mass for TD analysis (e.g., 
covalent bonds such as disulfide bridges in IgGs), or modifications are distant 
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in such way that upon BUP proteolysis those end up in two different peptides 
and connectivity between them is lost.  
Notably, once a new cleaving agent has been identified, in silico studies 
aimed at calculating the theoretical proteome coverage, and experiments 
based on model substrates, are fundamental to characterize the main features 
and potential use of the cleaving agent itself (vide infra, Chapter 2.8). 
Nevertheless, these studies cannot fully describe its effective utility in real 
proteomic applications. A protease recently described in scientific literature, 
Lys-N, which cleaves at the N-terminal side of lysine, [106] is a perfect example 
of the need for in-depth studies to determine the best application fields for 
novel peptide cleaving agents. In large-scale studies, for instance on a complex 
sample such as mouse heart, the use of Lys-N leads to the identification of a 
total number of proteins simply comparable to that achievable by digestion 
with trypsin or Lys-C [107]. This goes in agreement with our MS2 studies on 
synthetic model peptides, described in Paper II, which suggest that the 
positioning of basic amino acid residues at either the N- or C-terminus of a 
peptide can influence the relative abundance of N- or C-terminal-containing 
product ions but does not significantly change the overall peptide sequence 
coverage. Conversely, studies on specific sub-proteomes, like the human 
phosphoproteome, show large differences in the phosphorylation sites mapped 
after digestion by Lys-N or trypsin, demonstrating that the two proteases 
digested the same pool of proteins in a complementary fashion, and the use 
of both proteases dramatically increases the number of observable 
phosphorylation sites [108]. Considering that large scale shotgun studies 
showed comparable numbers of IDs between Lys-C/trypsin and Lys-N, the 
discrepancies observed in the case of the phosphoproteome are likely to be 
linked to different selectivity of phosphoproteins towards the two groups of 
enzymes. This example underlines that the substrate selectivity might play a 
role as important as enzymatic specificity in the final outcome of a proteomic 
experiment. 
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2.7. Data analysis 
High throughput proteomic analyses generate vast amounts of data for which 
manual analysis is close to impossible, as it would be extremely time-
consuming, hence, an automated interpretation of large proteomic datasets is 
indispensable. However, even with automated analysis, manual validation of 
results is often advised. In shotgun proteomics, the most common way for the 
processing of MS/MS data is through comparison to theoretical fragmentation 
patterns of peptide sequences generated in silico from protein sequence 
databases following to the specific cleavage rule of the used protease or 
chemical cleaving agent, as depicted in figure 2.5.  
?
?
Figure 2.5. Schematic representation of an automated database search 
workflow 
After the mass of the precursor is determined through deconvolution of the 
survey scan, and subsequently used to restrict the „search space“ to a sub-
group of potential peptides (according to mass accuracy tolerances set by the 
experimenter), the tandem mass spectrum is matched against all the 
theoretical ones generated from the candidates (using specific mass tolerances 
for product ions), finally leading to the identification of a candidate peptide 
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sequence. Various statistical methods are used to validate the candidate 
peptide sequences and corresponding protein matches (according to the 'two 
peptide per protein' rule introduced in BUP).  
One of the most utilized statistical methods for filtering the data is false 
discovery rate (FDR, see Nesvizhskii [109] and references therein). Simply 
speaking it is a rate of false-positives (arbitrary value by convention set to 1-2 
%) which is estimated based on results obtained by searching against a decoy 
database (containing „false“ protein sequences generated by scrambling or 
reversing the original ones), or in terms of MS, property of MS/MS spectra 
that defines expected proportion of incorrect assignements. The majority of 
database search algorithms initially developed for processing of BUP data, 
such as SEQUEST [110], Mascot [111], X!Tandem [112], OMSSA [113] and 
Andromeda, or proteomic computational platforms like MaxQuant [114] and 
the Trans-Proteomic Pipeline, readily calculate the FDR. However, it is to be 
stated how the FDR concept (as well as the entire database search pipeline) 
works under the assumption that peptides are generated with a residue-
specific protease and hence that the set of cleavage rule is known. However, 
proteases so far described for MDP are generally partially-specific or even non-
specific  [37, 115-117]. In such case, it is almost impossible to create a 
reversed database, and the theoretical peptide candidates can be as short as 
one amino acid residue. With the exponential increase in the number of 
candidates in decoy database, the traditional FDR procedure applied to BUP 
would now remove an insufficient number of false-positives, and still render 
final results ambiguous.To date, there is no dedicated database search 
algorythm for MDP. Most of the aforementioned BUP softwares fall short in 
interpreting these data, primarily because the search space is generated 
strictly using a well-defined cleavage rule, with the consequence that many 
peptides generated by unspecific cleavage, or that carry unexpected or not-
annotated PTMs produced by non-enzymatic cleavage (as in the case of certain 
chemical cleaving agents, that can modify peptides both through the main 
cleavage mechanism or also through side reactions) are excluded by the 
search process and therefore cannot be identified. 
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On the other hand, TD softwares can be adapted to the analysis of MDP 
experiments. This fact might be explained considering that large polypeptides 
like those typical of MD share several characteristics and MS-related features 
with small intact proteins analyzed in TD proteomic experiments: for instance, 
their isotopic distribution resembles that of a protein, with the monoisotopic 
peak being low abundant and located far from the apex of the isotopic 
distribution, differently from that of a short tryptic peptide, which is generally 
the most abundant of the isotopomers. Furthermore, the product ions 
generated by the activation of large MDP peptide ions are often multiply 
charged, similarly to those of proteins, and tandem mass spectra can be 
particularly convoluted, with overlapping ion species (a situation rarely 
encountered in BUP experiments). Hence, if we define three operations 
required for TD data analysis, and specifically: (i) peak picking, (ii) spectral 
deconvolution (for both MS and MS/MS) and (iii) product ion assignment, it is 
clear that the algorithms used for TD mass spectrometry can be successfully 
applied also to MDP. Particularly, steps (i) and (ii) rely in TD on the estimation 
of the protein monoisotopic mass applying an isotopic fitting model (for 
instance based on averagine [118], an amino acid of mass equal to the weight 
average of all amino acids present in proteomes, molecular formula C4.9384 
H7.7583 N1.3577 O1.4773 S0.0417 
and average mass of 111.1254 Da), rather than the identification of the 
monoisotopic peak in the m/z space as in BUP. Moreover, similar concepts 
are used also for the deconvolution of tandem mass spectra, which are 
acquired exclusively using high resolution MS (whereas in BUP they are 
generally acquired in low resolution). Finally, it is important to note that 
methods for the estimation of the isotopic distribution of large polypetide 
precursor or fragment ions would often not be accurate enough for small 
peptides [119]. In other words, TD data analysis methods would not perform 
perfectly for BUP analysis. 
In the works presented in this Thesis, data analysis was therefore carried out 
using mostly a combination of the BUP-dedicated algorithm Sequest (Papers 
III and IV), and softwares tailored for processing of TD data, such as MS Align+ 
[120] (for data interpretation where the detection of unexpected or not-
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annotated PTMs was crucial, Paper V)), ProSight PC, ProSight Lite (for the 
generation of graphical fragmentation maps)[121] and, finally, the recently 
introduced MASH Suite [122] (applied to the MD analysis of immunoglobulins, 
Papers VI and VII). ?
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3.1. Electrospray ionization 
Coupling of electrospray ionization (ESI) to (biomolecular) mass 
spectrometry was introduced in the 1980's by J. B. Fenn. In 2002 he was 
awarded the Nobel Prize in chemistry for his work on ESI MS. Briefly, ESI is a 
soft ionization technique which entails a non-destructive analyte charging 
phenomenon, resulting in formation of multiply-charged ions [123] (vide infra). 
ESI revolutionized the field of MS by enabling the analysis of large 
biomolecules. The m/z ratios of biomolecular ions were shifted couple of 
hundreds, even thousands Th down the m/z axis, thus allowing for ion 
detection within the nominal mass limits of mass analyzers such as 
quadrupole based ones. Further success of this method was due to the 
implementation of micro and nano-electrospray (known as ?ESI with flow 
rates in the ?l/min range and nESI with flow rates in the nl/min range) ion 
sources described by Wilm and Mann [124, 125] that facilitated on-line 
coupling of ESI with orthogonal front-end to MS separation techniques (such 
as reversed-phase liquid chromatography (RP-LC) and capillary 
electrophoresis (CE)) that require a constant flow of the liquid. Underlying 
concept of ESI stands on the basic principles of electrochemistry. Electrospray 
ion source can be considered as a controlled current electrolytic cell where 
high voltage (kV) is applied to a liquid and the process of 
protonation/deprotonation occurs. In terms of electrochemistry, if generation 
of protonated species [M+ zH]z+ takes place, the tip of the capillary  acts as an 
anode and MS source inlet as its counterpart electrode (cathode) or inversely, 
cathode and anode, respectively, when deprotonated species [M- zH]z- are 
formed. 
The ionization process depicted in Figure 3.1. starts with the accumulation 
of the charge at the liquid surface under the influence of the electric field 
(which is established between the tip of the capillary and the MS). In addition 
to the applied potential difference, liquid charging is aided by the presence of 
low concentration of acids (such as 0.1 -1 % formic acid) that act as proton 
donors. Ramping the voltage (typically between 1.5- 2 kV and 2-6 kV for nESI 
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and ?ESI, respectively) causes the supposed spherical droplets at the tip of 
the probe to elongate into the characteristic shape called the ‘Taylor cone’. 
 
Figure 3.1? Graphic representation of an electrospray ion source interfaced to a 
mass spectrometer and the electrochemical process of ESI. 
 
At an ‘onset voltage’ pressure is higher than the surface tension; droplets 
are released and the spray is formed. Evaporation of the excess of solvent 
contained in the charged parent droplets is aided by the vicinity of the heated 
inlet capillary (between 0.2-2 cm) and additionally by usage of the 
countercurrent gas (such as nitrogen). In practice, organic compounds such 
as methanol or acetonitrile are used as solvents in ESI; their surface tension 
is lower than that of water hence, those are easier to evaporate. Desolvation 
process causes the charged droplets to progressively shrink, thus increasing 
their charge per unit ratio. Once the droplets reach the ‘Rayleigh limit’ [126] 
defined as the maximum amount of charge a liquid droplet could carry they 
further break down in a process of Coulomb fission [127]. Moiety of the 
offspring droplets (charged analyte ions) that has either net positive or 
negative charge (depending on the analyte of interest and the setup applied) 
enters the MS. The resulting ESI mass spectrum is composed of signals 
(peaks) corresponding to the different charge states of the same analyte ion 
generating the charge state envelope. It is noteworthy to mention how the 
charges ESI generates on the ions are merely a consequence of the described 
charge accumulation in the droplets and redox processes occurring at the 
probe tip (vide supra), and do not exactly reflect the charge state of the analyte 
in solution, as showed by Kelly et al on protein myoglobin [128].  
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Finally, it is important to mention the ESI current sensitivity dependence on 
the concentration rather than the total volume amount of the sample. This 
dependence gave rise to the further development of the nESI technique which 
coupled with MS instruments nowadays allows detection limit (or lower limit 
of detection, LOD) in ranges of femtomoles [129] and even attomole detection 
for certain analytes has been reported [130].  
?
?
3.2. Hybrid mass spectrometers  
Mass spectrometers use a combination of electric and magnetic field 
generated within electrostatic lenses and other ion optics elements to confine 
and manipulate analyte ions. As mentioned in the previous Chapter, a 
proteomic-oriented mass spectrometer has to allow both the detection of intact 
ions and also their controlled fragmentation. To maximize the flexibility in 
performing all these different operations, MS instruments have been equipped 
with multiple mass analyzers in series. Such instruments are known as hybrid 
mass spectrometers [131]. Hereinafter, the two mass analyzers present in the 
instrument used for this Thesis, a linear ion trap Orbitrap Fourier transform 
mass spectrometer (LTQ Orbitrap Elite, Thermo Scientific), will be described 
in the general terms of their respective working principles. 
 
?? Linear ion trap 
Stand-alone linear quadrupole ion trap (LIT) mass spectrometers were 
introduced by Thermo Finnigan in 2002, as a high capacity alternative to three 
dimensional quadrupole ion traps (QIT) [132]. The claimed advantages of LITs 
over QITs include increased ion storage volume (reduction in space charge 
effect), enhanced sensitivity and higher trapping efficiency, as previously 
described by Syka and Fies [133]. A LIT as implemented by Thermo Finnigan 
consists of a quadrupole with rods split into three sections and front and 
backlenses (not shown), Figure 3.2.  
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Figure 3.2. A perspective view of a linear ion trap as it is implemented within 
the LTQ Orbitrap Elite system. The two x-rods are provided with slits to enable 
radial resonance ion ejection. The hyperbolic rods are divided into inner and 
outer sections to add a constant voltage in z-direction that causes ion trapping. 
Adapted from Schwartz and Senko [134]. 
 
Radiofrequency (RF) potentials with opposite phases are applied to the two 
pairs of quadrupole rods to confine ions in the radial direction Direct current 
(DC) potentials are applied to the separate sections of the rods confine ions in 
the axial direction (Figure 3.3.). As with QITs, a bath gas provides collisional 
cooling of the ion cloud.  
 
 
Figure 3.3. Schematic showing the application of RF, DC and AC potentials 
needed for operation of a linear quadrupole ion trap. Adapted from Schwartz 
and Senko [134] 
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Auxiliary alternating current (AC) waveforms with opposite phases are 
added to one pair of opposite rods for ion isolation and ion activation. Mass 
analysis is accomplished by ejection of ions (mass selective instability) through 
slots in the center section of the quadrupole rods. DC potentials on the front 
and rear lenses gate the flow of ions into and out of the ion trap. To enable 
ion/ion reactions, AC waveforms are also added to the front and back lenses 
of the LIT. This provides an axial trapping field for simultaneous storage of 
cations and anions.  
Stability of the ions within the linear ion trap is described by Mathieu 
equations that operate with two dimensionless parameters, a and q: 
? ? ? ??????????
???????????????????? ????? ? 
 
? ? ? ?????????
???????????????????? ????? ? 
where Q is charge, U is DC voltage, V is RF voltage and ? is oscillation 
frequency. Plotting a as a function of q gives a stability diagram (Figure 3.4.) 
 
 
Figure 3.4 Mathieu stability diagram for linear ion trap. Area indicated in orange 
shows combinations of a and q which provide a stable trajectory in x- direction, 
whereas purple area indicates combinations of parameters under which 
trajectories are stable in y-direction. Figure adapted from 
www.planetorbitrap.com. 
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This diagram is a graphical representation of all solutions to Mathieu’s 
equation for linear ion trap.? Overlap of regions in Figure 3.4 indicates 
combinations of a and q under which ions are stable inside the trap. By 
ramping the AC voltage (known as resonance ejection voltage) ions are passing 
the q = 0.908 instability barrier and are axially ejected. 
 
3.3. Fourier transform mass spectrometry (FTMS) 
High mass resolution and accuracy measurements in hybrid mass 
spectrometers are obtained thanks to specific mass analyzers positioned 
downstream of the low resolution mass analyzer (with respect to the ion inlet). 
Typically, two types of mass analyzers are capable of achieving resolution 
>20’000: time-of-flight (TOF) and Fourier transform (FT)-based ones. 
Conceptually, the working principle of TOF mass analyzer is relatively simple 
[135, 136]. Ions with identical starting position and velocity are accelerated to 
a final kinetic energy of zeV through a field-free space, such that their time-
of-flight when they will reach the ion detector can be described as: 
 
? ? ?? ? ????????
?
?                        (3.1.) 
 
where d is the length of the flight tube, z is ion’s charge state, e is an 
elementary charge, V is an acceleration potential, and m is the mass of the ion 
of interest. TOF mass analyzers are based on a “single-ion counting” principle, 
as every single ion may generate a signal by reaching the detector, if it has 
enough energy.  
 
Conversely, FT-based mass analyzers work by measuring frequency of 
motion of ion packets that are injected into the mass analyzers, where they 
are trapped, excited and, for a certain time, follow a specific periodic motion 
dictated by the use of magnetic or electric fields [137]. We can distinguish 
between two FT-based mass analyzers: i) the magnetic field-based ion 
cyclotron resonance (ICR) mass analyzer; and ii) the electrostatic field-based 
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Orbitrap mass analyzer. In FT-ICR MS, ions move immerged in a static, 
spatially uniform magnetic field B, and their cyclotron frequency is defined as: 
 
????? ? ???????                 (3.2.) 
 
with e being the elementary charge and m the ion’s mass. In reality, due to 
the presence of electric fields in ICR mass analyzers, for example trapping and 
space charge fields, the measured frequency is the reduced cyclotron 
frequency, which is shifted by the magnetron frequency compared to the 
cyclotron frequency. Importantly, frequency of ion motion is inversely 
proportional to the m/z ratio of ions. As a consequence, resolution of FT-ICR 
MS drops following the same dependence with an increase in m/z.  
In the Orbitrap, ions are confined using a quadro-logarithmic electrostatic 
potential. The frequency of ion oscillation along the central electrode (vide 
infra), also known as axial oscillation frequency, is determined as: 
 
?? ? ????? ?
?
??                 (3.3.) 
 
where k is a constant describing the field curvature. Contrary to FT-ICR MS, 
ion frequency is inversely proportional to ??? ? and thus resolution in Orbitrap 
FTMS reduces substantially slower than in FT-ICR MS as a function of m/z. 
 
For both mass analyzers, the signal of ion packets is recorded as a current 
induced by the passage of ions themselves close to pairs of electrodes. Such 
signal is then digitized and stored as a time-domain signal, commonly referred 
to as “transient signal” due to its characteristic decay in amplitude over time. 
Time-domain signals are Fourier transformed to obtain frequency domain 
spectra, which can be easily converted into m/z spectra using calibrants of 
known m/z and frequency as well as dependences presented in equations 3.2 
and 3.3. In the following subsection we focus on one of the FTMS instruments 
used in this Thesis. 
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3.3.1. Orbitrap-based mass spectrometer - design and working principle 
Our lab is equipped with a state-of-the-art hybrid LTQ Orbitrap Elite mass 
spectrometer from Thermo Scientific (Bremen, Germany), particularly suited 
for the selected research direction. The hybrid architecture of this instrument 
includes two different mass analyzers, a dual-pressure linear ion trap (LTQ) 
and the compact, high-field Orbitrap, arranged in series, Figure 2. 
 
 
 
Figure 3.5. Schematics of the hybrid LTQ Orbitrap Elite mass spectrometer. 
 
The Orbitrap technology, developed in 2000 by Makarov [138] represents 
the latest major achievement in mass spectrometry in general and in Fourier 
transform mass spectrometry (FTMS) in particular. This technology is based 
on the recording of the induced current produced by ion clouds trapped into 
the electrostatic Orbitrap cell. As in every FTMS-based mass analyzer, the final 
resolution is proportional to the length of the recorded transient signal.  
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Figure 3.6. Comparison between standard and high-field Orbitrap mass 
analyzers. Left panel, picture of both the mass analyzers, indicating the size 
reduction occurred passing from the old to the new generation of mass 
analyzers. Right panel, some dimensions and other features distinguishing the 
two Orbitrap generations. 
 
Among the figures of merit of the Orbitrap Elite series there are: the 
advanced signal processing algorithm (enhanced FT, or eFT) for absorption 
mode-type FT providing, together with increased frequency of ion axial 
oscillations, improved resolution up to 480’000 at m/z 400 (transient length 
1536 ms), high sensitivity of the front-end ion optics equipped with the S-lens 
(stacked ring ion guide) [139]. 
Furthermore, the LTQ Orbitrap Elite allows different activation methods for 
tandem mass spectrometry (described in the Chapter 2). CID [73] is performed 
in the high pressure region of the LTQ (gas used: helium), as well as electron 
transfer dissociation (ETD) [88]. In the LTQ Orbitrap Elite the injection of the 
ETD reagent radical anions, fluoranthene, is performed from the back of the 
instrument. The amount of fluoranthene injected is controlled by the 
automatic gain control function (AGC) in the LTQ, exactly like for the target 
value of precursor ions for MS/MS or ions analyzed in the survey scan. 
Finally, this mass spectrometer can perform also HCD[76]. Originally 
developed in the C-trap, this fragmentation method is now performed in a 
specific multipole trap positioned after the C-trap, see Figure 3.1. Importantly, 
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product ions generated by HCD are analyzed uniquely in the Orbitrap mass 
analyzer. Nevertheless, HCD activation is fast, so that it is still possible to 
apply it to bottom-up proteomics as demonstrated by Michalski et al. As an 
example, by using a top-15 routine (which consists in the fragmentation of the 
15 most intense precursors detected in the survey scan), the final duty cycle 
is of 3.3 s when the survey scan is performed at 240’000 resolution (at 400 
m/z) and product ion detection following HCD is performed at 15’000 
resolution (at 400 m/z). In addition to being a collision cell, HCD cell can be 
used for trapping of the large ions, to thermalize them via mild collisions with 
the bath gas, prior to squeezing of the ion package in the C-trap, thus 
improving their transfer efficiency when injected into the Orbitrap analyzer. 
 
 
3.4. Limitations of MS experiment in an Orbitrap FT MS  
FT-based instruments in general and Orbitrap-based instruments in 
particular are current state-of-the-art instruments used in proteomics 
research and could be considered condicio sine qua non tools for structural 
analysis of compounds for which high resolution is required. However, these 
instruments do meet their practical limitations. The mass analyzers described 
in this Chapter work by spatially confining ions within a limited space (gaining 
the generic name of ion traps). Although the motion of the ion inside the mass 
analyzer can be in a first approximation considered as dictated by a specific 
electric or magnetic field (for instance, the magnetic field produced by 
superconductive magnets used in ICR FTMS), ions also interact with each 
other. The observable ions behavior produced by these interactions, and 
particularly by Coulombic forces, take collectively the name of space charging. 
The most obvious space charge effect affecting high-resolution FTMS mass 
analyzers, ICR and Orbitrap cells, is known as ion coalescence. Originally 
discovered and studied in ion cyclotron resonance FTMS [140], coalescence 
has been recently reported also in Orbitrap-based mass spectrometers [141]. 
This effect, that for ICR seems caused by phase-locking of ion populations 
with very similar motion frequencies (and, thus, originally characterized by 
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very close m/z position in the mass spectrum), produces distortions in the 
peak positioning, as the peaks of neighboring analytes with very similar 
masses starts getting closer in the m/z space until they eventually become 
completely superimposed and, therefore, undistinguishable. Importantly, not 
only the two species will seem like one in the case of complete coalescence, 
but even when the phenomenon is only partial it still has detrimental effects 
on mass accuracy. 
Although a recent study would suggest that this phenomenon should not 
be a problem for general bottom-up studies [142], it has to be considered that 
ion coalescence, as any space charge effect, depends on the number of ions 
introduced in the mass analyzer. Therefore, selected applications differing 
from shotgun BUP experiments might suffer problems if a large population of 
ions within a small m/z window has to be used [143], for example in the 
attempt of increasing the SNR. For example, if too many ions of a single charge 
state of a highly-charged protein are simultaneously introduced in an Orbitrap 
(or ICR), ion coalescence might affect the relative positioning of the 
isotopologues composing the isotopic distribution of a single charge state 
(which are already extremely close in the m/z axis), with the ultimate effect of 
preventing the correct charge assignment of the ion cluster and thus a 
possible mistake in the calculation of the protein mass. 
Another application where it is of fundamental importance to keep ion 
coalescence under control is lipidomics, particularly during experiments 
aimed at distinguishing between lipidic species separated in mass by only a 
few milliDaltons.  
?
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Chapter 4. Towards a ‘stand-alone’ MDP 
pipeline  
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This Chapter is dedicated to the development and implementation of a 
rationale enabling a new subdomain, middle-down proteomics (MDP, as 
introduced in Chapter 1), in a well-defined field of mass spectrometry-based 
proteomics. To do so, we explored various middle-down (MD) approaches that 
will be presented through research articles in following Chapters. Throughout 
this Chapter we will refer to MDP when talking about the high-throughput 
shotgun identification of proteome(s), whereas MD will refer to distinct 
approaches within MDP. Herein, we addressed the initial requirements that 
would allow achieving the following goals set for MDP pipeline that targets 3-
15 kDa peptides:  
i)?Identify the most optimal target backbone cleavage site(s) in proteins 
for optimizing the desired peptide length and amino acid distribution,  
ii)? Identify and characterize a suitable protease or other cleaving agent,  
iii)?  Optimize front-end separation(s) for peptides in a targeted mass bin,  
iv)?  Determine MS instrument parameters set to analyze resulting 
peptides, 
v)? Optimize data analysis workflows to improve analytical 
characteristics of MD mass spectrometry, such as sensitivity and spectral 
dynamic range 
 
The final goal of the study was to better characterize complex biological 
systems by offering insights that currently employed approaches cannot 
provide. Hereinafter reported considerations are the initial premises later 
translated into research articles enclosed at the end of this Chapter: 
?? Proteome Digestion Specificity Analysis for Rational Design of 
Extended Bottom-up and Middle-down Proteomics Experiments (Paper 
I) 
??  Practical Considerations for Improving the Productivity of Mass 
Spectrometry-based Proteomics (Paper II) 
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Tailoring the proteolysis site to yield longer average peptides is the driving 
force for the development of MDP. Frequency of amino acids differs from 
proteome to preoteome, often even within sub compartments of a proteome.  
Hence, this fact alone implicates a priori a potential need for various proteome–
specific MD approaches to allow for a MDP on a given organism. At the same 
time, sample preparation, peptide separation, ionization conditions, 
fragmentation parameters, data acquisition and data analysis must be 
adjusted to analysis of long peptides. Figure 4.1 shows peptide ranges 
classified on the basis of the type and figures of merit of the mass 
spectrometers that can be employed, chromatography considerations, and 
available database search algorithms for data analysis. Note how here we 
categorized the proteomics approaches in four mass bins according to the 
molecular weight of proteolytic pool. The fourth category, extended bottom-up 
proteomics (eBUP) derived as a sub-category of MDP after initial 
considerations of available pipeline in terms of the instrument performance 
and the choice of front-end chromatography (reversed-phase LC (RP-LC) vide 
infra). The former meets its limitation in current software feature that does 
not allow change of settings (such as collision energy, isolation window, target 
value for MS/MS, number of microscans, etc.) ‘on a fly’. Hence, oftentimes 
analysis in MDP range has to be carried out in minimum of two repetitions, to 
accommodate the optimal settings for all peptides throughout the mass range. 
RP-LC on the other hand, emphasizes the hydrophobicity-based elution, while 
size-exclusion comes as a secondary, not strongly pronounced effect. This in 
turn means how shorter (30-50 residues) peptides could elute in close 
retention time window with longer (50-100 kDa) ones, if their hydrophobicity 
index is close. In respect to those two aspects, it seemed favorable to further 
split broad range of proteolytic pool of MDP (3-15 kDa) into lower molecular 
weight bin (3-7 kDa) and use that one as initial testing bed for MDP pipeline 
optimization. 
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Figure 4.1. Classification of mass spectrometry-based proteomic approaches 
based on the molecular size of the analytes. Adapted from Laskay et al. [144]. 
4.1. Liquid chromatography: adopted parameters and reflections on mass 
spectrometric analysis of large peptides.  
In general, the application of separation techniques to complex proteomic 
samples is essential for successful mass spectrometric analysis. Front-end in-
solution separation enhances the dynamic range of detection, minimizes ion 
suppression effect during the electrospray ionization process and greatly 
increases the depth of proteome analysis. 
The most commonly employed separation technology in MS-based proteomics 
is liquid chromatography (LC), and specifically reversed-phase LC (RPLC). As 
any chromatographic technique, LC is performed by distributing the analytes 
between two phases: the mobile phase, in this case a liquid which carries the 
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analytes, and the stationary phase, which is fixed inside a hollow column 
through which the mobile phase is forced. The distribution coefficient of each 
analyte between the two phases, which determines whether the analytes will 
be preferentially retained by one or the other phase, can be changed, 
primarily, by varying the composition of the mobile phase. In RPLC the 
analytes, in our case peptides, are characterized by certain degree of 
hydrophobicity. Therefore, they are initially loaded onto the chromatographic 
column using a very low percentage of organic solvent in the mobile phase, so 
that they will preferentially interact with the stationary phase, which is 
composed of hydrophobic material. The percentage of organic component in 
the mobile phase is then raised over time, progressively moving the 
distribution equilibrium of peptides from the stationary towards the mobile 
phase.  
Traditionally, columns are packed with particles conjugated to specific 
functional groups. For reversed-phase LC, silica-based microparticles are 
decorated with linear alkanes of different length, the most common being C18, 
C8 and C4 (where 4, 8, or 18 denotes the number of carbon atoms in the 
chain). Longer alkane chains are more hydrophobic, being ideal for 
polypeptides of reduced size (e.g., tryptic peptides), whereas shorter chains 
are typically used for longer polypeptides and proteins. The choice of the 
stationary phase is important, along with other parameters (vide infra), to 
determine the final chromatographic resolution, defined as capability of 
separating the elution peaks of two different analyte molecules. In proteomics, 
high chromatographic resolution is of fundamental importance as it allows to 
minimize the number of peptides that are simultaneously directed towards the 
mass spectrometer, greatly reducing problems of signal suppression and 
overlapping and ultimately leading to the detection of a higher number of 
species with high specificity and selectivity. 
Although a comprehensive discussion about liquid chromatography exceeds 
the scope of this Thesis, to better understand the choices of 
columns/stationary phases selected for the MDP platform (see Figure 4.1, 
bottom), and also discussing potential limitations of the currently available 
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commercial columns, it might be important to briefly introduce the Van 
Deemter equation [145-147], which describes how the height equivalent to a 
theoretical plate (HEPT) is related to the linear velocity of mobile phase (v) in 
relation to three parameters (A, B and C): 
???? ? ? ? ?? ? ?? 
The theoretical plate is the minimal stage or portion of the column in which 
the two phases establish an equilibrium. Increasing the number of theoretical 
plates enhances the chromatographic performance characteristics, including 
the resolution. Therefore, it is important to minimize HEPT as, for a column 
of given length l, the number of theoretical plates N is given by  
? ? ????? 
In the Van Deemter equation, the three parameters A, B and C refer to 
physico-chemical properties of the column. Specifically, A is the Eddy-
diffusion parameter, which is related to the quality of column packing by 
measuring possible variations in the analyte flow path due to inhomogeneities 
in the stationary phase; B represents the longitudinal diffusion coefficient, 
which is contrasted by increasing the mobile phase linear velocity, effectively 
concentrating in a tighter pack the analyte molecules; finally, C indicates the 
mass transfer coefficient, originated by the porous nature of the column 
packing material, and that is linearly proportional to the linear velocity of the 
mobile phase. Note, that increasing l to obtain a higher number of theoretical 
plates is a strategy that is widely pursued, but found its limit in the 
backpressure generated by the stationary phase, which is directly 
proportional to the column length. 
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Figure 4.2. Plot illustrating the Van Deemter equation. The three components A, 
B/v and Cv are indicated in three different colors, while the final HEPT function 
is displayed in black. The dotted line indicates the optimal linear velocity of the 
mobile phase, which corresponds to the minimum in the HEPT curve. 
For our MDP platform, we apply on-line LC nanospray (nESI) MS (i.e., with 
the column outlet directly linked to the nESI source) using a Dionex Ultimate 
3000 (Thermo Scientific). This LC system is equipped with a nano pump 
(allowing for flow rates between 0.05 and 1 μl/min) and a micro pump 
(operating at >1 μl/min). The former is used for peptide separation on 
analytical nano columns by reversed-phase LC, whereas in our setup the latter 
is used to wash peptides trapped on a guard column right after injection and 
prior to analytical separation. The choice of columns for MDP was done taking 
into account the characteristics of middle-down peptides, which are larger and 
more hydrophobic than typical bottom-up ones. Hence, highly hydrophobic 
stationary phases such as C18 were excluded, to prevent irreversible binding 
of peptides to the column stationary phase. From a mass spectrometry point 
of view, slightly broader LC elution peaks resulting from the weaker 
hydrophobic interactions might be advantageous on the MS/MS working 
timescale for large peptides. In fact, the longer the peptide, the more charges 
it normally carries, and the higher the chance that its tandem mass 
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spectrometry generates partially overlapping multiply charged product ions; 
therefore, high resolution is required for both MS and MS/MS in MDP 
experiments. This is translated into the need of using the high resolution mass 
analyzer for both survey scans and product ion detection, reducing the 
throughput. Furthermore, convoluted tandem mass spectra might require the 
implementation of strategies aimed at improving the spectral signal-to-noise 
ratio (SNR) that are generally detrimental for the speed of analysis (vide infra, 
paragraph 4.2). 
With all these considerations in mind, a silica particle-based nano-column 
with C8 stationary phase was used in combination with a C8 trap column for 
most of MDP applications. The adopted flow rate was 0.8 μl/min, which was 
required by the large pore size (300 Å) to maintain the linear velocity of the 
mobile phase sufficiently close to optimal values, avoiding detrimental effects 
on chromatographic resolution, without leaving the nano-flow rate regime, 
which is favorable over the micro-flow rate regime in terms of ionization 
efficiency and sample consumption.  
For selected applications, finally, a monolithic column was used [148]. 
Monolithic columns are produced by polymerizing the stationary phase 
directly inside the column. Differently from packed column, the stationary 
phase is in this case non-porous, and therefore the mass transfer is highly 
limited, with obvious benefits for the achievable resolution. Moreover, the 
monolithic stationary phase of these columns is characterized by high 
physical-chemical stability and allows to use columns of superior length due 
to the reduced back pressure. The monolithic column used in the here 
described MDP pipeline is a commercial PepSwift from Dionex, consisting of a 
cross-linked co-polymeric stationary phase based on divinylbenzene and 
polystyrene. Due to the relatively large internal diameter (100 um), the column 
was used at a flow rate of 1 μl/min, producing a slightly reduced ionization 
efficiency in comparison to that of its C8 counterpart. 
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4.2. Evaluation of MS/MS parameters for MDP  
CID remains the fragmentation technique of choice for BUP, due to its speed, 
efficiency for short peptides and the possibility to use the LTQ for low-
resolution product ion detection with high scan rate. For MDP applications, 
however, as the average size of analyzed peptides requires fragmentation 
methods leading to extensive sequence coverage and necessarily product ion 
detection performed in the Orbitrap, different techniques such as HCD and 
particularly ETD, could be considered as more suitable ion fragmentation 
methods.   
 Differently from CID, ETD produces extended sequence coverage even for 
extremely large peptides (or proteins), and the sequence information that it 
produces is generally not limited to the N- and C-termini. Furthermore, as 
mentioned in Chapter 2, ETD typically preserves labile PTMs. This feature is 
of a particular importance considering that one of the envisioned advantages 
of middle-down over the classical bottom-up approach is the possibility of 
determining with higher precision possible proteoforms, whose classification 
is essentially based on PTMs localization. It is to be noted how the loss of labile 
PTMs with CID is true for small systems such as peptides. However, if we 
recall how energy is randomized through 3N-6 or 3N-5 vibrational modes in a 
non-linear or linear molecule, respectively (where N indicates the number of 
nuclei present in the molecule), [63] it is obvious how for large biomolecules 
the number of available vibrational modes is significantly higher. This in turn 
means how the randomization of energy does not lead to the cleavage of the 
weakest bond present in a side chain, thus allowing preservation of PTMs. 
Given that percent fragmentation in ETD is dependent on the charge state of 
the selected cation, the higher average charge state of peptides in the mass 
range of MD experiments should be favorable for this activation method and 
provide better results than shorter and less charged peptides typical of BU. 
The ion-ion interaction time is decreasing with the increase in the precursor 
charge state, and this ensures that the duration of MS/MS event is 
substantially reduced (8-10-fold; 10 ms used in MD approach [149] vs 80-100 
ms in BU approach [92]) by passing from BU to MD ETD LC-MS/MS). The 
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overall fragmentation efficiency is lower than in energy threshold-based 
activation techniques (CID, HCD, IRMPD), which means that strategies aimed 
at improving the spectral signal-to-noise ratios are particularly important to 
achieve a high-quality ETD MS/MS spectrum. In hybrid FTMS instruments 
like the one used for this Thesis, it is possible to average several time-domain 
transients (the so-called micro scans) prior to their Fourier transformation 
(FT). This procedure is detrimental to the overall analysis throughput, as it 
requires a full cycle of ion injection, fragmentation and product ion detection 
to obtain the additional time-domain signals (micro scans). Furthermore, this 
strategy increases spectral SNR only with the square root of the number of 
averaged micro scans. 
With all this considered, despite the reduced complexity of the proteolytic 
peptide landscape in MD compared to BU, which should help the peptide 
separation, the time constraints imposed by the LC-MS/MS setup usually 
employed in any proteomics study render the actual implementation of ETD 
for MDP challenging. On the other hand HCD, despite being a low-energy 
fragmentation method, should still be favorable over CID for MD peptides, due 
to the fact that applied energy is calculated with consideration to the precursor 
mass to charge ratio and charge (as discussed in the Chapter 3) and therefore 
should be more sensitive and adaptable to the broad span of charge states 
and peptide masses that is intrinsic property of MD proteolytic pool, and in 
turn result in more successful overall fragmentation per LC run. Additionally, 
HCD is on average faster than ETD (0.1-1 ms vs 0.1 – 100 ms per ion-neutral 
and ion-ion interaction event, respectively, not accounting for the radical 
anion transfer and accumulation time in the LTQ) and due to the position of 
the HCD collision cell it has shorter path of the fragments to the orbitrap mass 
analyzer, which is of importance for the successful transmission of larger 
product ions, especially the (unstable) radical ones. Both the short duration 
of ion-ion interaction in HCD, as well as the shorter path for transmission of 
product ions to the analyzer cell render the overall duty cycle shorter and in 
turn allow more MS/MS scans and/or micro scans per chromatographic 
elution peak. Shortcoming of HCD however lies in the fact that it does not 
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preserve the labile PTMs which is detrimental to the PTM assessment goal of 
MD, as well as the fact that this activation method is known for prevalence of 
the y-ion series, whereas the b-series one is oftentimes missing.  
It remains to be stated how, both ETD and HCD individually, or combined 
into a hybrid technique (namely EThcD [150, 151]), yield better results in 
analysis of large biomolecules, in both MD and TD fashion, than other 
available ion activation methods, despite the here underlined current practical 
difficulties which are mainly a result of instrument software and limitations of 
the separation methods preceding the MS. Additionally, certain considerations 
listed here are made with particular regards to the hybrid instrument used for 
this Thesis (i.e., Orbitrap Elite mass spectrometer), and do not apply to some 
of the new FT-based hybrid instruments, such as those based on the 
Quadrupole Mass Filter-Orbitrap-Linear Ion Trap platform. The latest 
iteration of this line of Orbitrap-based mass spectrometers (Orbitrap Fusion 
Lumos, Thermo Scientific), for instance, is not only natively equipped for 
EThcD, but can also perform the so-called “high-capacity ETD”, which 
consists in ETD performed in the LTQ as in all other LTQ-Orbitrap 
instruments, but with precursor cations trapped in the central section of the 
high-pressure chamber, which can store a higher number of ions (three times 
higher, according to estimations) compared with the back section where 
traditionally precursor ions are stored [152]. As a final result, high-capacity 
ETD shows about 3-fold improvement in spectral signal-to-noise ratio of 
product ions when compared with the standard counterparts for the analysis 
of intact proteins. The importance of this achievement is apparent if we 
consider that, performing standard ETD, the averaging of nine micro scans 
would be required to match such signal-to-noise (S/N) gain. With continuous 
advancements in the state-of-the-art instrumentation like the one described 
above, it is easily expected that charge-dependent ion activations will become 
benchmark methods for MDP. 
 
 
?????????????????
???????????????????????? ???????????
93
?
 
 
 
 
 
 
 
 
 
4.3. Paper I: Proteome digestion specificity analysis 
for rational design of extended bottom-up and 
middle-down proteomics experiments  
 
 
 
 
 
 
 
 

95
???????????????????????? ?????????????????????
?????????????????
Proteome Digestion Speciﬁcity Analysis for Rational Design of
Extended Bottom-up and Middle-down Proteomics Experiments
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ABSTRACT: Mass spectrometry (MS)-based bottom-up
proteomics (BUP) is currently the method of choice for
large-scale identiﬁcation and characterization of proteins
present in complex samples, such as cell lysates, body ﬂuids,
or tissues. Technically, BUP relies on MS analysis of complex
mixtures of small, <3 kDa, peptides resulting from whole
proteome digestion. Because of the extremely high sample
complexity, further developments of detection methods and
sample preparation techniques are necessary. In recent years, a
number of alternative approaches such as middle-down
proteomics (MDP, addressing up to 15 kDa peptides) and
top-down proteomics (TDP, addressing proteins exceeding 15
kDa) have been gaining particular interest. Here we report on
the bioinformatics study of both common and less frequently employed digestion procedures for complex protein mixtures
speciﬁcally targeting the MDP approach. The aim of this study was to maximize the yield of protein structure information from
MS data by optimizing peptide size distribution and sequence speciﬁcity. We classiﬁed peptides into four categories based on
molecular weight: 0.6−3 (classical BUP), 3−7 (extended BUP), 7−15 kDa (MDP), and >15 kDa (TDP). Because of
instrumentation-related considerations, we ﬁrst advocate for the extended BUP approach as the potential near-future
improvement of BUP. Therefore, we chose to optimize the number of unique peptides in the 3−7 kDa range while maximizing
the number of represented proteins. The present study considers human, yeast, and bacterial proteomes. Results of the study can
be further used for designing extended BUP or MDP experimental workﬂows.
KEYWORDS: mass spectrometry, MS, proteomics, middle-down proteomics, top-down proteomics, bottom-up proteomics
■ (INTRODUCTION)
Bottom-up proteomics (BUP) is the current approach for high-
throughput identiﬁcation and quantitation of the proteins
present in a biological sample.1 This method entails digestion
of proteins into short (6−30 amino acid residue) peptides that
can be separated by liquid chromatography (LC) and analyzed
by tandem mass spectrometry (MS/MS). The robustness and
high throughput of the BUP approach combined with the state-
of-the-art LC−MS/MS technology allow identiﬁcation and
quantitation of thousands of proteins with and without post-
translational modiﬁcations in a single proteomic experiment.1,2
Modern high-resolution MS instruments, such as Orbitrap
Fourier transform mass spectrometer (FTMS), enable the
identiﬁcation of up to 2500 proteins from a human sample in a
90 min LC−MS/MS experiment.3 Signiﬁcant eﬀorts on
optimization of the ionization and subsequent fragmentation
techniques have resulted in increased sensitivity and speed of MS
instruments in use.4 Despite these eﬀorts, up to 85% of MS/MS
spectra acquired in a typical LC-MS/MS experiment remain
unidentiﬁed or result in false identiﬁcations, thus reducing the
sensitivity of the analysis.5 One of the shortcomings is related to
the properties of enzymatically derived peptides, for example,
their size and location of basic or acidic residues. For example, the
most widely used trypsin digestion produces a large number of
short (0.6 to 1 kDa) peptides. These can be eﬃciently
fragmented and identiﬁed, but their sequences bring little
speciﬁcity at the protein level and they are usually discarded as
ambiguous hits. Peptides with more than 30 residues are typically
multiply charged when electrospray ionization (ESI) source is
used. The presence of long peptides is detrimental in BUP
because all MS operation parameters such as the scanning rate,
resolution, and fragmentation parameters6 as well as the LC
parameters (column type, dimensions, and ﬂow rate)7 are
optimized for small, <3 kDa peptides.
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It has also been reported that several protein classes, such as
membrane proteins and highly ordered and compacted globular
proteins, are underrepresented in the shotgun proteomic
experiment due to the inability of the proteases to access the
cleavage sites embedded in the structure.8 As a solution, a two-
step digestion with two diﬀerent proteases, for example, LysC
followed by trypsin, has been found to oﬀer more comprehensive
sequence coverage of these proteins.9 Peptide fragmentation
eﬃciency as a function of peptide length and amino acid
composition has also been addressed by the use of comple-
mentary fragmentation techniques, for example, collision-
induced dissociation (CID) and electron-transfer dissociation
(ETD).10
Among the other major drawbacks of the bottom-up approach
in the case of using tryptic digestion is the large number of
peptides present in the sample. As a result, most of the precursor
ion isolation windows (typically 3 Da) contain coeluting
peptides. The fragmentation patterns of these peptides may
overlap, and, depending on the abundance of the product ions, a
search engine may return wrong sequence candidates. High-
resolution MS may not help to solve the issue with coeluting
abundant peptides of close masses due to, for example, the
coalescence phenomenon associated with ion trap mass
analyzers.11 Furthermore, peptide coisolation reduces the
accuracy of isotopic labeling-based protein quantitation strat-
egies, for example, of tandemmass tag (TMT)-based and iTRAQ
approaches.12 The problem associated with low precursor ion
fraction in the isolation windows or chimera MS/MS spectra has
also been recently recognized.5a,13 This creates a major limitation
for both speciﬁcity and sensitivity of the proteomic experiment.
Several approaches addressing the above shortcomings are
currently under evaluation at both the instrument development
level by increasing the sensitivity and the scan rate of high-
performance MS as well as by improved sample preparation, for
example, equalizing the protein abundances using ProteoMiner
technology14 or improving the accessibility of the digestion
site.15
Top-down MS is an alternative strategy for proteome analysis.
In this approach, the intact proteins or large protein fragments
(primarily in 15−50 kDa range) are analyzed without the need
for proteolysis.16 Protein sequence information is typically
obtained by fragmentation of the protein ions in the gas phase
using electron capture dissociation (ECD) in Fourier transform
ion cyclotron resonance (FT-ICR) mass spectrometers17 or
ETD in hybrid FT-ICR MS, Orbitrap FTMS, or time-of-ﬂight
(qTOF) MS instruments.18 The major advantage of top-down
proteomics (TDP) is the access to the entire protein sequence
and information about possible post-translational modiﬁcations
(PTMs) present.19 Therefore, TDP aims at proteoform-level
analysis of heterogeneous protein mixtures or proteomes.20 The
term “proteoform” encompasses protein molecular forms
produced from a single gene that are structurally diﬀerent as a
result of genetic variations at the DNA level, alternative splicing
at the RNA level, and PTMs at the protein level. However, the
analysis is greatly hindered, especially for large proteins, due to
the ineﬃciency of the MS/MS techniques, including ECD and
ETD, to provide extensive sequence coverage for proteins >50
kDa in a time-constraint experiment. In addition, the high charge
states of the precursor ions, overlapping charge-state distribu-
tions of diﬀerent proteins, and structural diversity of the intact
proteins render the isolation of a single protein, and especially
proteoform,20 technically unfeasible. The resulting product ion
mass spectra are convoluted and may contain product ions of
multiple charge states. The separation of intact proteins using
adsorption chromatography is also limited to small-size proteins
with a low level of diversity. Because of the above reasons, the
implementation of TDP approach has been limited to low-
complexity mixtures of proteins of relatively low molecular
weights (usually below 30−35 kDa). Therefore, TDP is routinely
employed in only a handful of research laboratories. Never-
theless, recent developments in online capillary electrophoresis
(CE)−MS/MS technologies, ETD and higher energy collision-
induced dissociation (HCD) methods, sensitivity, and resolving
power of mass spectrometry (MS), this strategy is gaining a
widespread interest in the ﬁeld of applied proteomic research.21
A third emerging technique toward protein identiﬁcation is
middle-down proteomics (MDP).22 This approach beneﬁts from
the undeniable advantages of both bottom-up and top-down
strategies and minimizes their above-mentioned shortcomings.
In MDP, proteins of interest are also subjected to proteolysis,
however, the resulting peptides are signiﬁcantly larger (up to
∼150 residues in a sequence and up to ∼15 kDa molecular
weight range). The complexity of a mixture is reduced compared
with BUP, allowing high-resolution mass analysis on LC
separation time scale of a larger fraction of peptides. In addition,
the increased peptide length typically results in a larger number
of charges per precursor ion, thus increasing the ETD/ECD
eﬃciency.23 With this approach, increased protein sequence
coverage can be obtained due to the longer average size of
peptides. In addition, the probability for localization of covalent
modiﬁcations such as PTMs and single-point mutations arising
from splicing variants increases for longer peptides.24 However,
PTMs may lead to increased combinatorial complexity in MDP
because a higher number of longer peptides containing multiple
PTMs may be required to represent all proteoforms. The
information on PTM connectivity provided by MDP on these
multiply modiﬁed peptides would be lost in BUP.
With recent advances in genome sequencing technologies, the
protein databases are rapidly populated with a multitude of
proteins that have unknown functions. Currently, one of the
most accepted approaches toward assigning protein function and
localization uses a similarity search by homology algorithms, such
as BLAST.25 Other approaches include a search for structural
motifs26 and prediction of secondary structures.27 Bioinformatics
studies using a database containing both prokaryotic and
eukaryotic species revealed that proteins possess diﬀerent
amino acid compositions depending on their function and vice
versa; the composition can hint toward protein function.28
According to Cedano et al.,28 besides the expected high
frequency of hydrophobic residues in membrane proteins, the
commonly targeted digestion site lysine (K) represents 6 to 8%
of all amino acids in extracellular, intracellular, and nuclear
proteins, whereas in membrane proteins it is less common with
the occurrence frequency of ∼4.4%. The mean value for arginine
(R) is 4.2 to 5% for all protein classes, except those present in the
nucleus, which had much higher frequency of 8.7% in R content.
Interestingly, histidine (H) was found to be uniformly present in
all protein classes at 2.1% frequency.
Importantly, the global amino acid composition of diﬀerent
kingdoms of life also varies signiﬁcantly. Bogatyreva et al. found
that the frequency of K is 5% in bacteria and 6.5% in archaea and
eukaryotes, cysteine (C) and serine (S) are more frequent in
eukaryotes than in other kingdoms, and tryptophan (W),
methionine (M), R, phenylalanine (F), and aspartic acid (D)
are uniformly represented in all kingdoms.29
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In summary, the currently employed “one enzyme for all
proteomes” approach is not always suitable for blind analysis of
complex protein mixtures, regardless of the targeted peptide size
range. In this study, we use the peptide size distribution after
single and two sequential cleavages as metrics for optimization of
the “shotgun” proteomics workﬂow. This optimization aims at
maximizing the number of proteins identiﬁed, thus improving
both speciﬁcity and sensitivity of the proteome analysis and
potentially increasing the probability of PTMs localizations.
In this bioinformatics assessment, we considered the possible
cleavages at each of the 20 common amino acids for human,
yeast, and bacteria proteomes. Figures of merit of commonly
used proteolytic and chemical cleavage methods are presented
herein. The comprehensive results containing all cleavage sites
are presented in the Supporting Information (Figures S2−S3).
Venn diagrams (not to scale) depicting the percentage of human
proteins identiﬁed by individual and combined approaches are
contained in the main text of the manuscript. Similar ﬁgures for
the yeast and bacterial databases and the numerical representa-
tion of all Figures can be found in the Supporting Information
(Figures S4−S12).
■ EXPERIMENTAL SECTION
In silico digestion of the Homo sapiens (human), Saccharomyces
cerevisiae (yeast), and Escherichia coli (bacteria) protein databases
(UniProt, release-2012_07) and calculation of peptide masses
were performed using the tools of in-house built open-source
Python library “Pyteomics”.30 We chose these three species as
representative data sets for the mammalian, fungal, and bacterial
kingdoms. The nonredundant databases contained 20 103
human, 6566 yeast, and 4243 bacteria proteins. Proteoforms
were not included in the calculations. In presenting the data, we
use the term “unique peptides” as accepted in the proteomics
literature. In brief, the term “unique” refers to peptides
representative of a single protein in a given proteome. In this
case, peptides that had a shared sequence between multiple
proteins were excluded from the statistics. For example, we
considered unique peptides for calculating the number of
proteins that could be potentially identiﬁed with a given pool
of peptides.
In the light of currently existing proteomic approaches, the
peptide size range identiﬁed by MDP and even the terminology
for the analysis of long peptides is not consistent. Fenselau and
others target the analysis of 3−10 kDa peptides and term the
analysis middle-down or middle-out proteomics,23,31 whereas
Kelleher and coworkers, based on their extensive top-down
experience, target 5−15 kDa peptides and also term their analysis
MDP.32 Wu and coworkers used the terminology of extended-
range proteome analysis (ERPA) for the analysis of long
peptides.33 On the basis of the working regime (scan speed and
mass resolution) of instruments employed in reported work as
well as our own experience, we suggest diﬀerentiating between
the analyses of 3−7 and 7−15 kDa peptides and use diﬀerent
terminology for their distinction. These peptide ranges were
chosen on the basis of the type and ﬁgures of merit of the mass
spectrometers that can be employed, chromatography consid-
erations, and available database search algorithms for data
analysis. Scheme 1 shows our proposed classiﬁcation for
distinction of the proteomics workﬂows. BUP has been chosen
to be delimited from eBUP based on experimental consid-
erations, such as chromatographic separation conditions and
mass spectrometer operation parameters (resolution setting, ion
accumulation time, etc.) For example, it has been found that 97%
of all tryptic peptides of the yeast proteome identiﬁed by BUP
have 7−35 residues, with an average peptide length of 10 amino
acids.34 Separation of these short peptides can be performed on
C18 reverse-phase columns, and collisional dissociation methods
can be used for MS/MS analysis. Because of the short average
length of the precursor ions, it is likely that the average charge
state is also low. Therefore, in most cases, there is no need for
time-consuming high mass resolution analysis of the product
ions. In contrast, to avoid strong and irreversible binding of
longer peptides on the hydrophobic chromatographic column, a
C8 column is more appropriate for separation of those. The
broader separation peaks resulting from the weaker hydrophobic
interactions are advantageous in the MS/MS working time scale,
considering that multiple microscans are to be averaged for
enhanced signal-to-noise ratio (S/N) of the highly charged
product ions. Several intact protein chromatographic and
electrophoretic separation technologies have been implemented
in top-down proteomics.35 In addition to the chromatographic
considerations, theMS working parameters also greatly aﬀect the
data quality. In principle, the longer the peptide, the more
charges it carries; therefore, high-resolution MS and MS/MS
scans are required for eBUP, MDP, and TDP. As a result,
practical issues such as the ion optics potentials or operating
pressure also need to be considered.
Scheme 1. Classiﬁcation of Mass Spectrometry-Based Proteomic Approaches Based on the Molecular Size of the Analytesa
a(1) Type of LC column, (2) activation method, (3) mass analyzer, and (4) database search engine.
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Figure 1. Theoretical distribution of the total number of peptides and percentage of the proteins identiﬁable with unique peptides in human (left
column), yeast (middle column), and bacteria (right column) proteomes after two-step consecutive cleavage with 7 kDa MW cutoﬀ after the ﬁrst
cleavage within (top row) 0.6−3, (middle row) 3−7, and (bottom row) 7−15 kDa ranges.
Journal of Proteome Research Article
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■ RESULTS AND DISCUSSION
Previous research eﬀorts in MDP have been using proteolytic
enzymes with well-established cleavage sites and optimized
proteolysis conditions that cleave selectively at a single residue or
at infrequently occurring dibasic sites. Herein, we investigated
the feasibility of these and other proteases for eBUP and MDP
using bioinformatics approach. Figure 1 shows the theoretical
number of peptides and their size distributions as well as the
percentage of proteome that can be identiﬁed in each mass range
from the complete human, S. cerevisae and E. coli proteomes. The
amino acid on the vertical axis represents the position of the ﬁrst
cleavage, whereas the position of second cleavage is shown on the
horizontal axis. The color scale shows the number of peptides
obtained for each cleavage. Cleavage combinations at those
amino acid residues that can be targeted with currently known
enzymatic or chemical methods are included in Figure 1, whereas
Figure S2 (Supporting Information) contains information on all
cleavages, regardless of the practical feasibility of the digestion.
The amino acids are presented in order of decreasing
hydrophobicity. For these calculations, we performed the ﬁrst
in silico digestion, removed the peptides with masses below 7
kDa, performed a second theoretical cleavage on the remaining
peptides, and summed the resulting peptides after both digestion
steps. The bottom-left to top-right diagonal positions therefore
represent the peptide size distributions after single amino acid
residue cleavage. For statistical purposes, and to illustrate sample
complexity, we have included herein all peptides. Those shared
between multiple proteins were counted once. The resulting
peptides have been classiﬁed into the four (BUP, eBUP, MDP,
and TDP) size ranges based on their lengths, Scheme 1 and
Figure 1. As expected, in all species studied the number of
peptides in the 3−7 kDa region is largest when both of the two
consecutive cleavages occur at rare amino acids. Interestingly, the
relative frequency of amino acids is diﬀerent for the three species
studied (Figure S1, Supporting Information); therefore, the
optimal cleavage site combinations are species-dependent. In the
following, we will consider selected amino acids and their pairs as
candidates for enzymatic cleavage sites.
Lysine, Lys (K), and Arginine, Arg (R)
Targeting basic digestion sites is the most common approach in
BUP, and trypsin is the most commonly used protease in
proteomics applications. The Venn diagram in Figure 2 top panel
shows the number of human proteins represented by unique
peptides in the BUP, eBUP, and MDP size regions following
tryptic digestion. Similar ﬁgures for the yeast and bacteria are
included in the Supporting Information (Figures S3 and S4).
Because of the high combined frequency of K and R in all
kingdoms, the number of peptides in higher mass regions and the
number of identiﬁed proteins in eBUP and MDP regimes are
greatly reduced, and 15.7% of human proteins can be identiﬁed
only by the BUP approach. Because Figure 1 reports on the two-
step consecutive cleavage with 7 kDa cutoﬀ ﬁlter after the ﬁrst
digestion step, the order of amino acids (K followed by R or R
followed by K) inﬂuences the number of resulting peptides in all
mass regimes. In contrast, the tryptic digestion data shown in
Figure 2 consider all possible cleavages at K and R residues
without an additional 7 kDa molecular weight ﬁltering.
If the side chain of K residues is chemically derivatized prior to
digestion, trypsin can be used to target only R residues. One
application of this approach used propionic anhydride to block
the K residues in histones, leading to increased average peptide
size and allowing relative quantitation of modiﬁed histones.36 If
this approach was applied to analysis of the entire yeast, bacterial,
or human proteome, the number of peptides in BUP would be
about three times greater than the eBUP peptides and an order of
magnitude larger than the MDP peptides (Figure 1). The Venn
diagram in Figure 2, middle panel, illustrates that for the human
proteome analysis of eBUP peptides after R cleavage may yield a
comparable number of protein identiﬁcations and requires a
signiﬁcantly smaller number of peptide MS/MS spectra.
The frequency of occurrence of K is diﬀerent than that of R in
both yeast and bacterial databases; therefore, targeting this
cleavage site showed a diﬀerent peptide distribution than
digestion at R only. Digestion after K residues yielded more
BUP and less eBUP and MDP peptides for yeast (Figure 1b,e,h).
Considering the 4.4 times larger number of peptides in BUP than
in eBUP, the 95.9 and 86.6% proteins identiﬁed, respectively,
suggest that analysis of peptides in eBUP region could be more
advantageous than that in the BUP approach. In contrast with
human, for bacteria the number of BUP peptides was greatly
reduced, whereas a 1.5-fold increase in MDP peptides was
obtained. Bacterial proteome digestion yielded 30 942 BUP
peptides, only 2.3 timesmore than in eBUP; therefore, in the case
of this organism, BUP still has the potential to provide
satisfactory protein identiﬁcation. Nonetheless, if the goal of
Figure 2. Venn diagrams (not to scale) of the number and percent of
human proteins identiﬁable by unique peptides in BUP, eBUP, and
MDP approaches using (top) tryptic proteolysis (both K- and R-speciﬁc
cleavages), (middle) only K-speciﬁc cleavage, and (bottom) only R-
speciﬁc cleavage.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr400522h | J. Proteome Res. 2013, 12, 5558−55695562
100
???????????????????????? ?????????????????????
?????????????????
the study requires the detection of higher protein sequence
coverage, then eBUP and MDP have the potential to be more
feasible than BUP.
There are other proteomics-grade enzymes that cleave around
basic amino acids. For example, LysC has been used for
characterizing protein glycosylation sites.24 The benchmarked
metallo-endoproteinase, Grifola f rondosa or LysN, has been
successfully characterized and implemented in the digestion of a
standard yeast cell lysate;37 peptides were analyzed in BUP
regime using CID. Because with LysN digestion the K is present
on the N terminus, this will sequester a proton and yield
informative c-ion series in ETD, potentially facilitating de novo
sequencing of peptides.38 As seen in the bottom panel in Figure
2, analyses of BUP and eBUP peptides obtained with LysC have
the potential to exclusively identify 3.7 and 1.5% of human
proteins, respectively.
Dibasic Cleavage Sites
One of the recently proposed cleavage sites for MDP is the
targeting of dibasic residues, that is, the positions where two
consecutive basic amino acids such as K or R are present.32,39
Several dibasic-site speciﬁc proteases have been characterized to
date. Kex2 is a commercially available protein construct, which is
described to be speciﬁc to KR and RR sites.40 In silico digestion
of the human database targeting these dibasic residues yielded a
total of ∼175 000 peptides with average length of 123 amino
acids (Supporting Information, Figure S4). OmpT is an outer
membrane protease that has less speciﬁc dibasic-site preference,
and, similar to Sap9, another aspartic protease described in the
literature, this protease is supposed to target sites where two
consecutive basic amino acids such as K and R are present.32,39,41
In practice, neither Sap9 nor OmpT is an exclusively dibasic-site-
speciﬁc protease.
When all dibasic site cleavages were allowed, the number of
potential peptides was increased to >240 000, with average
length of 75 amino acids (Figure S4 in the Supporting
Information). As summarized in Table S1 (Supporting
Information), by employing dibasic site cleavage for the human
proteome, the number of peptides increases for the high mass
range regions, except for the case when all dibasic site cleavages
are allowed. In this latter instance, the number of BUP and eBUP
peptides and their respective information value (number of
proteins represented by unique peptides) were similar.
Contrary to expectations, targeting the dibasic sites does not
oﬀer advantages regarding protein identiﬁcations by analysis of
long peptides, as 34.9% of proteins did not yield >15 kDa
peptides. Also, as shown in the Venn diagram in Figure 3, top
panel, when targeting all dibasic cleavage sites, all three peptide
mass ranges carry unique protein information. Therefore, when
this digestion strategy is chosen, it would be beneﬁcial to analyze
peptides in at least two diﬀerent size ranges. Although dibasic-
site-speciﬁc cleavage can be employed in all proteomics regimes,
BUP could be slightly more beneﬁcial than either eBUP orMDP,
considering that analysis of 48 600 short peptides can lead to the
identiﬁcation of 76% of all human proteins. eBUP, MDP, and
even the >15 kDa region contain a very large number of peptides,
requiring higher instrument eﬀort than analysis of short peptides.
On the basis of the information in Table S1 in the Supporting
Information, top-down analysis of the 28 761 >15 kDa peptides
can identify 79.5% of proteins. As expected, the less frequent
digestion occurrence also yielded fewer peptides in all other
peptide regions. Moreover, combined analysis of all three peptide
regions left as much as 15% of all human proteins unidentiﬁed,
suggesting that Kex2 digestion is most suitable when top-down-
type analysis (>15 kDa peptide analysis) is sought, Figure 3,
bottom panel.
Aspartic Acid, Asp (D)
One of the ﬁrst digestion approaches targeted for MDP was
microwave-assisted hydrolysis C-terminal to aspartic acid (D)
using formic acid or acetic acid and short (order of minutes)
microwave irradiation times.42 An estimated 3.8% of human
ribosomal amino acids are D, whereas tryptic sites (K and R)
constitute 21.65%; therefore, trypsin cannot be used for
comprehensive sequence analysis of these proteins. Swatkoski
et al. obtained identiﬁcation of 58 ribosomal proteins following a
20 min microwave-assisted acid hydrolysis that yielded peptides
in the 500−5000 Da mass range.42c Although this technique was
found to be beneﬁcial for analysis of this select class of proteins,
the strong cleavage conditions may lead to loss of phosphate
groups and therefore cannot be used for unambiguous PTM
localization.42c AspN and AspC are metallo-endoproteases that
selectively cleave the peptide bond N and Cterminals to D
residues, respectively. Therefore a similar peptide size distribu-
tion may be obtained with them as with acid hydrolysis without
the detrimental loss of phosphate groups.34 According to the
peptide size distribution after digestion of the human proteome
targeting D amino acid (Figure 1a,d,g, diagonal line, DD),
cleavage yielded 266 783 theoretical peptides in the BUP region,
111 257 in eBUP, and 24 360 in MDP.
Statistical analysis of the yeast and bacterial proteomes oﬀers a
similar picture on the utility of targeting D for proteomic
analyses. In silico digestion of yeast yielded 88 298 peptides in
the BUP region, 28 976 in the eBUP region, and only 4658 in the
MDP region (Figure 1). The number of long, >15 kDa peptides
was 301. BUP can therefore identify 92.1% of the yeast
proteome, whereas eBUP can identify 90.5% assuming that
Figure 3. Venn diagrams (not to scale) of the number of unique
peptides and percent of human proteins identiﬁable by BUP, eBUP, and
MDP approaches using dibasic site-speciﬁc proteolysis with cleavages
(top) at all combinations, KK, RR, KR, and RK, and (bottom) only at
KR and RR sites.
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identiﬁcation of a single unique peptide is suﬃcient for conﬁdent
protein identiﬁcation. Similarly, 40 415 BUP, 13 593 eBUP, 2185
MDP, and 140 >15 kDa peptides were found in bacterial
proteome, corresponding to identiﬁcation yield of 96.3 and
91.6% in BUP and eBUP, respectively. The number of eBUP
peptides was three times lower than those in the 0.6−3 kDa
region; therefore, the sample complexity can be greatly reduced.
Considering that a similar number of proteins may be identiﬁed
in BUP and eBUP, it is apparent that targeting D amino acid in all
kingdoms is beneﬁcial, and, as illustrated in Figure 4, top panel,
analysis of peptides only in the 3−7 kDa region can provide
similar information as BUP analysis.
Glutamic acid, Glu (E)
Certain protein families, for example, histones, are highly rich in
basic residues K and R; therefore, proteases targeting these
cleavage sites yield very small peptides with uninformative
sequence. GluC (Staphylococcus aureus Protease V8) is a serine
protease that has been shown to cleave selectively at C terminal
to E and has been previously used for mapping histone H3
PTMs.43
As shown in Figure 1b,e, in silico digestion of the yeast
database targeting cleavage after E yielded 97 667 peptides in the
BUP region compared with 26 560 with 3−7 kDa sizes.
Presuming that MS/MS analysis and identiﬁcation of all of
these peptides is feasible, BUP can identify 93.4% and eBUP can
identify 88.8% of the yeast proteome. Similarly, cleavage of the E.
coli and human databases at E residues yielded about four times
fewer peptides in the eBUP range than in BUP range, and these
peptides represent ∼90% of the bacterial and human proteomes,
respectively.
GluC digestion to with BUP can therefore be feasible for
protein identiﬁcation in less complex proteomes, such as
bacteria, where the separation and analysis of the maximum
number of peptides is not technically challenging. For more
complex proteomes, eBUPmay bemore advantageous given that
a comparable number of proteins may be identiﬁed with a smaller
number of required MS/MS spectra (Figure 4, middle panel).
Asparagine, Asn (N)
Currently, no enzymatic or chemical cleavage method exists that
is exclusively selective to N, regardless of the neighboring
residues. N is a more frequently occurring amino acid in yeast
(6.12%) than in human (3.6%) and bacteria (3.95%). Cleavage at
all N residues yielded 92 866 peptides in BUP, 29 146 in eBUP,
and 4351 peptides in theMDP range (Figure 1). In E. coli, 27 949
BUP and 13 656 eBUP peptides were obtained due to the rarer
occurrence of this amino acid in this species.
Hydroxylamine has been shown to selectively cleave the N−G
peptide bond; however, by using reducing agents and longer
interaction times, the cleavage of N−L, N−M, and N−Awas also
observed.44 These select cleavages can be beneﬁcial for analysis
of long peptides; as shown in Figure 4 bottom panel, eBUP may
identify 62.6% of human proteins, whereas MDP analysis could
identify 73.2% of the human proteome. The combination of the
two techniques may lead to identiﬁcation of 85.4% of human
proteins.
Tryptophan, Trp (W)
2-(2′-Nitrophenylsulfonyl)-3-methyl-3-bromoindolenine
(BNPS)-skatole is a brominating reagent that cleaves peptide
bonds C terminal toW.45 Another well-established protocol uses
o-iodosobenzoic acid; the yield is 80% with few side reactions. W
is one of the rarest amino acids in all three species studied;
however, the number of peptides in the BUP and eBUP regions
were comparable to those obtained in MDP ranges for all three
species (Figure 1). Yeast yielded 9270 BUP and 9529 eBUP
peptides (Figure 1b,e), whereasMDP and TDP ranges contained
8641 and 6535, respectively (Figure 1h,k). As expected, the
number of proteins identiﬁed by analysis of unique small and
midrange peptides was only 56.3 and 62.9%, respectively.
Unexpectedly, targetingW in the E. coli and human proteomes
resulted in a greater number of BUP peptides than in eBUP. This
could be indicating the preferential positioning of W residues
toward protein termini; cleavage at this residue resulting in a
short (6−30 amino acids) peptide and the complementary
remainder protein fragment. In E. coli, digestion at W residues
can enable identiﬁcation of 66.6% and 70.0% of the proteins by
BUP and eBUP, respectively (as shown in the Venn diagram in
Figure S10, Supporting Information). A similar trend was
observed for the human database. Contrary to the expected
beneﬁt of MDP, combined BUP and eBUP analysis provided
unique peptides suitable for the identiﬁcation of 85% of the
human proteins (Figure 5 top panel). This is a clear illustration of
how prior knowledge of the amino acid distribution of the
proteome can aid in decision on the working regime.
Figure 4. Venn diagrams (not to scale) of the number and percent of
human proteins identiﬁable by unique peptides in BUP, eBUP, and
MDP approaches using cleavage at (top) D, (middle) E, and (bottom)
select N−X.
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Cysteine, Cys (C)
2-Nitro-5-thiocyanobenzoic acid (NTCB) is a reagent that yields
peptides with N-terminal C. The resulting peptides will be
modiﬁed by an iminothiazolidine-carboxyl group.46 C is a rarely
occurring amino acid; therefore, a large number of long peptides
(7−15 kDa) would be expected as a result of C-site speciﬁc
digestion. However, as seen in Figure 1b,e,h, in the yeast
proteome very similar numbers of BUP, eBUP, and MDP
peptides are to be expected, and analysis in either regime would
identify ∼70% of the proteome. Surprisingly, digestion of the
bacterial proteome yielded four to ﬁve times more peptides in the
BUP region than in eBUP or MDP, and a similar trend was
observed for the human proteome. It would therefore be
unusually beneﬁcial to perform the combined analysis of the
BUP and MDP peptides to achieve identiﬁcation of 94.6% of
human proteins, as shown in Figure 5, middle panel.
Methionine, Met (M)
CNBr is a toxic reagent that has been used for decades for
attaining cleavages N-terminal to M.47 The three kingdoms
studied again presented diﬀerent trends of peptide size
distribution when cleaved at M. Yeast showed comparable
number of peptides in the three mass ranges, allowing
identiﬁcation of ∼80% of the proteome in either regime. A
dramatic diﬀerence in the number of BUP peptides was obtained
for bacteria, yielding 15 325 BUP peptides that represent as
much as 95.5% of the proteome. Analysis of eitherMDP or eBUP
peptides would be less beneﬁcial in this case. Contrary to the
expected large number of long peptides, the human proteome
showed a uniform distribution of short, medium, and long
peptides. Combined analysis of any two peptide regimes would
therefore allow identiﬁcation of ∼95% of the human proteome,
as indicated in Figure 5, bottom panel.
Pairwise Cleavages
We investigated in detail those pairwise cleavages that would
maximize the number of proteins identiﬁed in the 3−7 kDa
eBUP range, with the least number of peptides analyzed. In brief,
the peptide size distribution was investigated by in silico cleavage
at the ﬁrst amino acid, followed by a cleavage of peptides >7 kDa
at the second amino acid. Therefore, the most logical choice was
the coupling of two rare amino acid cleavage sites, while keeping
in mind the practical feasibility of the experiment. For example,
methionine oxidation can be induced by various experimental
steps; therefore, it would be beneﬁcial to target this amino acid as
ﬁrst cleavage site.
C followed by W. The peptide size distribution after two
sequential cleavages was investigated by in silico cleavage at C,
followed by a second cleavage of peptides >7 kDa at W. As a
result, the number of short and medium-length peptides
increased when compared with the number of peptides
obtainable by single cleavages. For the yeast and bacterial
databases the number of peptides in the 7−15 kDa (MDP)
region also slightly increased when compared with the individual
C orW cleavages (Figure 1). In contrast, for the human database,
the number of MDP peptides remained very similar, or slightly
decreased when compared with individual W and C cleavages,
respectively. However, a second digestion at W of the 38 381
MDP peptides obtained after C cleavage resulted in 39 463 more
BUP peptides, and 37 064 more eBUP peptides than C cleavage
alone. Because 34 331MDPpeptides still remained, it is apparent
that 4050 very long (>15 kDa) peptides exist in the human
database that are highly rich in W. One source of such peptides is
NADH dehydrogenase (UniProt accession O95167), a 9.3 kDa
protein with no C residues and two W amino acids in close
proximity of both termini. This sequential cleavage increases the
number of proteins identiﬁed for all databases in BUP and eBUP
regimes, and the most signiﬁcant improvement was estimated for
the human database. As shown in Figure 6, top panel, the overall
number of proteins that can be identiﬁed in the human database
using pairwise C and W cleavage increased in all mass regimes,
and a combined analysis of BUP and eBUP peptides left only
2.6% of proteins unidentiﬁed versus 15% for individual W
cleavage and 6.7% for C, respectively.
M followed by W
Targeting M followed by W yielded signiﬁcant improvement in
the number of proteins represented in BUP and eBUP regions
for all databases when compared with individual W and M
cleavages (Figure 1). For the E. coli and human databases, 92 and
91.1% of proteins were represented in the BUP region, and 93.4
and 94.1% of proteins were represented in the eBUP region,
respectively. In contrast, this cleavage combination was not as
beneﬁcial for the yeast database, with a modest 85.3% of proteins
represented in BUP and 88.8% in the eBUP region. As shown in
Figure 6, middle panel, 99.3% of human proteins can be
identiﬁed by a combined analysis of the three mass regions, with
the eBUP range oﬀering the most identiﬁable proteins
individually (94.1%).
Figure 5. Venn diagrams (not to scale) of the number and % of human
proteins identiﬁable by unique peptides in BUP, eBUP, and MDP
approaches using cleavage at rare amino acids: (top) Trp (W), (middle)
Cys (C), and (bottom) Met (M).
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M followed by C
The last pairwise cleavage exempliﬁed herein yielded peptides
representing a higher number of yeast and human proteins in the
short andmidrange peptide regions when compared with the two
previous examples. This improvement comes with the added
beneﬁt that in the case of yeast the number of peptides required
to identify more proteins in the eBUP region is decreased. For
the human proteome, this cleavage pair yields slightly more
proteins identiﬁed than the C−WandM−Wcleavages (Figure 6,
bottom panel), leaving only 0.6% of proteins not represented in
the three mass regions. This slight improvement, however,
comes at the price of a signiﬁcant increase in the number of
peptides generated.
Comparison of Proteomics Approaches
Figure 7 shows a general overview of the results previously
presented and summarizes the potential of the three techniques
(MDP, eBUP, and BUP) for the in-depth characterization of the
human proteome. The total number of peptides produced by
each pairwise cleavage presented in Figure 7 was plotted against
the percentage of proteins identiﬁable by unique peptides in the
three mass ranges. Figure 7a shows the proteome coverage range
between 10 and 100%, whereas the inset in Figure 7a,b shows
expanded regions of the proteome coverage axis, between 90.5
and 94% and 95−98.5%, respectively. It becomes apparent that
identiﬁcation of tryptic peptides in the classical BUP mass range
(Figure 7a) oﬀers the highest proteome coverage (98.61%). This,
however, can be achieved with the identiﬁcation of ∼574 000
peptides. In practice, even the most modern, state-of-the-art MS
instruments are not capable of achieving this performance.
Michalski et al. was able to detect in excess of 100 000 peptides in
MS mode in a 90 min gradient; however, only ∼16 000 of these
yielded identiﬁable MS/MS spectra with the search parameters
utilized.5a Increasing the gradient length does not scale
proportionally with the number of peptides characterized; in a
4 h gradient Wisniewski et al. identiﬁed ∼40 000 peptides.15
Utilizing an LC-ion mobility separation approach, as it is
available on the Waters Synapt G2 instruments, allows for a
three-fold increase in the protein identiﬁcation rate when
compared with a data-dependent LC-MS/MS approach.48 This
improved duty cycle is possible due to the high speed of the time-
of-ﬂight mass analyzer coupled to the data-independent peptide
fragmentation. However, despite recent improvements in nano-
LC separation technologies and MS instrumentation, the speed
of peptide fragmentation and analysis does not allow the timely
identiﬁcation of all peptides, and implicitly of proteins, from a
highly complex proteome. It is also apparent from Figure 7b that
a multitude of cleavage sites can be targeted for BUP analysis. For
example, a combination of consecutive cleavages at E and R (or
vice versa) would decrease the number of peptides by ∼100 000
in BUP with a loss of only 0.5% of identiﬁable proteins.
In contrast, none of the MDP approaches described herein
allows for identiﬁcation of more than 80% of the human
proteome (Figure 7a, blue dots). The most optimal cleavage site
was found to be Cys, oﬀering the possibility for identiﬁcation of
77.2% of the human proteome, albeit with only∼38 000 peptides
in the 7−15 kDa range. Digestion at all possible dibasic sites or at
Trp would be slightly less optimal, permitting identiﬁcation of
73.5 or 76.6% of the proteome, respectively, with ∼37 000
peptides. The LC separation eﬃciency of these peptides may be
reduced because of their length. In addition, current MS
instruments require signiﬁcantly longer acquisition times for
the MS/MS spectra of these larger species. This greatly reduces
the duty cycle and number of peptides that can be identiﬁed in a
single LC−MS/MS experiment.
The inset in Figure 7a,b shows the performance of several
eBUP approaches (red dots). It becomes apparent that several
digestion protocols are suitable for the identiﬁcation of >90% of
the proteome with a single-step, well-established protocol.
Digestion with LysC or GluC and analysis of the 3−7 kDa
peptides are therefore the simplest means for reducing sample
complexity while achieving high proteome coverage. It is not
surprising that combination of a cleavage at a rare amino acid site
(M orW) followed by a second digestion of the long peptides at a
more frequent amino acid (D, K, R) or vice versa, optimizes the
number of peptides in the 3−7 kDa size range. With such two-
step cleavages, up to 97% of the human proteome could be
identiﬁed, with as few as ∼125 000 peptides. The separation of
these midsize peptides is less challenging, and the MS
instrumentation parameters (fragmentation, ion accumulation,
transfer, and detection) are closer to those required by a classical
BUP experiment, as previously discussed.
■ CONCLUSIONS
On the basis of our ﬁndings, we propose that the analysis of
peptides in the 3−7 kDa range is more optimal than targeting
bottom-up (0.6−3 kDa) or middle-down (7−15 kDa) peptides
Figure 6. Venn diagrams (not to scale) of the number and percent of
human proteins identiﬁable by unique peptides in BUP, eBUP, and
MDP approaches using two-step cleavages at amino acid pairs: (top)
Cys (C) followed by Trp (W), (middle) Met (M) followed by Trp (W),
and (bottom) Met (M) followed by Cys (C).
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due to several reasons. First, the number of theoretical peptides
is, in some cases, an order of magnitude lower than that in the
bottom-up regime. This may lead to the detection of a larger
fraction of peptides on a chromatographic time scale. In addition,
the identiﬁcation of longer peptides inevitably oﬀers better
sequence coverage than short peptides, which can improve
protein identiﬁcation and may enhance PTMs localization
eﬃciency. It was also demonstrated that it is desirable to
maximize the number of proteins represented while minimizing
the number of unique 3−7 kDa peptides. Theoretically, two-step
cleavages targeting two distinct rare amino acids (combination of
W, C, or M) are more appropriate for this purpose than targeting
Figure 7.Comparison of the performance of the BUP, eBUP, andMDP approaches for identiﬁcation of the human proteome shown as a dependence on
the number of peptides on the percent of proteins represented by unique peptides. The total number of peptides shown on the y axis corresponds to
Figure 1 and describes peptides produced in a single digestion or in a two-step process with a cleavage at the ﬁrst amino acid, followed by a cleavage of
peptides >7 kDa at the second amino acid. Also shown are the data corresponding to the cleavages by trypsin and dibasic enzymes. (See Table S1 in the
Supporting Information.) The dotted black lines represent examples of detectable and identiﬁable peptides in a 90 min and 4 h LC−MS/MS
experiment, respectively. The dotted red line shows the total number of peptides detected from a 90 min LC gradient reported in the corresponding
reference.
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a single cleavage site. In contrast, the analysis of long (7−15 kDa)
peptides alone did not seem to provide the expected advantages
foreseen by promoters of the middle-down approach. None of
the individual cleavage sites or a two-step cleavage seem to be
yielding a complete protein identiﬁcation for whole protein
databases. It is also apparent that because of the variability in the
amino acid frequencies of diﬀerent species a diﬀerent protease,
chemical, or combination of these might be required for optimal
protein identiﬁcation. Therefore, to increase the number of
proteins represented by these very long peptides, the digestion
approach should be carefully tailored toward the subset of
targeted databases or protein families studied. In the Supporting
Information, a comprehensive analysis of all pairwise cleavages
has been included for the yeast, bacterial, and human databases.
This information can be further mined for the judicious selection
of the cleavage agents for assessment of these species.
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Proteome digestion specificity analysis for rational design of extended 
bottom-up and middle-down proteomics experiments 
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Tsybin* 
Table S1. Number of peptides in the human protein database for the dibasic site 
cleavages in the different peptide mass ranges. Also included are the percentage values of 
proteins that can be identified with at least one peptide by each cleavage, if peptides from 
a single mass range are analyzed. 
 
Figure S1. The relative frequency of amino acids for the three species studied. 
?????????????????
???????????????????????? ??????????????????????
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Figure S2. Theoretical distribution of LC unique peptides in the human (left), yeast 
(middle), and bacteria (right) proteome after two-step cleavage within a) 0.6-3 kDa, b) 3-7 
kDa, c) 7-15 kDa, and e) >15 kDa ranges. 
 
?????????????????
???????????????????????? ??????????????????????
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Figure S3. Theoretical distribution of proteins that remain unidentified in the human 
(left), yeast (middle), and bacteria (right) proteome after analysis of strictly unique peptides 
within a) 0.6-3 kDa, b) 3-7 kDa, c) 7-15 kDa, and e) >15 kDa ranges obtained after a two-
step cleavage. 
?????????????????
???????????????????????? ??????????????????????
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Figure S4. Peptide length distribution of unique peptides from dibasic-site specific 
digestion of the human proteome.  
?????????????????
???????????????????????? ??????????????????????
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Figure S5. Venn diagrams of the 
number and % of yeast proteins identified 
by unique peptides in BUP, eBUP, and 
MDP approaches using (top) tryptic 
proteolysis (both K and R-specific 
cleavages); (middle) only K-specific 
cleavage; and (bottom) only R-specific 
cleavage. 
 
Figure S6. Venn diagrams of the 
number and % of bacterial proteins 
identified by unique peptides in BUP, 
eBUP, and MDP approaches using (top) 
tryptic proteolysis (both K and R-specific 
cleavages); (middle) only K-specific 
cleavage; and (bottom) only R-specific 
cleavage.  
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Figure S7. Venn diagrams of the number 
and % of yeast proteins identified by 
unique peptides in BUP, eBUP, and MDP 
approaches using cleavage at (top)D; 
(middle) E; and (bottom) select N-X. 
 
 
 
Figure S8. Venn diagrams of the 
number and % of bacterial proteins 
identified by unique peptides in BUP, 
eBUP, and MDP approaches using 
cleavage at (top) D; (middle) E; and 
(bottom) select N-X. 
. 
?????????????????
???????????????????????? ??????????????????????
113
 
Figure S9. Venn diagrams of the 
number and % of yeast proteins identified 
by unique peptides in BUP, eBUP, and 
MDP approaches using cleavage at rare 
amino-acids: (top) Trp (W); (middle) Cys 
(C); and (bottom) Met (M). 
 
Figure S10. Venn diagrams of the 
number and % of bacterial proteins 
identified by unique peptides in BUP, 
eBUP, and MDP approaches using 
cleavage at rare amino-acids: (top) Trp 
(W); (middle) Cys (C); and (bottom) Met 
(M). 
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Figure S11. Venn diagrams of the 
number and % of yeast proteins identified 
by nique peptides in BUP, eBUP, and MDP 
approaches using two-step cleavages at 
amino-acid pairs: (top) Cys(C) followed by 
Trp (W); (middle) Met (M) followed by Trp 
(W); and (bottom) Met (M) followed by Cys 
(C). 
 
 
Figure S12. Venn diagrams of the 
number and % of bacterial proteins 
identified by unique peptides in BUP, 
eBUP, and MDP approaches using two-
step cleavages at amino-acid pairs: (top) 
Cys(C) followed by Trp (W); (middle) Met 
(M) followed by Trp (W); and (bottom) Met 
(M) followed by Cys (C). 
 
?????????????????
???????????????????????? ??????????????????????
115
?
 
 
 
 
 
 
 
 
 
4.4. Paper II: Practical consideration for improving 
the productivity of mass spectrometry-based 
proteomics 
 
 
 
 
 
 
 
  

117
???????????????????????? ??????????????????????
?????????????????
??? ??? ?? ????? ??? ??? ? ?????????? ?????? ??? ??????? ??? ???? ??????? ????
??????????????? ??????????? ??? ?? ?? ?????? ??????? ? ?????????????? ????????? ????????????
???????????????? ????? ??? ?? ?? ???????
????? ??? ?? ??? ?? ??
??????? ???????????????????
????????????? ???? ???????????? ??????????
????? ????????????? ???????? ?? ????????
???? ???? ??? ????
??????? ????????
??????????? ?? ???????????
?????? ??????????? ????????????? ???????
??????? ????????
????????? ?????????????? ??? ? ??????? ???
???????????? ?? ???? ??????????????????
??????????
????? ?? ????????? ???????? ????????? ?? ???? ?????????? ????? ?????? ????? ?? ??????????
?????? ??????? ??? ???? ?? ????????
???????????? ?????????? ????? ??? ???? ???? ????????????
????????? ???? ???????????? ? ?? ?? ????????? ??? ???? ????????? ??? ????????? ?????????? ????????? ??? ???????
??????? ??? ??????? ????????? ????????? ???????? ?????????? ?? ????? ?? ?????? ???? ???????????? ? ??
??? ?? ?????? ????????? ????? ???????? ??????? ????????? ???? ??? ?????????? ?? ??? ??? ?????? ????????? ??
???????? ???????? ?? ???????? ??????? ????????????? ?? ????? ????????????????? ???????? ????? ???? ???????? ??
??? ????? ???? ??? ??? ????? ?? ??????? ????????? ????????? ???????????? ?? ?????????????????? ????????????? ???
?????????????? ?? ?????? ????????? ????????? ?????????? ?? ???????? ??? ??????? ??????????????? ??????? ??????????????
??? ???????????? ???? ??????? ?????????? ???????? ??? ???????? ??? ????? ????????????? ???????? ???? ????? ????????
???? ???? ??? ? ???? ????????? ????? ??? ?????????? ?? ?? ?? ?????? ??????? ????????? ??????????? ??????????
??????????? ?? ???????? ??? ?? ???????? ?? ????? ?????????? ????? ????????? ????? ????????? ???????????
?????????? ??? ???????? ???????? ????? ??? ???????? ??? ???????? ???? ???? ????? ???? ???????? ??? ??????????
??????????? ???????? ?? ??? ????? ???????? ?? ??? ???????? ??????? ???? ???????????? ?? ??????????????? ??
??? ?????? ??????????? ??????? ? ???????????? ?? ??? ??????????? ???????? ??? ???? ???? ????????? ???????
?? ??????? ??? ?????? ?????????????? ???????????????? ?????? ????? ?????? ?? ??? ??????????? ?????????
???????? ??????? ???? ??????? ??????????????
????????? ???????? ???????? ???????????? ????? ? ????????????? ??????????? ???????????? ????? ?
?? ???? ??????????? ? ??????????? ?????????? ? ??????????? ?????????????
?????? ??????? ???????? ????? ????
???????????? ???? ?? ??????? ?? ??????
??? ????????? ?????????? ??? ????????
???????????? ?????? ??? ?????? ?????????
?? ??? ???? ?? ??? ?????? ????? ??? ????
???????? ???????? ?????????? ??? ????
??????? ????????? ??? ??? ????? ??????
??? ??????????? ?????????????? ?????
????????? ?????????? ??? ?? ?????????
?? ????? ?????????? ??? ??????????????
???????????? ???????? ??? ???????????
?????????? ??? ???? ?? ????????? ??????
?????????? ??????????????? ?????????? ????
?? ??????? ????????? ??? ????????? ?????
????? ???????? ??? ????????? ?? ?????????
??????? ?????????????? ????? ???????????????
????????? ?????????? ?? ?????????
???? ??? ??????????????? ??????? ?????????
??????? ????????????? ??? ???????? ?????????
?????? ?? ?????????????????? ?????????????
??????? ????? ???????? ??? ??????? ????
????? ????? ???? ??? ? ???? ???????? ???? ??
??????? ??????? ???????? ??? ???????? ???
????????? ?? ? ??????????????? ??????
??? ???????? ????????????? ????????? ?????
?????????????? ?????? ???? ????????????
???? ??? ???????????? ????????? ??? ????
??????????? ??? ?????? ????????? ?? ????????
??? ???? ??????? ?????????? ?? ??? ?????
???????? ?? ????????? ?????????? ????? ????
?????? ??? ???????? ???? ?????? ???????
???????? ????? ??? ??????????????? ?????
?????????? ?? ????????? ?? ???????? ?? ????
????? ???? ? ?????? ??????????????? ???
????? ????? ??????????? ????????? ??? ???
?? ?????????? ?????? ??? ???? ?? ????????
?? ???????? ??? ??????? ?? ??? ???? ?????
???? ????????????????? ???????????? ?????
?? ????????????? ??????????? ????????????
????? ?? ????? ??????? ???????? ?? ???????
???? ?????????? ??? ??? ?????????????? ?? ???
???? ??????? ?? ???????????????? ????????
????? ??????????? ?????????? ??????? ???? ??
???????????? ???????? ?? ??? ???? ????????
?????? ????????? ???????????? ?? ???? ??
??????????? ???????? ??????? ??? ?????
???? ???????? ???????????? ???? ??? ????
??? ?????????? ???? ??? ?? ???? ??? ?????
????????? ?? ???????? ??????? ?????????
????? ??? ???? ????????? ?? ??? ???
??? ?? ???? ??? ?????? ???? ??? ??????????
???????? ????????????? ?? ???????? ????
????? ???? ???? ????? ??????? ?? ???????????
??? ??? ??? ? ??????? ?? ????? ??? ?????
??????????????
???????? ? ???? ?????? ?? ????????
??????? ??? ????????? ????????? ????????
???? ???? ???????????? ???????? ???????
??????? ??????????? ??????? ???? ??? ????
?????? ?????????? ??? ??????? ??????????
??? ??????????????? ????????????? ??????????
??????? ????????? ??????? ????????? ??
???????? ?? ? ???? ????????????? ?????? ???
?????????? ????????? ?? ????? ????? ?? ????
?? ????????? ?? ????????? ????? ???????
????????? ?????? ??????????? ??? ?? ???
??????? ?????????? ???????????? ?? ??????
?????????????? ??? ??? ???? ???????? ???
???? ??? ? ????? ???? ??? ???? ????????
118
???????????????????????? ??????????????????????
?????????????????
?????????? ?????? ??? ??????? ??? ???? ??????? ???? ??? ?? ????? ??? ??? ? ???
??????????? ??????????????
???????? ??????? ?? ? ???????????????
???? ???????? ???? ?? ????????? ???? ?? ????
?????? ??????????? ?? ?? ??? ?????? ????? ??
???????? ???? ?? ????????? ?? ????? ?????
???????? ?????????????? ?? ????? ?? ?????????
??? ??? ?? ??????????? ??? ?? ??? ?? ??????
???? ??? ???????? ??????? ????? ??? ?????
????? ?? ????????? ??????? ?? ?????? ?????
????????? ????????? ?? ????????? ?? ??? ?
???? ?? ????????? ?? ??? ???????? ???????
????????? ???? ???? ?? ??????? ??????? ?????
?? ? ?????? ??????? ??????? ??????????
???? ?? ????? ???????? ??? ?? ?????????
?? ??? ????????? ?? ?????????? ?????? ?????
????????? ????? ????????????? ???? ?????
??? ??? ????? ??? ??????? ????? ??? ?????
??????? ???? ??? ???????? ?? ?????? ?? ?
?????????? ??????? ????????? ???? ????????
??? ??????? ??????? ???????? ????? ????????
??? ???? ??? ?? ??????? ????? ?? ????????
????? ????????? ?????? ??????? ??????
???????? ???????? ?? ??? ?????????? ????????
?????????? ???? ??? ???? ???? ?? ??????
????? ?? ?? ????????? ????????? ?? ???????
??? ??????????? ?? ???? ???????? ????? ????
????? ?? ???????? ????? ???? ???????? ???? ?
???????? ?????????? ?????
??? ?????? ?? ??? ????? ???????? ???
???? ?? ???? ?? ????? ??? ????????? ???? ???
????? ????? ???????? ???? ???????? ?? ?????
??? ???????? ??????? ????????? ??? ??????
?? ???????? ??????? ?? ???????????? ???? ?
????? ??? ??????????? ??????? ???? ?????????
???? ?? ??????????? ???????? ???????? ???
?? ?????? ????????? ?? ??? ?? ???? ?????????
???? ???? ?????? ????????? ???????? ????
??????? ???? ?????? ??? ???? ? ????????
???? ??????? ?????? ???? ??????? ????? ???
???????? ????? ????? ?????? ???????? ???
??????? ???? ?????? ??????? ???????? ? ?????
?????? ?? ???????? ???????? ???? ??????
?????????? ??????? ?? ????? ???? ??????
??? ?????? ????? ?? ???? ????? ???? ?????
???? ??? ??? ?? ??????? ?????? ?? ???? ????
?????? ?? ????????? ??? ??????? ???? ????????
??????? ??? ??????? ????????? ???? ??????
?????? ??? ?????? ????? ?? ????? ????????
??? ??? ?? ??????? ?????? ?? ???? ?????????
??????? ??? ???????? ???????? ???? ???????
??????? ???????? ??? ???? ????????? ????
???????? ?????? ??? ?????? ????? ???? ????
?????? ??? ??? ?????? ???? ??? ?????????
??????? ?????????? ?? ????? ???? ?? ????
?????????? ????????????? ??? ??????? ???? ??
?????? ????? ? ????? ???????? ??????? ??
? ??????? ? ?????? ?? ???????? ?? ??? ?????
??? ???????? ??? ?? ????????? ???? ?? ???
??????? ???? ??????????? ???? ????? ??????
??????? ???????? ????? ???????? ???????
??????? ????? ????????? ???? ??????????
???? ???????? ???? ????????????? ??????
??????????? ???? ??? ??? ? ????????
???????? ?? ???????? ?? ????? ???????? ??
? ???? ???????????
????????? ??? ??????????? ???? ?? ??????
?? ??? ?????????? ???????? ??? ???????? ??
????????????????? ????? ???? ??? ?? ????
?????? ???????? ?? ???? ??????????? ???
?? ??????? ??????? ?
??? ?? ???????
????? ??? ???????? ??????? ?? ? ????? ???
?????? ??? ?????????????? ???????????
???????? ?? ???? ????????? ??? ????????
???? ??? ??? ?????????? ???? ?? ?????????
??????? ?? ??? ????? ?? ????? ??????? ????
?????????? ?? ?????????? ??????????? ?? ????
?????? ?????????? ?? ???? ???? ????????
??? ??????? ?? ???????? ???????? ??????
?????? ????????? ????????? ?? ? ??????? ?? ????
???? ?? ???? ??? ???????? ???? ?????????
?????? ??????????????? ??? ??? ?????????
?????????? ????????? ??? ???? ????????????
??? ?????????????? ?? ???? ???????? ?? ???
?????????????? ?? ??? ???????? ??? ????
???????? ???????? ???????? ??????? ?????
????????? ?? ??? ?????? ?? ????????? ??
?? ???????? ???????? ?????? ??? ????????????
??????? ??? ???????? ??????? ??? ??? ?????
??????? ??????? ???????? ?? ????????
?? ????????? ???????? ?????????? ??
??? ???????? ?????? ??? ??? ???????? ??
?????? ????????? ??????????????? ?????????
?????? ?? ???????? ??? ?????? ???????? ???
???? ???????? ?? ?????? ?????? ??????? ??
?????????? ?? ???????? ???????? ?? ????
??????????????? ??? ??????????? ????????
???? ?????????????? ??????????? ????
???? ???????? ?? ??? ?? ??? ?????? ????
????? ??????? ??? ??? ?????????????? ?? ???
???????? ??????? ?? ???? ?????????? ?????
?????????? ??? ???????????? ?? ???? ????
????? ????? ???????? ??????????? ???? ???
????????? ?????????? ???? ???????? ?? ????
????? ????????????? ???????? ?? ???????
???? ? ??????? ????????? ????????????????
????????????? ??? ???????? ?????? ?
???? ???? ????????? ????? ?? ? ???????
??????????? ???? ??????? ?????? ?????
?????? ??? ?????????? ??? ??????? ??????????
???? ?? ????????? ??? ?? ??????? ????????
??? ????????? ?? ?????????? ?? ???????? ??
??????????? ???? ????????? ?? ??????? ????
?? ?? ??? ????????? ????? ???????? ??? ????
???? ?? ???????? ?????? ?????? ?? ??? ????
????????? ?????????? ???????? ????? ????
??????????? ??????? ???? ?????? ??? ??????
???? ?? ??? ?????????? ??????? ???????? ??
????????? ??????? ????????????? ?? ????
?????????? ???? ??????? ??? ? ??????
???? ??? ??? ????????????? ???? ???????
????? ??????? ???????????? ???????? ??????
????? ??????? ??? ???????? ????????? ?
???? ?????? ?????? ?? ??? ? ????? ???
?? ???? ???? ?? ??????????? ??? ???????
??? ?????????? ?????? ?? ????? ????? ?????
?? ??? ???????? ????? ??????? ??????????
???? ?? ??? ????????? ??????? ??????? ?????
??????? ?? ? ??????? ???????? ????????
???????? ?? ????? ???????? ???? ???? ???
?? ????????? ??????? ????? ??????????
?????????????? ??? ? ???????? ?? ??????
???????? ?? ??? ???????? ????????? ?? ?? ???
???????? ???????? ?? ???? ??? ??????
?????????? ?????????? ??? ???????? ?????
???????? ???????? ???????????? ????? ?? ??
???????? ???? ??? ?????????????? ??? ??
???? ?? ?? ???????? ??????? ????????????
????? ?? ?????? ??????? ???????? ???
????? ???????????????? ???????? ?? ????
??? ???? ??????? ??? ?? ?? ?????????
????? ?? ??? ???????? ??? ??? ???????? ??
??? ????????? ?? ?? ??????????? ?? ????????
??????????? ?? ??????? ?? ???????? ??????
?????? ???????? ???????? ???? ???????????
???????????????? ??? ?? ????????????? ??
??? ??????? ?? ?????? ?????? ?? ??? ?????????
????????? ?? ????????? ?????? ??????????
???? ?? ??? ???????? ???????? ????? ?? ???
????????? ?? ?????? ??? ? ???????
??????????? ?????????? ?? ?? ???
?????? ???? ???? ?? ??????? ??? ????????
?? ????????? ??? ???????? ???????????
????? ?????????? ????? ???????????????
???????????? ????? ????????? ?? ??????????
???????? ??? ????????? ???????? ? ??????????
????? ????????? ??????????? ?? ???????? ??
???????? ??? ??????? ???? ?? ??? ?????????
???????? ????? ????? ?? ???????? ??????
??? ?? ??? ????? ?????? ?? ????????? ????
?????? ??? ?????? ?? ???? ??????? ???? ?? ???
????????? ????????? ??? ??? ? ????????
??? ????? ?? ????????? ?? ? ???????????????
??????? ????????????? ????????? ??????????
?? ????? ???? ???????? ??? ?? ??????? ????
?????? ?? ?????????? ???????????????
???????? ??? ??? ??????? ??????? ??? ??
???? ?????????? ??? ?????????? ?? ?????
?? ??? ????????? ????????? ????????? ???
?? ??? ????????? ?????? ??????????? ???
?????? ?? ?????????? ???????? ?? ???? ???
?????? ?? ???????? ??????? ?????? ????????
? ?????? ??????????? ???? ?? ????????? ???
????????? ?? ???? ?????????? ??? ? ?????
???? ???? ?? ?????????? ???? ?????? ???????
?????????? ???? ?? ??? ???????? ????? ??
????????? ??? ???? ????? ???? ?????? ???
?????? ??? ?????????? ?? ??? ???????? ???
????????? ??? ?????? ??? ?????????????? ??
???????? ???? ????? ? ?????????????
?????????? ?? ???????? ???? ????????
????? ??????? ???????? ?? ?????? ????????
?? ?? ??? ??? ??? ????????? ????????? ???
????? ????? ?? ??????? ??????????????
??? ??????????????? ?????????????? ?? ????
????? ??????? ????????? ???????? ??????
???????????? ??????? ??????????? ???????
???? ??????????? ????????????? ???????????
???? ??????????? ??? ???? ???????? ???? ??
????????????? ???????? ?? ???????? ?? ????
????????? ??????? ?? ????? ???????? ? ?????
???? ???????? ??? ??? ??????????? ???
?????? ???? ??????? ? ???? ????????? ????
???? ???????? ??? ??????? ?? ???? ???????
???????? ????????? ?? ????????? ?? ????
???? ??????????? ????????????? ????????
?? ???????? ??? ??????? ?????? ????? ?? ???
???? ????????? ???? ????????????? ??? ?????
????????? ??????????? ??? ??????? ????????
??? ????????? ??????? ?? ???? ????? ??? ?????
?????????? ??????? ?????????
119
???????????????????????? ??????????????????????
?????????????????
??? ??? ?? ????? ??? ??? ? ?????????? ?????? ??? ??????? ??? ???? ??????? ????
??????? ?? ???????? ??? ?????????????? ???
??? ???????? ??????????? ?????? ??????????
???????? ????????? ??????? ???????? ????
?????? ???????????? ??? ??? ????????
???? ???? ?? ?? ???? ?????????????? ???
??? ?????? ?? ??? ?? ????????? ?????????
?????? ???????? ??????? ??? ????? ?????
?????????? ?? ?? ??? ???? ??????????? ???
????????? ???????????? ???????? ???? ???
????? ?????? ??? ????? ?????? ????????
???? ???????? ???? ??? ?????? ???????????
?????????? ??? ??? ????????? ?? ? ?? ????
??? ??????? ??????????? ?? ??? ? ??? ???
?? ????? ? ?? ???? ???????? ???????
??????? ????????? ?????? ???????? ???? ???
?????? ????? ??? ???????? ????? ????
???????? ???? ? ?????????? ???????? ????
???????? ??? ???????? ???? ??? ??? ??????
?????????? ?????????? ?? ???? ??? ????
?????? ?? ?????? ?????????? ??? ??? ????
????? ??? ???? ??????? ???? ???????? ??
?????? ?????????? ???????? ??????? ????????
?????? ??? ????????? ????? ??????? ???
?????? ??????? ??? ??? ?????? ?????????
?? ????????? ? ????? ??????? ?????? ??????
??? ??? ???? ?????? ?????????? ?? ???? ?? ?
????????? ?????? ?? ????? ??????? ?? ???
??????? ??????? ????????? ???????? ??????
???? ? ????? ??? ???????? ????????
???????? ?? ??????? ???????? ??? ??????
????? ???? ????? ?? ???????????? ??? ???????
?????????? ?? ???? ?????????? ??? ????? ??
????? ???????? ????????? ??? ???? ????????
????? ?????????? ????? ????? ??????? ??
???? ??????? ???????? ??? ? ???????? ?????
????? ?? ??? ???????????? ??????????
????? ???? ????? ?? ?????????? ?????
? ????? ??????? ???????? ?????? ???? ????
?????? ???????????????? ?????????? ?????
?? ??? ???????? ????????? ????????? ???
??????? ??????????? ??? ??? ???? ???????
????????? ???????? ??????? ???????? ?????
???????? ????????? ??????? ??????? ????
??? ???? ??? ??????? ??????? ?????????????
??????? ?? ??? ??? ???????? ?????????
?? ?????? ?? ?????? ???????? ??????????
???? ?????????? ? ????????? ???????
?? ???????? ??? ???????? ????????
?????? ??????? ???????? ?? ??? ??????? ?????
??? ??? ??????????? ?? ??????????? ????
???????? ???????? ??????? ?????????? ????
??????? ???? ??? ????? ?? ???? ?? ??????
????????????? ???? ??????????? ???? ????
???????? ??? ????????? ???? ????????????????
??? ?????????? ?? ????? ????? ???? ?????
????? ??? ?????? ?? ???? ???????? ???? ???
?????????? ?? ??? ???????? ????? ?????????
?? ? ??????? ????????? ??? ??????? ????????
??? ???????? ?????? ???? ????????? ???????
???? ?????? ???????? ??? ???????? ????
???? ?????????? ????????? ?? ???? ?????
??? ???? ???????????? ???????? ???????????
???? ?? ???????? ???? ?? ?? ??? ??? ???
??? ?? ??? ?? ????? ????????? ??????????
??? ???????? ????????????? ??? ??????????
??? ??????? ??????? ???? ?????? ??? ?? ???
???? ?????? ??? ??????? ?????? ??? ????
???? ???????? ?????????? ??? ???????? ???
??????? ????? ???? ??? ?? ??? ??? ????
???????????? ????????? ?????????? ????
?? ???????????? ???????? ??? ????????? ?????
?????? ??? ?????? ?????????????? ????
?? ? ??????? ????????? ????? ??????? ?? ??
?????????? ?? ???????? ???????? ????????
??? ????? ???????????? ??? ?? ??? ???? ?????
?? ??????????? ?????? ?? ????? ????? ??????
?? ?????
????? ? ????? ???????? ??? ???????
???? ??????????
?? ??? ????????? ?? ?????? ?? ?????????
??? ????????? ???????? ?? ??? ??????? ?????
???? ???????? ???????? ???? ?????????????
???????? ????????? ??? ???????? ??????????
?? ?????? ????????? ??? ??? ????? ?? ????? ?? ??
???????? ?? ??? ????????????? ??????? ???
??? ?? ???????????? ???????? ???? ??? ??????
?????? ????? ??? ??????? ????????? ?? ???
???? ?? ???? ?????????
???? ?? ???????????
???????? ?? ??? ?????
??????? ????? ???
?????? ??? ?? ??????
????????? ?? ??? ??
???? ???????? ????????
???? ??????? ?????? ??
??? ? ??????? ????
????? ???? ?????? ???
???? ?????? ??????
???? ???? ??????? ??
??? ?????????????
??
??
???? ?? ???????? ???????? ?? ?????? ???????? ????????? ???????? ??? ? ? ???? ???? ?? ?? ???? ??
??? ?????????????? ????? ????? ?????? ?? ?????? ?? ??? ??????? ??????? ????????? ?? ???????? ?? ?????
??? ????????? ??? ??????? ????????? ?? ???? ??????? ??? ??????? ???? ????????? ??? ??????? ??????
????????? ????? ? ?? ?????? ???????
120
???????????????????????? ??????????????????????
?????????????????
?????????? ?????? ??? ??????? ??? ???? ??????? ???? ??? ?? ????? ??? ??? ? ???
???? ???? ???????? ?? ??? ?? ????? ??????
???? ????????? ???? ? ???????? ?? ???????
?????? ?? ???? ??????? ??? ?? ?????????????
?? ????????? ?? ???????? ?? ???????? ????
???????? ?????????? ?? ??????????? ?????
????? ???? ? ???????? ???? ???????? ????
??????????? ? ???????? ????? ???? ? ?? ??
??????? ????????? ????? ??? ?? ??????? ?
??????????? ?? ????? ??? ???? ??? ????
???? ???? ????????? ????? ?????? ??????
?????? ????? ???? ?? ??????? ????????????
??????? ?????????
??? ???????? ??????? ???????? ???? ?? ???
?????????? ????? ???? ?? ??? ???? ???????
??? ???? ??????????? ?? ??? ?????? ????? ??? ???
?????????? ?????????? ????????? ?????? ??
???????? ? ????????? ??????????? ???????
??????????? ???????? ?? ???????? ?? ???
????? ?????? ?? ??? ????????? ?????????????
??? ??????? ??????????? ?????????? ?????
???????? ??????????? ?? ???????? ??????
???? ??????????? ??????? ????? ??????? ???
???????? ???????? ?? ????? ???????????? ?????
??????? ????????????? ?????
?? ?????? ?? ????????? ??? ?????????? ???
??????? ?? ??? ???? ??????? ???????? ?????
??? ??? ???? ???????? ???? ??????????
???? ??????????? ??? ??? ???? ???????
?? ??? ???????? ?? ??????????? ????? ????
?????? ????????????? ?? ???????????????????
??? ????? ???????? ?? ??? ??????? ???? ??????
???? ???? ??????????? ????? ?? ??????? ???
??? ???????? ????? ????????? ??? ?? ??????
?? ??? ??????? ?? ??? ??? ? ???? ?????
???? ?? ????????? ? ?????? ?? ???????????
????? ??? ??? ?????????? ?????? ??? ???
???????? ???? ??? ????????? ?????? ??? ???
?????????????? ?????????????????????????
????? ????????? ?????????? ? ????????
???????? ????????? ????????? ?????????? ??
????????? ???????????? ???????????
????????????????????????
??? ??????????????????????
?????????????? ???????? ???? ????
?????? ?? ????? ??????? ??????? ???????
?????????? ???? ?? ?????? ???? ?? ??? ?????
?????????????? ?? ??? ?? ??? ???? ????
???????????????????????????????? ???????
???? ?????? ??? ?????? ????????? ?????????
?????? ???????????? ??????? ??? ???? ??
? ???? ???? ?? ??? ??? ??????? ??? ????
??????? ????????? ?????? ????? ??? ??????
??????? ? ??? ?? ?? ?????????? ?? ?? ?????
??? ??????????? ???? ??? ?????? ???? ???
?? ??? ?? ?? ?????????? ?? ? ??? ???? ?
????? ??? ?????????????? ??? ? ???????
??? ??? ?? ?????? ????? ?? ??? ??? ????????
???????? ?? ??? ?? ??? ?? ?? ??? ?????
???? ????? ????????????? ??? ???? ???????
?????????? ??????? ??? ??? ???? ???????
?? ??? ??? ???????? ?? ??? ??????? ?? ??? ???
?? ??? ?????? ???? ???? ??????? ??????? ???
?? ???? ?? ?????? ??? ?? ??? ?????????????
?? ??? ?????? ?? ??? ? ?????????? ???? ???
????? ??????????????? ?????????????? ??
????????? ?? ??? ?????? ?????? ??????????
?? ????????? ?? ??? ??????? ?? ????????
???? ??? ????????? ?????????? ??? ?????? ???
????????? ?? ??? ??? ????? ??????? ?? ??????
?????? ??? ??? ???????? ?? ??????? ????? ??
??? ?????? ?? ??? ????????? ???? ?? ??? ????
?????? ?????? ????? ????????? ?? ?????????
??? ???????? ?? ????????? ??? ????? ??? ??????
?? ?????????? ?????? ???? ??? ??? ????
???????? ?? ??? ??????? ???? ???????? ?????
????????? ?????????? ????? ??? ????? ???????
????? ??? ?????????? ?????? ?? ???????????
???? ???????? ???????????? ??? ????????
?????? ?? ???? ???????? ??????? ???????????
???? ??????? ??? ?????? ???????? ?????
???????? ????????? ?? ????????? ???????
??????? ?? ???????? ???????? ???? ???????
???????? ?? ???? ????? ????? ?? ?????????
???????? ???????? ?? ???????? ??? ????
???? ?? ?????????? ?? ??? ????????????? ???? ??????? ?? ??? ?? ????????? ???? ?? ??? ???????? ??????????????????????????????????
??? ?????????????????????????????????? ???????? ???? ??? ??????? ? ??? ?? ??? ??? ??????? ? ??? ??? ??? ?????????? ?????????? ?????
??? ?? ??? ???? ??? ?? ?? ?? ??? ?????????? ?? ? ??? ???? ??? ????? ?? ????? ? ???????????? ??? ??????? ?? ???? ?????????? ?? ??? ????????????? ??? ???
???????? ?? ??????? ?????
??
??
??
??
121
???????????????????????? ??????????????????????
?????????????????
??? ??? ?? ????? ??? ??? ? ?????????? ?????? ??? ??????? ??? ???? ??????? ????
??? ??? ??? ????????????? ???? ???
???????? ????????? ??? ?????? ????? ?? ????
???????? ?????????? ?? ??? ??????????? ?? ???
???????? ????? ?????????
??????????? ?????????????
?? ?????? ???? ??? ???????? ????? ???
??????? ?????? ?? ??????? ??? ?? ???
?????? ??? ?????? ?? ????? ?????????? ?????
?????????? ??? ????? ?????? ?? ??????
??????? ?? ???????? ??????????? ??????
????????? ??? ????? ? ??????? ?? ???? ????
???????? ???????? ????????????? ????? ???
???????? ??????? ???? ??? ???????????????
?????? ???? ???????????? ??????? ????
???? ????? ?????????????? ???????? ??
?????? ????? ???? ?????????????? ???
??????? ??? ?????????? ??? ? ??????????
?????? ? ???????? ?????? ??? ???????
???? ?? ??????????? ?? ???? ?? ??? ??????
???????? ??????? ???? ??? ??? ?? ?????
??? ???? ???? ??? ?????? ???? ??????? ??
???????? ??????????? ??? ????? ?? ???? ?
????? ??? ??????? ?????? ?? ???????????
????????????? ?? ??? ???????????????
???? ?????? ?????????????? ???? ???????
???????? ???? ??? ??????? ?????????????
??? ????? ?? ???? ?? ??? ????? ????????????
?????????? ??? ???? ????? ????? ????????
?????? ?? ????????? ????? ??????? ???
????????? ????? ???? ?????????? ????????
???? ??? ???? ??? ???? ???????????? ??
?????? ???? ??? ?????? ?? ?????? ????? ????
????????? ?? ??? ?????? ?? ?????? ??? ???
? ??????????????? ??? ??? ????????????????
?????????? ?? ??????? ???????
??? ???? ??????? ?? ???? ? ??????? ????
???? ???????? ?????????? ?????????????? ??
??? ??? ????? ????? ?????? ?????????? ???
?????????????? ??? ?????? ??? ????? ???????
??? ??????? ????? ???? ????????? ??????
?????? ???? ??? ??? ??? ???? ????? ??? ??????
?????????? ???????????? ?? ??? ?? ??????
??? ??? ???? ???????? ?????? ????? ??? ???
????? ??? ?????? ???????? ???? ??? ??? ???
????????????? ???? ??? ????????????? ????
???? ??? ?????? ??? ????? ?????????????
?? ??? ????? ?? ??? ?? ?????? ?????? ????
??????? ??????????? ????? ??? ?? ???? ???
??? ??? ??????? ???? ?????????? ??? ?????
?? ??? ?? ??? ?? ?????????? ?? ??? ??????
??????? ????????? ???? ??? ?? ????? ????
? ????? ??? ????? ???? ??????? ?????? ??
????????? ???? ???? ????????? ?????? ??????
???????? ???? ??? ??????? ??????????????
?? ????????? ?? ??? ????? ?? ??? ??? ???
???? ???????? ??? ?????? ?? ?? ?????????
???? ????????? ????????? ????? ??? ??????
?? ??? ? ??????? ???? ??? ????????? ????
?? ?? ??????? ?????????? ???? ????? ????
??? ??????? ??? ?? ???? ?????? ????? ????
???? ????????? ??? ???? ????????? ???? ???
???????? ??? ??? ? ?? ??? ???? ?????????
???????? ?????? ???? ?? ?? ????????? ??????
??? ??????????? ??????????? ????? ??????
??? ????????? ??? ?????? ?????? ??????????
?? ??????? ??? ???????? ??????? ????????
??????
???????????
???? ?? ? ????????? ???????? ??? ????
???????? ?????????? ??? ?????? ????? ??
???????? ???????? ???????? ?? ?? ?????
?? ???? ????? ?? ?????????? ????? ?? ?????
???????? ??? ??????????? ??? ????????? ???
???????????? ?? ???? ??? ??? ??????????????
?? ?????? ????????? ?? ??? ???? ?? ?????????
???? ??? ???? ?? ??? ????? ?? ?? ???????????
??????? ???????? ???? ???? ??????? ???
???????? ???? ?? ?? ???????? ??????? ?????
?????????? ????? ?? ? ????????? ????????????
?? ??????? ??? ?? ??? ??? ? ???? ?????
???? ??? ??? ?? ?????? ??????? ????????
??? ?? ????????? ?? ???????????? ?? ???
????????????? ??????? ???? ??????? ????
??? ??? ????????? ?? ??? ??????????? ????
??? ?????????? ?????? ????????? ???????????
?????????????? ??? ?????????? ??????? ??
??????????????? ??????????? ????? ???
?????????? ?? ??? ????????? ????????
??? ?? ??????????? ??? ??? ???? ????????
??? ???????? ?? ??????? ??????? ????????
????? ???????????????? ???? ?????????? ???
???? ?? ?????????
?????????????? ???
??? ???????????? ??
??? ?????????????
??????? ????? ???????
????????? ???????????
????? ? ??????????
?????? ? ??????????
??? ????? ????? ????
??? ???????????????
???? ????? ?? ???
???????????? ????????
???? ???????????? ??
??? ????????
???? ?? ????? ???????
??? ??? ?????? ?????
???????????? ???? ?????
??? ??????? ??????
??????????? ??????
???????? ??? ? ???????
?? ??? ???????? ????
????? ???????? ?????
????? ???? ?????
???? ?? ?????? ?????
???? ??????? ?? ????
????? ?????? ???? ???
??????????????? ????
??? ?? ??????? ?? ????
???????? ?? ???? ??
??? ?????????????
???????? ??? ??? ??
???? ?????? ?????? ???
???????? ????????? ??
??? ??? ???? ????????
?? ?? ??????????????
????? ??? ?????? ?? ???
?????? ?????? ??? ????
????????? ?? ????????
??
??
122
???????????????????????? ??????????????????????
?????????????????
?????????? ?????? ??? ??????? ??? ???? ??????? ???? ??? ?? ????? ??? ??? ? ???
?????????????? ?? ????????? ??? ??? ???????
???? ????? ?? ???? ??????? ???????? ??????
??????? ???? ??????????? ??? ?????????
?????????? ???????? ??? ??????? ??? ??
???????????? ????????? ??????? ??? ????
??? ?????????? ???????? ????? ???????????
????????????????
??? ???? ??? ????????? ?? ??? ?????
???????? ??????? ?????????? ????????? ???????
???????? ??? ??????? ??? ??? ????????
???????? ??????? ???? ???????? ?????
???????? ?? ????? ?????????? ?????? ??? ???
??????? ????????????
????????? ????? ?? ????
??? ?? ????? ???? ??????? ????? ??? ????
??? ?? ?? ??????? ?? ????????? ?? ?? ????????? ??
????????? ?? ?? ???????????? ?????? ????? ???
????
??? ?? ?????????? ?? ?????? ?? ?????????? ??
??????????????????? ???????? ?? ???????? ??
???? ?? ????? ?? ???????????? ????? ????????
????? ??? ????????????????????????
??? ?? ?? ??????? ?? ?????????? ?? ?? ?????????
???? ??????????? ????? ??? ????
??? ?? ?????????? ?? ???? ?? ????? ?? ????????
???? ????? ??? ?????
??? ?? ??????? ?? ???? ??????????? ????? ????????
????? ?? ?????
??? ?? ?? ??????? ?? ???????? ?? ????? ?? ?????? ??
????????? ?? ??????? ?? ??????? ?? ??????????
???? ????? ?????????? ????? ??? ????????????
??? ?? ????????? ?? ????????? ?? ??????????? ??
????????? ????? ????? ?? ????? ?? ???
??? ?? ?? ?????? ?? ?? ????????? ?? ??????? ??
????????? ?? ???????????????? ?? ?? ???? ??
????????? ?? ???????? ?? ??????? ?? ????????
?? ???????? ?? ????????????? ?? ??????????
?? ????? ?? ???? ?? ??????? ?? ?????????
?? ???????????? ?? ??????????? ?? ?????????
?? ????? ?? ?????? ?? ????? ?? ?????????
?? ?????? ?? ??????????? ?? ??????? ?? ???
?? ???????? ?? ?????????? ?? ??????????? ??
????????? ???? ??????? ????? ??? ????
???? ?? ????? ?? ?????? ?? ????? ?? ?????? ?? ???????
?? ????????? ?? ????????? ?? ??? ?? ?????? ??
??????????? ?????? ????? ????? ??? ????
???? ?? ?? ????? ?? ????????? ?? ?? ????? ?? ?? ????
?? ?? ?????????? ?? ?? ??????? ?? ?? ??????? ??
???????????? ?? ?? ??????? ?? ??? ?? ??? ?? ??
?????? ?? ?? ?????? ?? ?????? ?? ?? ?????? ?? ??
???????? ?? ?? ??????? ?? ?? ????????? ??????
????? ???? ????
???? ?? ????????? ?? ?????? ?? ?? ??????? ?? ??
????????? ?? ???????? ?? ???????? ?? ????????
?? ?? ??????? ???? ????? ???????? ????? ???
?????
???? ?? ?? ???????? ?? ?? ??????????? ?? ???? ?? ??
???????? ?? ?? ????? ?? ???????????? ?? ?? ??????
?? ?? ????? ?? ?? ?????? ????? ????? ????? ????
???? ?? ????? ???? ?????
???? ??????? ?? ?? ??????? ?? ???? ?? ?? ??????? ??
???????? ???? ????? ?? ?????
???? ?? ???????? ?? ????????? ?? ???????? ??
????????? ?? ?? ???? ?? ?? ?????? ?? ???????????
?? ?? ??????? ?? ???????? ???? ????? ?? ?????
???? ?? ?? ??????? ?? ???? ???? ????????? ?? ???????
?? ???????? ???? ????? ?? ?????
???? ?? ?????????? ?? ?????????? ?????????? ???????
?? ?? ??????? ?? ???????? ?? ????????? ??
???????? ???? ????? ?? ????
???? ?? ??????? ?? ??????? ?? ???????? ?? ??
??????? ?? ????? ?? ?????????? ?? ???????? ??
?????? ???? ?? ???????? ????? ???? ????
???? ?? ??? ?? ?? ????? ?? ????????? ?? ?? ???????
?? ??? ?? ?? ????? ?? ?? ?????? ?? ??????? ?? ??
????????? ?? ?? ????????? ???? ??????? ????? ??
????
???? ?? ???????? ?? ?????? ?? ?????? ?? ????????? ??
?????? ?? ???????? ?? ????????? ?? ?? ???????????
?? ????????? ?? ?? ?????? ?????? ??????????
??????? ???? ????? ??? ????
???? ?? ?? ??????? ?? ?? ?????? ?? ???????? ?? ??
???????? ?? ??? ???? ???? ????? ???? ?????
???? ?? ?? ??????? ?? ????????? ?? ?? ???????? ??
?? ??????? ?? ?? ??????? ????? ???? ???? ?????
???? ???????????????????
???? ?? ?? ???????????? ?? ????????? ?? ??? ?? ??
?????? ?? ?? ???????? ?? ?? ??????? ????? ?????
????? ??? ?????
???? ?? ?? ??????? ?? ????? ?? ?? ??????? ?? ?? ??
???????? ?? ?? ??????? ???? ?? ?? ???????? ?? ??
???????? ????? ????? ????? ???? ????
123
?
 
 
 
 
 
 
 
 
Chapter 5. Enabling MDP proteolysis: a quest for a 
novel protease 
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This Chapter is dedicated to the characterization of a novel protease for 
middle-down (MD) approach. Particularly, we addressed prerogative 
physical/chemical properties of suggested protease and investigated its 
efficiency in generating peptides in required mass bin with MS. Finally, we 
developed and applied the novel pipeline to a case study of immunoglobulins 
structural analysis, tackling one of the major PTM (deamidation) for this class 
of proteins. 
Hereinafter reported considerations and results are translated into research 
articles enclosed at the end of this Chapter: 
• Extended bottom-up proteomics with secreted aspartic protease Sap9 
(Paper III) 
•  Advantages of extended bottom-up proteomics using Sap9 for analysis of 
monoclonal antibodies (Paper IV) 
 
?????????????????
????????? ????????????????????????????????????????????
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5.1. Paper III: Extended bottom-up proteomics with 
secreted aspartic protease Sap9 
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Extended bottom-up proteomics with secreted
aspartic protease Sap9
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We investigate the benefits and experimental feasibility of approaches enabling the shift
from short (1.7 kDa on average) peptides in bottom-up proteomics to about twice longer
(~3.2 kDa on average) peptides in the so-called extended bottom-up proteomics. Candida
albicans secreted aspartic protease Sap9 has been selected for evaluation as an extended
bottom-up proteomic-grade enzyme due to its suggested dibasic cleavage specificity and
ease of production. We report the extensive characterization of Sap9 specificity and
selectivity revealing that protein cleavage by Sap9 most often occurs in the vicinity of
proximal basic amino acids, and in select cases also at basic and hydrophobic residues.
Sap9 is found to cleave a large variety of proteins in a relatively short, ~1 h, period of time
and it is efficient in a broad pH range, including slightly acidic, e. g., pH 5.5, conditions.
Importantly, the resulting peptide mixtures contain representative peptides primarily in
the target 3–7 kDa range. The utility and advantages of this enzyme in routine analysis of
protein mixtures are demonstrated and the limitations are discussed. Overall, Sap9 has a
potential to become an enzyme of choice in an extended bottom-up proteomics, which is
technically ready to complement the traditional bottom-up proteomics for improved
targeted protein structural analysis and expanded proteome coverage.
Biological significance
Advances in biological applications of mass spectrometry-based bottom-up proteomics are
oftentimes limited by the extreme complexity of biological samples, e.g., proteomes or
protein complexes. One of the reasons for it is in the complexity of the mixtures of
enzymatically (most often using trypsin) produced short (<3 kDa) peptides, which may
exceed the analytical capabilities of liquid chromatography and mass spectrometry.
Information on localization of protein modifications may also be affected by the small
size of typically produced peptides. On the other hand, advances in high-resolution mass
spectrometry and liquid chromatography have created an intriguing opportunity of
improving proteome analysis by gradually increasing the size of enzymatically-derived
peptides in MS-based bottom-up proteomics. Bioinformatics has already confirmed the
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Extended bottom-up proteomics
Middle-down proteomics
Enzymatic digestion
High-resolution mass spectrometry
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Abbreviations: AGC, automatic gain control; ETD, electron transfer dissociation; FTMS, Fourier transform mass spectrometer/mass
spectrometry; HCD, higher energy collision dissociation; IAA, iodoacetamide; MeOH, methanol; PTM, post-translational modification;
RFU, relative fluorescence units; Sap9, secreted aspartic protease 9; TFA, trifluoroacetic acid; TFE, 2,2,2-trifluoroethanol.
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envisioned advantages of such approach. The remaining bottle-neck is an enzyme that
could produce longer peptides. Here, we report on the characterization of a possible
candidate enzyme, Sap9, which may be considered for producing longer, e.g., 3–7 kDa,
peptides and lead to a development of extended bottom-up proteomics.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
With the development of increasingly faster andmore sensitive
high-resolution mass spectrometers, qualitative and quantita-
tive protein analysis is becoming routine in various research,
clinical, and industrial laboratories [1–6]. The twomain avenues
for protein identification with mass spectrometry (MS) are
the “bottom-up” and the “top-down” approaches. In
bottom-up proteomics, the mixtures of proteins are digested
into short (0.6–3 kDa) peptides, which are then analyzed
individually with a high-throughput liquid chromatography–
tandem mass spectrometry (LC–MS/MS) [1,2,5]. The advan-
tage of this approach lies in the ease of separation, fragmen-
tation and detection of these short peptides. The specificity
toward basic residues of trypsin, the most widely employed
enzyme in bottom-up proteomics, ensures that more than
95% of proteins from diverse proteomes can be, theoretically,
represented by unique peptides [7]. Naturally, this is themost
commonly used approach in routine proteomics [8]. Howev-
er, due to the large sample complexity and wide dynamic
concentration range of the proteins oftentimes present in the
sample [9,10], it may fail to characterize the entire proteome
without rigorous pre-fractionation and multiple technical
replicate experiments [10,11]. Orthogonal or restricted
cleavage specificities provided by other enzymes show
certain advantages for increased proteome coverage with
bottom-up proteomics [8]. Nevertheless, the number of
enzymatically-produced peptides remains extremely high
and the information about the presence of multiple proteoforms
(isoforms, point mutations, and post-translational modifications
(PTMs)) is often lost [12].
In contrast, top-down proteomics involves fragmentation
and analysis of proteins in their intact form directly in the gas
phase [13–16]. Since the primary structure is preserved, identifi-
cation of proteins on the proteoform level is, in principle,
possible [17]. However, this technique is far from being
routinely implemented for complete proteome analysis due
to the difficulties arising from the chromatographic separa-
tion of the proteins on the timescale of the experiment. Small
(<40 kDa) proteins can be readily separated on C4 reverse
phase columns, whereas separation of larger (up to 100 kDa)
proteins requires multidimensional separation involving
polymeric reverse phase stationary phase (PLRP-S) columns
[15] or capillary electrophoresis [18]. Although these emerging
separation techniques enable on-line MS/MS analysis of intact
proteins, extensive pre-fractionation of the mixture is required
prior to analysis [19]. In addition, the MS/MS spectra obtained
are highly convoluted due to the large number of product ions
present with different charge states. Due to the presence of
PTMs and their combinations, proteoform-level characteriza-
tion requires specialized mass spectra deconvolution tools
and database search algorithms [13,20], which require further
development.
A third, newly emerging direction is analysis of larger,
>3 kDa, peptides, dubbed “middle-down proteomics” [21–24].
This approach entails the chemical or enzymatic digestion of
the proteins, much as in the case of bottom-up proteomics;
however, the resulting targeted peptides should be in the
3–15 kDa range. We previously proposed the division of this
wide mass range due to practical considerations into the
3–7 kDa (extended bottom-up) and 7–15 kDa (middle-down)
mass ranges [7].
Recent comprehensive bioinformatics study of the
human, yeast and bacterial proteomes revealed that there
is no unique cleavage site that allows for whole proteome
complete identification based on unique peptides in the
3–7 kDa mass range [7]. In-silico digestion using cleavage rules
of currently utilized proteases such as LysC, GluC, AspN, and
acid hydrolysis [25] yielded prevalently small (0.6–3 kDa)
peptides. Other proteases, such as Kex2 [26] or OmpT [21] have
been previously described as dibasic-site specific enzymes
capable of yielding large (>3 kDa) peptides. However, bioinfor-
matics studies also showed that ~25% of human proteins
remain unidentified with unique peptides with this cleavage
rule. Also, the true dibasic-site specificity has not yet been
confirmed experimentally for any enzyme. Moreover, proteins
such as serum albumin were not identified after digestion with
OmpT, likely to the large size (>20 kDa) of the peptides
generated [21].
Limiting the enzymatic reaction time for known proteases,
e.g., trypsin, to ensure missed cleavage sites has been also
previously investigated and is finding renewed interest [27].
A recent study on the trypsin digestion kinetics by Lowenthal
and co-workers has determined that tryptic peptides have
complex formation kinetics depending on their primary
sequence, relative position in the protein tertiary structure
and the presence of missed cleavage sites [28]. Long peptides
containing missed cleavages were found to be formed slower
than short peptides. Other proteases, such as chymotrypsin,
pepsin and thermolysin, could potentially find an application
for extended bottom-up proteomics. However, digestion repro-
ducibility and substrate specificity of these enzymes at short
reaction times remain unclear. Therefore, an optimumprotease
for either extended bottom-up or middle-down proteomics is
yet to be found.
Candida albicans Sap9 is an aspartic protease from the yapsin
family and fulfills a major role in maintaining cell wall integrity
in fungi. Figure S1 (Supplementary Information) details Sap9
primary structure information [29]. Sap9 has been proposed to
cleave peptide backbone primarily after Lys–Arg and Arg–Arg
tandem sequences. This specificity has been reported for Sap9
processing of a small number of synthetic, 8–9 amino acid long
peptides containing dibasic residues [29], but notwholeproteins.
In a separate study, Aoki and coworkers used a FRETS-25Xaa
library containing 475 peptides, and concluded that Sap9
cleaves preferentially peptides containing basic residues, albeit
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also cleaves at leucine [30]. More recently, it has been shown
that this protease has broad substrate specificity and cleaves
several cell wall proteins [31]. Cleavage at select Lys or Arg
residues and the importance of neighboring residues on the
cleavage position was also noted. Overall, the enzymatic
activity of Sap9 has been previously investigated at different
pH values but only at 37 °C. Sap9 was found to be active in
acidic sodium citrate buffer at pH 3.5–6.0 [31]. Despite these
encouraging preliminary results, the proteomic-grade utility
of this enzyme has not been established. The effect of pH,
temperature, digestion time, and enzyme:protein (E:P) ratio
on the protein cleavage specificity (i.e., the amino acid sites
targeted under different conditions) has not yet been studied.
To summarize, although the general ability of Sap9 to cleave
proteins on the cell surface of fungi has been revealed, only the
limited cleavage specificity study was carried out using short
synthetic model peptides.
Hereinweevaluate the applicability of Sap9 to cleaveproteins
into mid-range peptides, suitable for extended bottom-up
proteomics. We first search for the optimal proteolytic condi-
tions of Sap9 using fluorescence-based enzyme activity assay
and proteomics experiment-derived enzyme specificity analysis
under different experimental conditions (pH, temperature,
E:P ratio, and digestion time). In the following, we apply the
optimized digestion conditions to evaluate the performance of
Sap9-based proteomics for analysis of model protein mixtures
with up to 48 proteins.
2. Experimental procedures
2.1. Production of recombinant proteases
Recombinant C. albicans His6-tagged Sap9 was produced using
Pichia pastoris as an expression system. The sense and antisense
primers (5′-ATGCTCGAGAAAAGAGCTAAGGCACCTTTCAAAAT
C-3′ and 5′-GAATCTAGATTAATGGTGATGGTGATGGTGAGCAC
CAATGACTTCAATCGA-3′) were used to generate a PCR
fragment encoding His6-tagged Sap9 with genomic DNA of a
C. albicans clinical isolate as a target. The PCR product was
digested with XhoI and XbaI, and subsequently inserted
into the P. pastoris–Escherichia coli shuttle vector pPICZαA
digested with the same restriction enzymes to generate the
expression plasmid pSap9_H-6. P. pastoris KM71 (Invitrogen,
Carlsbad, CA, USA) was transformed by electroporation with
SacI linearized plasmid DNA, and transformants were select-
ed on YPD agar medium (2% (w/v) Difco Bacto Peptone (Difco
laboratories, Detroit, MI, USA), 1% (w/v) Difco Bacto yeast
extract, 2% (w/v) dextrose, 2% agar) containing 100 μg/mL
zeocin.
For enzyme production, P. pastoris transformants were grown
to near saturation (OD600 = 10) at 30 °C in 1 L of glycerol-based
yeast media (0.1 M potassium phosphate buffer at pH 6.0,
containing 10 g/L yeast extract, 20 g/L peptone, 13 g/L yeast
nitrogen base without amino acids (Becton-Dickinson, Sparks,
MD), 10 mL/L glycerol and 40 mg/L biotin). Cells were harvested
and resuspended in 200 mL of the same medium with 5 mL/L
methanol instead of glycerol and incubated for 48 h. Then, the
culture supernatant was harvested after centrifugation (3000 ×g,
4 °C, 5 min).
2.2. Purification of heterologously produced Sap9
The secreted proteins from 200 mL of P. pastoris culture
supernatant were concentrated by ultrafiltration to 6 mL using
a Centricon Plus-70 (30 kDa cut-off) (Millipore, Volketswil,
Switzerland). The His6-tagged target protein was extracted
with a Ni-NTA resin (Qiagen, Hilden, Germany) column with
histidine elution buffer (50 mM histidine in PBS 1×) as previ-
ously described [29]. Active fractions were pooled and concen-
trated by ultrafiltration using Amicon Ultra (Millipore 30 kDa
cut-off). Protein concentrations were measured with Nanodrop
(Thermo Scientific, Wilmington, DE, USA). The image of the 1D
SDS-PAGE gel of the supernatant before and after His6-tag
purification is shown in Figure S2 (Supplementary Information).
2.3. Enzymatic activity assay
The effect of pH, temperature, and E:P ratio on proteolytic activity
of C. albicans Sap9 was determined using fluorescence-based
kinetic assays. The pH-insensitive green-fluorescent BODIPY FL
dye-labeled casein was used as a substrate (EnzChek Protease
Assay Kit, Molecular Probes, Eugene, OR, USA). Activity assays
were performed at 25, 37 and 45 °C, 3.5–6 pH with 0.5 pH unit
increment and E:P (w/w) ratio from 1:2.5 to 1:100. Lyophilized
casein was reconstituted with 50 mM sodium citrate buffer
(pH 6) to a concentration of 1 μg/μL, and further diluted to final
concentration of 0.01 μg/μL in assay buffers (pH 3.5–6). 100 μL of
substrate solutionwas placed in eachwell of 96wellmicroplate
(8 × 12 size Wallac black/clear bottom). Enzyme dilutions were
prepared using sodium citrate buffer at different pH, and a
solution containing substrate in absence of protease was
monitored as reference control set. Measurements initiated
immediately upon the addition of reaction buffer in all wells
(~10 min from initializing reaction in first well) and were carried
out using a Victor X3 multilabel plate reader (Perkin-Elmer,
Waltham, MA, USA). Fluorescence was monitored using a
485 nm wavelength excitation, 535 nm emission, and cut-off
filter at 580 nm. The sensitivity setting was varied as required,
and the fluorescence datawas acquired utilizing bottom reading.
Each assay was measured with 300 plate reading repeats (up to
12 h, 60 s delay between repeats, shaking for 5 s prior to each
reading) in triplicate. Baseline casein fluorescence was found to
be pHdependent, therefore all experimental data presentedwere
normalized to the fluorescence recorded without addition of
protease at each working condition by subtracting the baseline
fluorescence values.
2.4. MS-based enzyme specificity analysis
The substrates employed included a single protein (bovine
carbonic anhydrase 2 from Protea Biosciences, Morgantown,
WV), a 7 protein mixture (yeast enolase 1 and 2, bovine apo-
transferrin, serumalbumin, pancreatic ribonuclease A, chicken
eggwhite lysozyme (all fromSigmaAldrich, St. Louis, MO, USA))
and bovine carbonic anhydrase 2, the standard equimolar 48
protein mixture (UPS-1, Sigma Aldrich), and the proteomics
dynamic range standard set of the same 48 proteins (UPS-2,
Sigma Aldrich). Proteins were resuspended in 6.8 M urea,
100 mM ammonium bicarbonate buffer, reduced with 3 molar
equivalents of DTT at 50 °C for 1 h, and alkylated with 100 mM
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iodoacetamide for 30 min at room temperature in dark. The
protein mixture was then diluted 20× in 50 mM sodium citrate
buffer pH 5.5, anddigestedwith Sap9 in varying E:P ratioswith a
reaction time between 30 min and 8 h at room temperature.
Peptides were desalted using C4 and C18 ZipTip (Millipore,
Billerica, MA), the eluents from the two desalting columns were
pooled. 5–8 pmol peptide mixture was loaded on a 75 μm ID
precolumn (C8, 2 cm long, 100 Å pore size, 5 μm particles) for
10 min at a flow rate of 8 μL/min with 0.1% TFA, and separated
using a Dionex Ultimate 3000 nanoLC system fitted with
150 mm C8 Acclaim PepMap300 column with 300 Å pore size,
5 μm size particles, 75 μm ID (Thermo Scientific, Bremen,
Germany) at a flow rate of 0.8 μL/min. Compositions of the
eluents were A: 0.1% formic acid, B: 50% methanol, 20%
acetonitrile, 10% 2,2,2-trifluoroethanol (Alfa Aesar GmbH & Co
KG, Karlsruhe, Germany), 0.1% formic acid. This solvent
composition has been found by Mitulović and co-workers to
minimize carryover and extend the column lifetime without
detrimental effect on the separation and analysis of peptides in
the LC system employed herein [32]. The percentage of the
organic phase was increased from 5 to 60%, the length of the
gradient varied between 10 and 60 min, depending on the
sample complexity. Eluted peptides were nanoelectrosprayed
with 2.4 kV needle potential and analyzed using an Orbitrap
Elite ETD FTMS (Thermo Scientific, Bremen, Germany). MS
survey scans were acquired at 60,000 resolution at m/z 400.
Isolationwindowwas set to 3.0 Th,monoisotopic peak selection
was disabled. Precursor ionswith charge states 1, 2 or 1, 2, and 3
were excluded forMS/MS. Fragmentation of the top 5 peakswas
carried out using higher energy collision dissociation (HCD)
with normalized collision energy 27%. Alternatively, ion trap
collision induced dissociation (CID) of the top 10 peaks was
performed using 35 V collision energy. Three microscans were
acquired and averaged for each MS/MS spectrum at resolution
15,000 at m/z 400 in the Orbitrap for both activation methods.
Themaximum injection timewas set to 200 ms for bothMS and
MS/MS, and the automatic gain control (AGC) was set to 106
charges for MS scan and 5* 104 charges for MS/MS, respectively.
In a reference study, the UPS-1 standard was digested
overnight with sequencing grade modified trypsin (Promega,
Madison, WI, USA) in E:P ratio 1:25 (w/w) following the
manufacturer's protocol. Peptides were desalted using C18
ZipTip and separated onaDionexUltimate 3000nanoLC system
fitted with 150 mmC18 Acclaim PepMap100 columnwith 100 Å
pore size, 3 μm particles, 75 μm ID (Thermo Scientific, Bremen,
Germany) at a flow rate of 0.3 μL/min using the same gradient
elution as described above. MS survey scans were performed at
60,000 resolution setting (at m/z 400). The top 10 peaks were
fragmented using either CID or the top 5 peaks with HCD. A
single microscan was recorded for each MS/MS spectrum in
Orbitrap FTMS at resolution setting 15,000 (at m/z 400).
Peak listswere generatedusing ProteomeDiscoverer 1.4, and
the MS/MS spectra were analyzed using Sequest. The precursor
ion mass tolerance was set to 10 ppm, product ion tolerance to
0.02 Da. For the study of carbonic anhydrase and the 7 protein
mixture searches were performed against a database contain-
ing 756 proteins, including reviewed sequence homologs of the
7 proteins from all species in the UniProt knowledgebase.
The UPS-1 digestion data was searched against a database
containing the non-redundant UniProt human proteins (ver.
2013_02), the 48 UPS-1 proteins and their shuffled sequences
(in total, 40,527 entries). Cys carbamidomethylation was set as
fixed modification, N-acetylation and oxidation of Met were
allowed as dynamic modifications. The cleavage specificity
was set to trypsin with two missed cleavages for the trypsin
experiments and to no enzyme for Sap9 peptides. To determine
the occurrence of Sap9 autolysis, data was additionally searched
against a C. albicans database containing 1218 reviewed entries.
Peptide andprotein false discovery rates (FDRs)were determined
using Scaffold (Proteome Software, Inc., Portland, OR).
The performance of other search engines such as Mascot
has also been investigated. After manual validation, peptide
score threshold was set to 15 for HCD and to 20 for CID mass
spectra.
3. Results
3.1. Enzyme activity characterization
The effect of the temperature on Sap9 enzyme activity was
studied performing the digestion at constant pH and different
E:P ratios. Fig. 1 shows the activity curves at pH 4.5 recorded at
25, 37, and 45 °C, at E:P ratios 1:2.5, 1:10, and 1:25. At all E:P
ratios the curves show high enzyme activity within the first
2 h of digestion, and a considerable enzyme activity was
observed even at the very first time point recorded (~10 min).
At 2 h the slope of all curves decreased, but fluorescence
response did not reach plateau even at 12 h under the
experimental conditions employed (data not shown). The
highest activity was obtained at E:P ratio 1:2.5 at 37 °C (red
line), the fluorescence recorded at 2 h was ~4 fold higher than
at 1:10 ratio, and a ten-fold higher compared to 1:25 ratio. This
ratio was optimal at all temperatures, although activity at 2 h
and 45 °C was 2.5 times lower than at 37 °C. Another two-fold
decrease in activity was recorded at 25 °C. Based on the enzyme
activity assay, we concluded that Sap9 is most aggressive at
pH 4.5, 37 °C.
The effect of pH and E:P ratio on Sap9 enzyme activity was
studied performing the digestion at selected reaction temper-
atures and time points. Fig. 2 shows the Sap9 enzyme activity
Fig. 1 – Effect of temperature on enzymatic activity of Sap9
protease at pH 4.5, E:P ratios 1:2.5, 1:10, and 1:25. The substrate
is green fluorescent β-casein.
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within one standard deviation obtained at 25, 37, and 45 °C at
different pH values and E:P ratios achieved at 4 h reaction
time with the green fluorescent casein substrate. The com-
plete activity curves recorded demonstrate that at this time
point the slope of all curves decreased, indicating that the
enzyme is saturated with substrate (Figures S3, S4, and S5 in
Supplementary Information). As expected, enzyme activity
increased with increasing the relative enzyme quantity. At
optimal pH conditions (~4.5) the protease maintained its
activity even at very low (1:100) E:P ratios. At all temperatures
studied, the protease maintained its activity in the entire pH
range studied with the highest fluorescence values recorded
at pH values between 4 and 5.
3.2. Sap9-proteolysis of carbonic anhydrase
To determine which temperature yields optimal number of
peptides for extended bottom-up proteomics, we tested the
dependence between size and charge distribution of peptides
obtained when proteolysis of a single protein is performed at
different temperatures. Carbonic anhydrase 2 (~29 kDa) was
selected as a first substrate because it contains anRRandanRKK
sites positionedwithin the first 120 aminoacid residues from the
N terminus, yielding two peptides in the targeted 3–7 kDa mass
range. The E:P ratio 1:2.5 and pH 4.5 were chosen as starting
conditions because they provide the highest proteolytic activity,
Figs. 1 and 2. LC–MS/MS experiments on carbonic anhydrase
digests showed that at this E:P ratio temperature does not
noticeably affect average peptide lengths at a given pH. At 1 h,
the average size of proteolytically-derived peptides obtained for
this protein was 2.8–3.0 kDa at 15, 25, and 45 °C. In contrast, at
37 °C the average size of peptideswas 2.4 kDa, indicating amore
aggressive enzymatic activity (Table S1, Supplementary Infor-
mation). At the database search filtering parameters employed,
Sequest was more suitable for identification of longer peptides
than Mascot.
100% sequence coverage was obtained at the shortest time
point sampled (1 h) at all temperatures, except at 37 °C, and
even after 8 h digestion at temperatures above or below 37 °C.
Presumably, at around 37 °C Sap9 digested the protein into short
peptides that were not retained on the C8 LC column. Further-
more, considering the increasing number of short peptides
detected at longer sampling times, it is apparent that the
protease continues to further digest the long peptides. Therefore,
a short digestion time is, perhaps, more suitable for Sap9
proteolysis-based extended bottom-up MS. We have found
Sap9 autolysis products at 37 and 45 °C, E:P ratio 1:2.5, but
not with lower relative amount of enzyme and/or lower
temperatures.
3.3. Sap9-proteolysis of a seven protein mixture
We proceeded with characterization of Sap9 for the digestion
of a mixture containing seven proteins of different sizes
and tertiary structures (see Experimental section). Table S2
(Supporting Information) shows the resulting size and
charge state information of Sap9-derived proteolytic pep-
tides identified, as well as the average sequence coverage of
the considered proteins. At pH 4.5 Sap9 is very active at all
temperatures, and comparable average sequence coverage
was obtained at all time-points between 1 and 4 h, regardless
of the experimental conditions. Based on the short average
peptide sizes obtained as soon as 1 h after digestion was
started, we concluded that, naturally, either the E:P ratio of 1:2.5
was too high, or the digestion time was too long. Therefore, to
establish the effect of the pH, the reaction time was limited to
30 min, and a lower E:P ratio of 1:10 was employed. Tempera-
ture of 25 °C was chosen for following experiments as the
practically most convenient for experimental setup.
Table 1 shows the effect of pH on the size of peptides
obtained by 30 minute Sap9 digestion of the seven protein
mixture at 25 °C in 1:10 E:P ratio. Based on this study, we
established that at these experimental conditions the prote-
ase was active at all pH values and average protein sequence
Fig. 2 – Sap9 enzymatic activity recorded at 4 h time point at
25, 37, and 45 °C and pH values between 3.5 and 6. Error bars
indicate one standard deviation of themean from the triplicate
measurement. The substrate is green fluorescent β-casein.
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coverage of 40–56% was obtained. pH 5–5.5 was found to be
the most optimal for extended bottom-up approach, since the
highest average peptide length and charge statewere obtained at
these conditions. In addition, similarly to a single protein study,
we have found that Sequest was, in general, more suitable for
identification of long peptides thanMascot, as the latter failed to
identify peptides with charge states >7+.
An important consideration in establishing the utility of
Sap9 for MS-based proteomics was the study of the digestion
reproducibility by performing parallel digestions and comparing
theextracted ion chromatogramsof the LC–MSexperiments. The
resulting peptides were identical in three replicates performed,
albeit, in some cases, with slightly varying relative intensities,
Figure S6 (Supplementary Information). Whether the change in
the relative abundance of some peptides is a result of parallel
or competing digestion reactions or an artifact arising from
spraying conditions remains to be determined.
3.4. Sap9-proteolysis of a 48 protein mixture
Digestion conditions where the Sap9 enzyme is less aggressive
(25 °C, pH 5.5, 1:10 E:P ratio, 1 hour digestion) were applied to
the equimolar mixture of the commercial 48 protein standard
UPS-1. These conditions were determined to be those at which
longer than tryptic peptides were observed for the 7 protein
mixture.
The extracted ion chromatogram of the UPS-1 peptides
produced after 1 hour digestion with Sap9 is shown to
demonstrate the performance of the method in Fig. 3. As
expected, shorter, less hydrophobic peptides were eluted at
the first minutes of the gradient, whereas with increasing the
organic component, longer, more highly charged peptides
were separated. This aspect of peptide separation, although
predictable, is particularly important for scheduling data
dependent analysis of peptides with broad charge state distribu-
tion using an Orbitrap mass analyzer. To optimize the number
of peptides identified throughout LC separation, two or more
activation methods could be employed, monoisotopic peak
selection can be enabled/disabled, and differentminimumsignal
threshold, number of microscan events, or injection time could
be set for the different stages of the gradient, depending on the
length and charge state of eluting peptide ions [33,34].
As exemplified in Fig. 4, HCD MS/MS produced extensive
sequence coverage of large proteolytic peptides on the LC time
scale. As shown in the insets of Figs. 3 and 4, high resolution is
necessary for the accurate charge state determination of the
precursor ions, as well as that of the resulting product ions in
MS/MS. CID yielded similar fragmentation mass spectra, al-
thoughwithmore prevalence of the b ion series, as expected [35].
A comparison between the number of proteins and
peptides identified from the 1 hour Sap9 digestion of the
protein mixture using different data dependent MS/MS
strategies is presented in Table 2. Precursor ion activation
with CID and HCD was performed including or excluding
peptide precursor ions of charge state 3+. Precursor ion charge
states 1+ and 2+ were excluded in all Sap9 experiments. Also
included is the summary of a typical bottom-up proteomics
experiment on an overnight tryptic digest, fragmented using
data dependent top 10 CID in LTQ excluding charge state 1+,
followed by ion detection in Orbitrap FTMS. Using these
conditions, the average peptide mass identified from Sap9
was between 2.7 and 3.3 kDa, depending on the activation
method, whereas with trypsin we identified peptides with
average mass of 1.9 kDa.
The peptides generated by 1 hour Sap9 digestion and
fragmented using CID MS/MS (charge states >3+) resulted in
identification of 41 proteins with at least 2 peptides (and of 46
proteins with 1 peptide) at FDR level 1%. Of these, 39 proteins
(43 with 1 peptide, respectively) were from the listed UPS-1
standard, as detailed inTable 2. Inaddition, tetranectin (E9PHK0)
and malate dehydrogenase (P40926) were also identified.
With the same filtering criteria, HCD MS/MS yielded the
identification of 42 proteins with >2 peptides, and 50 proteins
with at least 1 peptide, ofwhich 46wereUPS-1 standard proteins.
When peptides with 3+ charge state were included in the
data dependent analysis, CID MS/MS led to identification of
46 proteins (2 peptides rule), including 44 UPS-1 proteins,
malate dehydrogenase, and tetranectin. Inclusion of the 3+
charge state peptides increased the sequence coverage of the
proteins identified previously, and the average sequence cover-
age of the UPS-1 proteins was 60% using CID and 59% with HCD
activation, with an average of ~12 peptides/protein.
The only protein from the UPS-1 protein mixture formula-
tion that was not identified after digestion with Sap9 was
C-reactive protein P02741. Thisprotein didnot produce peptides
in the targeted mass and charge range, most likely due to the
presence of 5 dibasic sites in its sequence. Furthermore, we
have identified keratin in the Sap9-digested UPS-1 mixture,
with a single peptide of 3+ charge state fragmented with HCD.
This observation indicates that perhaps this protein family
is very quickly degraded by Sap9 and is in line with the
physiological activity of this protease, Sap9 is used by the
fungus for host cell adhesion and causes epithelial cell damage
[29,30].
In comparison, at protein FDR setting of 1%, 64 proteins
containing 45 UPS-1 proteins were identified with at least 2
peptides by LC–MS/MS of UPS-1 sample subjected to a
standard overnight trypsin proteolysis, Table 2. In addition to
the ambiguous assignment to hemoglobin delta chain instead
Table 1 – Effect of pH on Sap9 activity: size and charge
distribution of proteolytic peptides from seven protein
mixture after 30 minute Sap9 digestion obtained by
Sequest and Mascot database search engines.
pH Average Maximum Coverage
(%)
Total #
peptides
MW,
kDa
Charge MW,
kDa
Charge
Sequest
4 2.6 4 6.6 8 55 156
4.5 2.5 3.7 5.5 8 52.1 193
5 2.7 3.9 7.1 9 56.5 196
5.5 2.8 4 7.1 9 56.3 203
6 2.9 4.3 7.1 10 40.6 149
Mascot
4 2.3 3.3 5.1 6 52.1 165
4.5 2.2 3.3 4.2 7 47.1 155
5 2.2 3.3 4.2 7 46.2 145
5.5 2.4 3.4 5 7 48.9 145
6 2.2 3.3 4.2 5 31.4 97
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Fig. 3 – Extracted ion chromatogram of the UPS-1 peptides obtained after 1 h digestion with Sap9. The insets show examples of
them/z distribution of peptides of varying size in the LC gradient. 15 cm C8 column, 300 Å, 5 μm, 70 min gradient MeOH:ACN:
TFE:0.1%FA (5:3:1:1), solvent A 0.1% FA (8 pmol on column).
Fig. 4 – Orbitrap FTMS HCD mass spectrum of a 7+ precursor peptide ion from UPS-1 component ribosyldihydronicotinamide
dehydrogenase acquired on the LC timescale.
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Table 2 – Sequence coverage of UPS-1 proteins after 1 h Sap9 and overnight trypsin digestion obtained by Sequest at protein
FDR 1%, peptide XCorr score thresholds 2.5 (2+), 3.5 (3+), and 3.8 (≥4+). Data dependent MS/MS fragmentation was triggered
at signal threshold 15,000. Peptides were fragmented using CID and HCDMS/MS and precursor ions of charge state 3+ were
either included (>2+) or excluded (>3+) from the data dependent ion selection. Searches were performed against a database
containing human proteins, UPS formulation proteins and their shuffled sequences. Sap9 data was searched using
no-enzyme setting and trypsin data was searched using trypsin with 2 missed cleavages.
Protein Accession
#
MW,
kDa
Trypsin
overnight
Sap9 1 h
CID >3+ CID >3+ HCD >2+ CID >2+ HCD
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
Alpha-lactalbumin P00709 16 5 38% 6 79% 5 42% 10 100% 8 63%
Annexin A 5 P08758 36 22 74% 2 13% 2 13% 4 26% 3 13%
Antithrombin-III P01008 53 30 71% 6 28% 9 36% 16 42% 17 51%
BH3 interacting domain death agonist 1 P55957 22 15 70% 1 10% 2 17% 4 38% 6 55%
Beta-2-microglobulin P61769 14 5 49% 4 77% 5 77% 7 77% 8 77%
C-reactive protein P02741 25 7 27%
Carbonic anhydrase 1 P00915 29 15 73% 2 35% 3 37% 3 41% 2 28%
Carbonic anhydrase 2 P00918 29 17 71% 3 11% 4 20% 6 26% 6 26%
Catalase OS = Homo sapiens P04040 60 46 71% 14 38% 16 42% 18 48% 25 56%
Complement C5 P01031 188 1 18% 13 66% 4 76% 3 79% 7 86%
Creatine kinase M-type P06732 43 25 67% 4 54% 14 44% 20 48% 22 54%
Cytochrome b5 P00167 15 5 41% 13 1 16% 2 22%
Cytochrome c P99999 12 7 46% 5 68% 10 100% 7 68% 12 99%
Fatty acid-binding protein, heart P05413 15 7 51% 12 100% 12 100% 15 100% 19 100%
Gamma-synuclein O76070 13 13 82% 12 99% 12 99% 15 99% 16 99%
Gelsolin P06396 86 29 48% 17 57% 15 44% 21 49% 29 57%
Glutathione S-transferase A1 P08263 26 7 30% 6 23% 6 21% 11 43% 9 28%
Glutathione S-transferase P P09211 23 13 71% 1 13% 2 22%
GTPase HRas [Chain 1189] P01112 21 12 62% 6 71% 7 62% 10 62% 10 62%
Hemoglobin subunit alpha P69905 15 9 84% 5 80% 7 92% 11 92% 9 88%
Hemoglobin subunit beta P68871 16 11 84% 5 77% 5 77% 8 77% 9 85%
Histidyl-tRNA ligase, cytoplasmic P12081 57 32 64% 6 20% 7 16% 18 35% 13 32%
Insulin-like growth factor II P01343 20 4 76% 5 76% 7 28% 10 37% 11 100%
Interferon gamma P01579 19 11 50% 9 87% 10 75% 12 87% 13 87%
Interleukin-8 P10145 8.4 7 74% 10 85% 13 96% 14 96%
Lactotransferrin P02788 78 56 72% 21 36% 25 46% 36 58% 37 56%
Leptin P41159 19 6 41% 5 53% 5 53% 10 65% 12 65%
Lysozyme C P61626 17 4 45% 3 65% 2 25% 7 64% 4 27%
Microtubule-associated protein tau P10636 79 23 60% 28 52% 34 52% 31 52% 37 52%
Myoglobin P02144 17 18 92% 6 92% 8 71% 9 92% 11 92%
NAD(PH dehydrogenase) [quinone] 1 P15559 31 16 49% 4 34% 6 41% 6 29% 8 40%
NEDD8 Q15843 9 3 41% 7 54% 6 94% 9 94% 7 94%
Peptidyl-prolyl cis-trans isomerase A P62937 18 12 77% 3 46% 3 46% 6 64% 6 46%
Peroxiredoxin 1 Q06830 22 16 68% 2 13% 3 13% 3 13% 4 18%
Platelet-derived growth factor subunit B P01127 27 6 26% 6 69% 11 99% 18 100%
Ubiquitin P62988 26 3 43% 1 49% 1 49% 1 49%
Pro-epidermal growth factor P01133 134 1 87% 1 87% 4 83% 4 87%
Retinol-binding protein 4 P02753 23 9 72% 10 62% 10 61% 13 56% 14 65%
Ribosyldihydronicotinamide
dehydrogenase [quinone]
P16083 26 14 73% 4 34% 9 50% 7 34% 9 50%
Serotransferrin P02787 77 54 73,00% 32 62% 47 66% 56 73% 67 78%
Serum Albumin P02768 69 32 66% 27 69% 29 75% 31 78% 34 74%
Small ubiquitin-related modifier 1 P63165 39 23 57% 5 32% 8 39% 14 53% 15 58%
SUMO-conjugating enzyme UBC9 P63279 18 7 58% 4 78% 4 60% 7 94% 10 94%
Superoxide dismutase [Cu-Zn] P00441 16 8 66% 4 62% 4 40% 4 48% 6 56%
Thioredoxin P10599 12 6 63% 3 40% 4 43%
Tumor necrosis factor [TNF-alpha] P01375 26 8 54% 2 36% 2 24% 3 30% 3 16%
Ubiquitin-conjugating enzyme E2 C V = 1 O00762 20 13 81% 1 11% 6 39% 4 39%
Ubiquitin-conjugating enzyme E2 E1 P51965 21 3 16% 1 7% 2 17% 2 20% 3 29%
Total Number of peptides identified 681 326 390 520 590
Average # peptides/protein 15.1 7.6 8.5 11.8 12.6
Average peptide mass, kDa 1.9 3.3 3.0 2.9 2.7
Average peptide charge 2.7+ 4.6+ 4.6+ 4.0+ 4.0+
Average sequence coverage 60% 54% 51% 60% 59%
(continued on next page)
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of hemoglobin beta, 6 keratins, 2 IgG chains, as well as
tetranectin, apolipoprotein A-I, and malate dehydrogenase
were also identified. Similarly to the work of Mann and others,
interleukin-8 (P10145), platelet-derived growth factor B (P01127),
andpro-epidermal growth factor (P01133) belonging to 48protein
standard were not identified with trypsin [36]. Interestingly,
these proteins were detected using Sap9 in all data acquisition
modes.
An important aim of the present study was to establish the
specificity and determine the preferential digestion sites of
the Sap9 protease. The peptides identified from the 1 hour
UPS-1 digest were aligned to include the four amino acids
prior and the four amino acids following the digestion site,
respectively. Duplicate sequences were removed, and the fre-
quency of each amino acid in the resulting P4–P4′ positions was
plotted using iceLogo against the non-redundant humanUniProt
database, Fig. 5 [37]. Here, the x axis represents the amino acid
position between P4 and P4′ (with cleavage occurring between P1
and P1′), and the y axis shows the frequency of each amino
acid expressed as percent difference between the experi-
mental dataset and the UniProt database. As a result, amino
acids present in the peptides identified more frequently than in
the human proteome set have positive y values, whereas those
underrepresentedhavenegativey values. It is therefore apparent
that Sap9 cleavage occurs more likely in the vicinity of basic
residues, Lys and Arg, and it is more likely to occur before acidic
amino acids, such as Asp and Glu. Sap9 digestion is not likely in
the vicinity of Pro, and, although possible, cleavage at hydro-
phobic residues such as Ile, Val or Leu is less prominent than in
the vicinity of basic residues.
In agreement with a typical bottom-up proteomics exper-
iment [11], only 21% of the 10,095 CID MS/MS mass spectra
acquired for the tryptic digest resulted in peptide identifica-
tion. In contrast, 42% of the 3848 CID MS/MS mass spectra of
the 1 h Sap9 digestwere assigned. This two-fold improvement in
spectral identifications illustrates the utility of long peptides for
unambiguous peptide and protein assignment, the decreased
likelihood for hits against a shuffled, non-existing sequence, as
well as the ability of the existing data acquisition and analysis
software to handle peptides in this size and charge range.
Importantly, when charge state 3+was excluded, Sap9 identified
a similar number of proteins with 2 times lower number of
tandem mass spectra compared to trypsin (326 identified
peptides versus 681 for Sap9 and trypsin, respectively).
Lowering the data dependent acquisition precursor ion
intensity threshold from 15,000 to 5000 greatly increased the
number of tandem mass spectra triggered, and enhanced the
number of peptides identified, whereas the sequence coverage
did not improve significantly (Table S3, Supplementary Infor-
mation). Increasing the minimum signal threshold inherently
increases the number of precursor ions isolated and enhances
the quality of the tandem mass spectra [33]. This is especially
important for long peptides with high charge states, as it is the
case of those produced by Sap9 digestion.
The peptide size distributions obtained after 30 min or
1 hour Sap9 digestion in comparison to those observed with
trypsin were extracted using RawMeat 2.1 (VAST Scientific,
Cambridge, MA) and are shown in Fig. 6. Note, the y-axis
values in the top and middle panels are the total number of
peptides that were selected for fragmentation, not only those
that were identified. As it can be seen from Fig. 6, top panel,
the peptides generated with Sap9 after 30 minute digestion
(average 4.1 kDa) were considerably longer than after 1 hour
digestion (average 3.5 kDa). However, with the LC–MS/MS
conditions applied not all proteins could be identified. Many of
the peptides produced with 30 min Sap9 digestion were not
reliably identified using the fragmentation methods, data
acquisition strategies, and interpretation algorithms employed
herein. Therefore, the results from this set of experiments were
excluded from further discussion. In comparison with Sap9
results, tryptic peptides were, on average, considerably shorter
(~1.9 kDa), Fig. 6 middle panel. Finally, Fig. 6 bottom panel
shows the theoretical peptide size distributions for the 48
Table 2 (continued)
Protein Accession
#
MW,
kDa
Trypsin
overnight
Sap9 1 h
CID >3+ CID >3+ HCD >2+ CID >2+ HCD
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
#pept. Seq.
cov.
% spectra identified 21% 34% 46% 42% 55%
Total Number of UPS-1 proteins/total proteins with 2 peptides 44/61 39/41 40/42 44/46 46/48
Total Number of UPS-1 proteins/total proteins with 1 peptide 45/64 43/46 46/50 44/46 47/54
Fig. 5 – IceLogo representation of Sap9 cleavage specificity
determined based on the peptides generated from the 48
proteins present in the UPS-1 standard mixture.
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proteins digested with trypsin (1 missed cleavage allowed) and
LysC. Both enzymes would yield shorter peptides than Sap9
digestion.
Table S4 (Supplementary Information) shows the perfor-
mance of Sap9 in the identification of proteins from the UPS-2
dynamic range standard. Both trypsin and Sap9 have identified
proteins in the 50 fmol–50 pmol range (1 fmol–1 pmol on the LC
column) with comparable average sequence coverage of 56%
for trypsin and 54% for Sap9. Sap9 identified only 3 proteins in
the lowest concentration, whereas trypsin identified 7, albeit
trypsin also identified several contaminant proteins and some
that were not in the UPS-2 formulation (such as ATP-binding
cassette sub-family D member 2 Q9UBJ2).
4. Discussion
The characterization of Sap9 protease is a part of our effort for
benchmarking novel digestion procedures for production of
the mid-size (3–7 kDa) peptides for extended bottom-up prote-
omics. Sap9 has been found to be active in the pH range 3.5–6,
temperature range 25–45 °C, and at E:P ratios (w/w) down to
1:100. As expected, enzyme activity increased with increasing
the enzyme quantity, whereas at optimal pH conditions the
protease maintained its activity even at very low E:P ratios. At
37 °C, thehighest fluorescencewas recorded at pH 4.5. However,
one important observation to make is that optimal conditions
for most aggressive enzyme activity (37 °C, pH 4.5, E:P 1:2.5)
were not themost suitable for obtaining peptides in the 3–7 kDa
range. Under experimental settings were the enzyme is most
active, the peptides detected were on average shorter, and
lower protein sequence coverage values were observed with
the employed extended bottom-up proteomics conditions. In
contrast, by performing the digestion at room temperature, at
pH 5.5, and E:P ratio of 1:10 (w/w), the enzyme activity was
reduced and longer peptides were detected, leading to in-
creased sequence coverage. At room temperature and pH 5.5, a
30 minute incubation yielded peptides fromapproximately 50%
of the proteins in the UPS-1 mixture. The substrate specificity
and ability to digest a variety of proteins using shorter digestion
times (less than 1 h) at pH 4.5, 37 °C remains to be investigated.
The MS/MS-based study of peptides generated from the 48
protein mixture revealed that Sap9 cleaves at adjacent basic
residues or in their vicinity. It most likely cleaves when a basic
or a hydrophobic residue is followed by an acidic amino acid.
This restricted but not exclusive cleavage specificity is impor-
tant for ensuring that a variety of proteins can be processed
within a short incubation time, regardless of their primary
sequence. As a result, proteins that are rich in basic residues
and cannot be identified with trypsin or even LysC (such as a
large number of ribosomal proteins and interleukin-8 (P10145),
platelet-derived growth factor B (P01127), and pro-epidermal
growth factor (P01133) investigated in this study) can be readily
studied using Sap9 digestion. Therefore, Sap9 could be used as a
complementary protease for identification of proteins that
could not be detected using other benchmarked proteases due
to their primary amino acid sequence.
WhenDTTwas added in 1:3molar ratio prior to digestion, no
Sap9 autolysis products were observed. However, when higher
concentration of DTT was used for reduction of disulfide bonds
(i.e., 5 mM), several Sap9 peptides were observed, indicating
autolysis. This is most likely caused by the reduction of the
disulfide bond linking the two Sap9 subunits by the excess DTT
remaining in the digestion solution.
Importantly, state-of-the art mass spectrometers, e.g.,
time-of-flight (TOF) MS or Orbitrap FTMS, are capable to
efficiently analyze 3–7 kDa peptides without any hardware
modification [18,38–40]. MS/MS analysis of a complex protein
mixture digested with Sap9 shows that the size distribution
of the peptides generated by Sap9 is suitable for separation on
a chromatographic column. The single change in the workflow
of currently employed bottom-up proteomics technique is the
requirement for the C8 stationary phase, instead of the more
commonly utilized C18. In addition, increased size and charge
Fig. 6 – Peptide size distribution of the 48 protein mixture
UPS-1 obtained with a) 30 minute or 1 hour Sap9 digestion,
b) overnight trypsin digestion (the inset shows an expanded
view of heavy peptide distribution), and c) theoretical size
distribution of peptides obtained with trypsin (one missed
cleavage allowed) and LysC.
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of peptides in extended bottom-up proteomics may be advan-
tageous forMS/MSperformance, specifically for electron transfer
dissociation (ETD) [41,42]. In general, we identified slightly more
proteins and peptides using HCD compared to CID. This is likely
due to the fact that HCD activation energy is calculated for each
precursor ion in part and it is based on the initial energy setting
normalized to themass and charge of the selected precursor ion.
Includingpeptideswith charge state 3+ as precursor ionshas the
benefit of increasing slightly the number of proteins identified,
albeit it does not significantly improve the sequence coverage of
proteins already identified.
Data analysis software already employed in conventional
bottom-up proteomics can be employed for data interpretation,
although the search algorithms Sequest andMascot used herein
could be further improved to take into account the high mass
resolution andmass accuracy of the product ions [43]. Therefore,
with minor adjustments to the data acquisition strategy and to
the chromatographic separation, extended bottom-up proteo-
mics is straightforward and can be readily implemented on high
resolution MS/MS platforms.
The advantages of using the Sap9 protease versus themore
commonly employed enzymes, e.g., trypsin, are the shorter
digestion time (1 h vs. overnight) and higher protein sequence
coverage obtainable from a single peptide analysis. This, in
turn, may aid in proteoform-level protein identification by
enabling localization of point mutations, deletions, insertions
and/or consecutive PTMs from a single peptide. In addition to
the peptides identified using the data acquisition and analysis
workflow described herein, a large number of highly charged
species (>10+) have been observed. These, inmost cases, did not
yield good quality MS/MS spectra and were therefore discarded.
Optimization of the data dependent fragmentation and acqui-
sition parameters, such as number of charges (AGC setting),
maximum injection time, as well as of the physical instrument
operation parameters, such as gas pressure in the transfer
region between linear ion trap and Orbitrap, may further
improve the identification of the long peptides generated by
Sap9.
Another important advantage of Sap9 for proteome anal-
ysis arises from its high activity in acidic environment, under
conditions where conventional proteases (i.e., trypsin) are
inactive. In acidic pH thiol-disulfide exchange reaction is
inhibited, therefore no disulfide bond rearrangements can
occur [44]. Also, at basic pH values oxidation by ambient
oxygen is more likely to occur than at acidic conditions [45].
This aspect is important, for example, in the proteomic
analysis of therapeutic antibody samples [24,46].
The main disadvantage of using a non-specific protease for
high throughput proteomics is that multiple peptides with
partially overlapping sequences might be generated, increasing
the complexity of themixture. This phenomenon is increasingly
severe at longer digestion times and at digestion conditions
approaching the optimal enzyme activity conditions. However,
in certain application areas, the presence of multiple peptides
with varying lengths from the same sequence regionmight also
be beneficial. For instance, we have successfully employed Sap9
for characterization of monoclonal antibodies, where the long
peptides with partially overlapping sequences aid in determina-
tion of the variable regions and in chain identification [47].
Similarly, Sap9 could be utilized for the study of purified protein
extracts, such as immunoprecipitated samples, where the aim
of the study is proteoform-level characterization.
It can be envisaged that the specificity of Sap9 (or that of
other non-specific enzymes) could be tailored by increasing
the rigidity of the protein structure using protein engineering.
A reduced specificity aimed towards exclusively dibasic and
proximal basic residues would reduce the number of peptides
generated. This, in turn, would further add to the utility of the
enzyme in high-throughput proteomics.
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Figure S1. Amino acid sequence of C. albicans Sap9 from UniProt database 
(accession number O42779). 
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Figure S2. 10% 1D SDS PAGE gel with a) 10 uL of P. pastoris supernatant 
(SN), b) 5 uL of the E2-E4 fractions eluted from the Ni column. 
?
?
His6 affinity column allow the production of highly purified Sap9 where non-
tagged proteins are not retained on the column. The bands below the 43 kDa 
marker on FigureS2 panel b arise from degradation products of the 
recombinant Sap9. This was confirmed by western blotting using an anti-Sap9 
antiserum (data not shown). An advantage of the P. pastoris expression system 
is that this yeast secretes very low level of native proteins. 
? ?
?????????????????
????????? ???????????????????????????????????????????????????????????
143
Figure S3. Fluorescence-based enzyme activity assay recorded at 25 °C, pH 
3.5-6, enzyme:protein ratios a) 1:2.5-1:25, b) 1:50-1:100. 
 
 
Figure S4. Fluorescence-based enzyme activity assay recorded at 37 °C, pH 
3.5-6, enzyme:protein ratios a) 1:2.5-1:25, b) 1:50-1:100 
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Figure S5. Fluorescence-based enzyme activity assay recorded at 45 °C, pH 
3.5-6, enzyme:protein ratios a) 1:2.5-1:25, b) 1:50-1:100. 
 
 
Figure S6. Extracted ion chromatograms of three technical replicates of LC-
MS/MS of carbonic anhydrase digested with Sap9. 
 
 
 
  
?????????????????
????????? ???????????????????????????????????????????????????????????
145
Table S1. Effect of temperature on digestion at E:P ratio 1:2.5 (w/w) at pH 
4.5. Size and charge state distribution of proteolytic peptides from bovine 
carbonic anhydrase 2 after 1 to 8 hours Sap9 digestion obtained by Sequest 
and Mascot. 
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Table S2. Effect of temperature on Sap9 cleavage. Size and charge state 
distribution of proteolytic peptides obtained from seven protein mixture after 
1 to 4 hours Sap9 digestion at E:P ratio 1:2.5 (w/w) identified by Sequest and 
Mascot. 
 
Table S3. Sequence coverage of UPS-1 proteins after 1 hr Sap9 and overnight 
trypsin digestion obtained by Sequest at protein FDR 1%, peptide XCorr score 
thresholds 2.5 (2+), 3.5 (3+), and 3.8 (4+). Data dependent MS/MS 
fragmentation was triggered at signal threshold 5000. Database search was 
performed against a database containing human proteins, UPS-1 formulation 
proteins and their shuffled sequences. Sap9 data was searched using no-
enzyme setting and trypsin data was searched using trypsin with 2 missed 
cleavages. 
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Table S4. Sequence coverage of UPS-2 proteins after 1 hr Sap9 and overnight 
trypsin digestion obtained by Sequest at protein FDR 1%, peptide XCorr score 
thresholds 2.5 (2+), 3.5 (3+), and 3.8 (4+). Data dependent MS/MS 
fragmentation was triggered at signal threshold 5000. Database search was 
performed against a database containing human proteins, UPS-2 formulation 
proteins and their shuffled sequences. Sap9 data was searched using no-
enzyme setting and trypsin data was searched using trypsin with 2 missed 
cleavages. 
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ABSTRACT: Despite the recent advances in structural anal-
ysis of monoclonal antibodies with bottom-up, middle-down,
and top-down mass spectrometry (MS), further improvements
in analysis accuracy, depth, and speed are needed. The re-
maining challenges include quantitatively accurate assignment
of post-translational modiﬁcations, reduction of artifacts intro-
duced during sample preparation, increased sequence coverage
per liquid chromatography (LC) MS experiment, and ability
to extend the detailed characterization to simple antibody
cocktails and more complex antibody mixtures. Here, we eval-
uate the recently introduced extended bottom-up proteomics
(eBUP) approach based on proteolysis with secreted aspartic
protease 9, Sap9, for analysis of monoclonal antibodies. Key ﬁndings of the Sap9-based proteomics analysis of a single antibody
include: (i) extensive antibody sequence coverage with up to 100% for the light chain and up to 99−100% for the heavy chain in
a single LC-MS run; (ii) connectivity of complementarity-determining regions (CDRs) via Sap9-produced large proteolytic
peptides (3.4 kDa on average) containing up to two CDRs per peptide; (iii) reduced artifact introduction (e. g., deamidation)
during proteolysis with Sap9 compared to conventional bottom-up proteomics workﬂows. The analysis of a mixture of six
antibodies via Sap9-based eBUP produced comparable results. Due to the reasons speciﬁed above, Sap9-produced proteolytic
peptides improve the identiﬁcation conﬁdence of antibodies from the mixtures compared to conventional bottom-up proteomics
dealing with shorter proteolytic peptides.
Immunoglobulin Gs (IgGs) are glycoproteins involved in theadaptive immune response in animals and represent 75% of
human immunoglobulins circulating in serum. IgG structure is
composed of two identical light chains (∼25 kDa each) and two
identical heavy chains (∼50 kDa each), with a total molecular
weight of approximately 150 kDa. Currently, monoclonal recom-
binant IgGs are the most popular biotherapeutics and are
employed in the treatment of a variety of pathologies such as
cancer and inﬂammatory diseases.1 Mass spectrometry (MS) has
emerged as the analytical technique of choice for the in-depth
characterization of IgGs,2 and the technique is particularly im-
portant for product quality control (QC) in biotechnology and in
the pharmaceutical industry. During bioproduction, puriﬁcation,
and storage, monoclonal IgGs are subject to a variety of post-
translational modiﬁcations (PTMs). Prior to approval for thera-
peutic use, thorough qualitative and quantitative characterization
of IgGs is required by sanitary authorities. Furthermore, with
the impending patent expiration of some originator IgGs and
the arrival of biosimilar IgG products to the market, the need
for high-throughput analytical methods allowing comparability
studies between originator and biosimilar molecules became
urgent. MS-based peptide mapping and PTM assignment of IgGs
is primarily conducted following a bottom-up proteomics (BUP)
approach, entailing proteolytic digestion of the antibody with
one or a cocktail of the BUP benchmarked proteases of choice
(most commonly trypsin, GluC, or LysC), which yields peptides
with an average mass of ∼2 kDa.3−5 Recently, top-down (TD)
mass spectrometry approaches have been applied for the study of
intact IgGs.6−8 TD MS oﬀers certain advantages over BUP, in-
cluding limited sample manipulation and, hence, reduced pro-
bability for introducing artifacts in the sample. Nevertheless,
BUP is better supported by the current state-of-the-art in terms
of both technical equipment and data analysis software, therefore
remains the technique of choice for most MS laboratories and
QC units. Furthermore, the use of proteolytic enzymes with
diﬀerent cleavage speciﬁcities combined with multiple liquid
chromatography-tandem mass spectrometry (LC-MS/MS) ex-
periments can result in up to 100% sequence coverage of IgGs,
whereas TD MS is currently limited to ∼30%.6
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One of the major limitations in BUP studies of the IgGs is
introduction of artifacts. These may ensue from the lengthy
sample preparation and protein digestion protocols carried out
under basic pH conditions, which are typical, for instance, in
denaturation with urea prior to trypsin proteolysis. Speciﬁcally,
these conditions can favor deamidation, which consists in the
replacement of Asn and Gln amino acid residues with Asp and
Glu, respectively, through the formation of a cyclic intermedi-
ate.9,10 This phenomenon implies the introduction of charged
residues in the polypeptidic chain. Moreover, the process can
generate both stereo and structural isomers of Asp and Glu,
potentially altering also the high-order structure of the protein.
Deamidation is therefore responsible for the loss of biological
activity of IgGs when located in the antigen-binding domains and
speciﬁcally in one of the complementarity-determining regions
(CDRs).11,12 Harris et al. showed that∼17% of Trastuzumab, an
important IgG1 biotherapeutic, contains deamidations at two
diﬀerent sites in its CDRs (one in the light chain and one in heavy
chain). The deamidated IgGs were separated with ion exchange
chromatography, and deamidation sites were assigned using
Edman degradation and matrix-assisted laser desorption ion-
ization time-of-ﬂight (MALDI TOF) MS. It was found that the
deamidated IgG variants present signiﬁcantly reduced potency.
Tandem mass spectrometry (MS/MS) is an eﬃcient tool
for the assessment of protein deamidation, notably by radical-
drivenMS/MS.13 Pioneering studies byO’Connor and co-workers
demonstrated the capability of electron capture dissociation
(ECD)14 and electron transfer dissociation (ETD)15 for distin-
guishing structural isomers derived by deamidation of Asn and
Gln through the detection of diagnostic c- and z-type product
ions.10,16,17 Zubarev and co-workers extended the application of
this technique to large-scale proteome investigations, with ECD
performed under LC-MS/MS time constraints.18
Some of the above-mentioned limitations of BUP might be
solved by the modiﬁcation of the IgG digestion protocol. Middle-
down (MD) MS, performed with limited proteolysis targeting
the IgG hinge region using enzymes such as papain or IdeS,
was proven to lead to sequence coverage of up to ∼65% and
has shown potential for the identiﬁcation of post-translational
modiﬁcations (PTMs) like Met oxidation without noticeable
introduction of artifact PTMs, as shown by Fornelli et al.19,20
Nevertheless, the analysis of ∼25 kDa IgG subunits requires the
availability of ion activation/fragmentation techniques eﬃcient
on large biomolecules and high-resolution mass analyzers.
Similarly to TD MS, ETD is currently the MS/MS technique
of choice for MD MS of IgGs. Novel MS/MS techniques, such
as the recently introduced ultraviolet photodissociation (UVPD)
at 193 nm by Shaw et al.,21 are expected to improve the per-
formance of both TD and MD MS. Finally, the impetus in
modern drug discovery is to extend the MS approaches for the
characterization of IgG mixtures, ranging from simple cocktails
containing 3−10 IgGs, to complex mixtures of IgGs present in
serum. However, the current performance level of TD MS and
MD MS for analysis of complex (>5 proteins) IgG mixtures is
limited, speciﬁcally by the ineﬃcient separation and fractionation
of solution-phase protein mixtures. The analysis of IgG mixtures
is further complicated by the high proteoform-level complexity of
each IgG and high structural similarity of IgG constant regions.
Following the path signed by MD MS studies, herein we
describe a method for characterization of IgGs which is aimed at
maintaining and strengthening the advantages inherent to BUP,
particularly the high sequence coverage, while minimizing some
of its characteristic drawbacks. The proposed approach, referred
to as extended bottom-up proteomics (eBUP),22 is based on IgG
proteolysis by the secreted aspartic protease 9 (Sap9) from C.
albicans, which oftentimes produces peptides substantially larger
(∼3.5 kDa on average) than in BUP.23 The entire protocol
centered on Sap9 digestion was designed for keeping the sample
under slightly acidic conditions during all the preparation steps.
This is important for reducing de facto Asn and Gln deamidation
in respect to typical BUP workﬂows, as assessed here by LC-MS/
MS for Asn deamidation. The advantages of the proposed eBUP
approach for IgG structural analysis are demonstrated for an
isolated IgG and a cocktail of IgGs, with envisioned method ex-
tension for analysis of complex IgG mixtures.
■ EXPERIMENTAL SECTION
Samples and Sample Preparation. Monoclonal antibod-
ies, IgGs, of subclasses IgG1, Adalimumab (Humira, Abbott Labo-
ratories), Bevacizumab (Avastin, Genentech/Roche), Rituximab
(Rituxan, IDEC Pharmaceuticals/Genentech) and Trastuzumab
(Herceptin, Genentech), IgG2, Panitumumab (Vectibix, Amgen),
and IgG4, Natalizumab (Antegren, Biogen IDEC) were obtained
in their formulation buﬀers and versions approved by European
Medicines Agency. Ammonium bicarbonate, urea, iodoacetamide,
tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT),
and sodium citrate were obtained from Sigma-Aldrich (Buchs,
Switzerland). Protein-grade guanidinium-chloride (GdnCl) was
purchased from Carl Roth GmbH (Karlsruhe, Germany). Aceto-
nitrile (ACN), methanol (MeOH), formic acid (FA), and 2,2,2-
triﬂuoroethanol (TFE) were obtained in LC-MS purity grade.
Acetonitrile and methanol were purchased from Fluka Analytical
(Buchs, Switzerland). Formic acid was obtained fromMerck (Zug,
Switzerland), and 2,2,2-triﬂuoroethanol from Alfa Aesar GmbH &
Co KG (Karlsruhe, Germany). Proteases trypsin and Glu-C were
purchased from Promega (Dübendorf, Switzerland). Secreted
aspartic protease 9 (Sap9) from C. albicans was recombinantly ex-
pressed in P. pastoris and puriﬁed as previously described.24
Sap9 Proteolysis. Single IgG (Trastuzumab) or an equimo-
lar mixture of six IgGs were subjected to two sample preparation
procedures at diﬀerent pH values before digestion at pH 5.5,
as follows. Procedure I: Sample was diluted with 6.8 M urea in
100 mM ammonium bicarbonate buﬀer (pH 7.8), reduced by
addition of DTT to a ﬁnal concentration of 5 mM and incubated
at 50 °C for 1 h, followed by 45 min alkylation at room tem-
perature in the dark with 18 mM ﬁnal iodoacetamide. To reduce
urea concentration below 0.6 M and to obtain optimal digestion
pH, samples were further diluted 20×with 50mM sodium citrate
buﬀer (pH 5.5). Procedure II: Samples were diluted with 6 M
GdnCl in 50 mM sodium citrate buﬀer (pH 5.5) and reduced
withTCEP (ﬁnal concentration 5mM) for 1 h at room temperature.
Alkylation of reduced thiols was omitted due to acidic environment.
Reduced samples prepared either with Procedure I or II were
digested in triplicate with Sap9 in enzyme to protein (E/P) ratio
1:10 (w/w) for 1 h at 25 °C and at pH 5.5.23 Reactions were
quenched by addition of TFA to 1% ﬁnal concentration.
Trypsin and GluC Proteolysis. Single IgG was diluted with
6 M GndCl in 100 mM ammonium bicarbonate buﬀer (pH 7.8),
followed by reduction and alkylation as described above. Sample
was further diluted 20× in ammonium bicarbonate buﬀer
(pH 7.8) and digested with trypsin, E/P ratio 1:20 (w/w), at
37 °C overnight.25 The mixture sample was reduced and
alkylated as described in Procedure I, diluted 20× in 100mM am-
monium bicarbonate buﬀer (pH 7.8), and subjected to overnight
proteolysis with trypsin or GluC in E/P ratio 1:20 (w/w) at
37 °C.
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LC-MS/MS Analysis. Proteolytic peptides obtained by diges-
tion with Sap9, trypsin or GluC were desalted oﬀ-line using
pooled C4 and C18 (described in Supporting Information) or
just C18 ZipTip cartridges (Millipore, Billerica, MA), respec-
tively, prior to LC separation. Approximately 8 pmol of peptide
mixture was loaded onto C8 (2 cm, 100 Å, 5 μm) or C18 (2 cm,
100 Å, 3 μm) trap-columns for 10 min with 0.1% FA at a ﬂow rate
of 8 or 4 μL/min, respectively. Reversed-phase nano LC was
performed using a Dionex Ultimate 3000 system (Thermo
Scientiﬁc, Bremen, Germany) equipped with C8 column (i.d.
75 μm, 150 mm, 300 Å, 5 μm) for separation of Sap9 proteolytic
peptides or C18 column (i.d. 75 μm, 250 mm, 100 Å, 3 μm) for
peptides obtained from trypsin and GluC digestions. Solvent A
was composed of 0.1% of FA in water and solvent B of 50%
MeOH, 20% ACN, 10% TFE, and 0.1% FA. The percentage of
the organic phase was increased from 5 to 60% over 60min for all
performed analyses.
The outlet of chromatographic column was coupled online
with a nano electrospray ionization (ESI) source (Nanospray
Flex ion source, Thermo Scientiﬁc) equipped with a metallic
emitter at a 2.2 kV potential. Mass spectrometric analysis was
performed on a hybrid high-ﬁeld LTQ Orbitrap Elite FTMS
(Thermo Scientiﬁc) equipped with ETD. Analysis of peptides
was carried out using diﬀerent ion activation/fragmentation tech-
niques in data-dependent mode. In all LC-MS/MS runs, the
survey scan was performed at 60 000 resolution (at 400 m/z) in
the Orbitrap FTMS with automatic gain control (AGC) set at
1E6. Dynamic exclusion of the precursor ion masses was enabled
with 60 s duration.
Isolated precursor ions of Sap9-produced peptides were sub-
jected to higher-energy collision induced dissociation (HCD),
collision-induced dissociation (CID), or ETD in separate LC-
MS/MS runs. Singly and doubly charged precursor ions were
excluded from triggering MS/MS event. The AGC (number of
charges) target value for MS/MS events was always set to 5E4.
HCD was performed in a top-5 mode with product ion detection
in theOrbitrap FTMSoperating at 15 000 resolution (at 400m/z)
with 3 microscans per each scan. Normalized collision energy
(NCE) was set at 27% (default charge state: 3+).26 CID was per-
formed in a top-10 mode with product ion detection in the LTQ
(normal scan speed) and NCE of 35%. Finally, ETD was per-
formed (for IgG mixture only) in a top-5 mode (AGC target
value for ﬂuoranthene radical anions 5E5, max injection time 50
ms) with charge-dependent duration enabled (default value of 80
ms for charge state 2+). ETD product ion detection was carried
out in the Orbitrap FTMS operating at 15 000 resolution (at 400
m/z) with 3 microscans. Signal-to-noise (S/N) threshold was set
to 15 000 throughout all experiments (relative intensity units).
Peptides obtained from trypsin and GluC proteolysis were anal-
yzed by CID in a top-10 mode with the instrument operating
with the same parameters indicated above, with the exception of
rejecting only singly charged peptide ions for MS/MS triggering.
For diﬀerentiation of stereoisomers produced by deamidation,
either single Trastuzumab or IgG mixture digests obtained with
trypsin were analyzed in a LC-MS/MS fashion with the instru-
ment working in targeted mode, using a predeﬁned precursor ion
list. Dynamic exclusion was disabled and ETD was performed
with AGC target value for ﬂuoranthene of 2E5. Product ion
detection was performed in the Orbitrap FTMS at 15 000 reso-
lution (at 400 m/z) averaging 7 microscans. This LC-MS/MS
experiment was repeated for the Sap9 IgG digest (Sap9 sample
preparation Procedure II).
The MS/MS spectra were analyzed using Sequest (Proteome
Discoverer 1.4, Thermo Scientiﬁc). The Sequest XCorr
threshold values were empirically determined and set to 3.5
for CID and 3.0 for HCD. In case of ETD, the threshold values
were 2.0, 2.5, and 2.8 for charge states 3, 4, and >5, respectively
(arbitrary values determined by visual inspection of mass
spectra). The precursor ion mass tolerance was set to 10 ppm,
Figure 1. CID mass spectra and sequence coverage of (top) light and
(bottom) heavy chains of therapeutic antibody IgG1 Trastuzumab
obtained by analysis of Sap9-derived peptides from a single LC-MS/MS
analysis. Sequenced regions are shown in bold letters, CDRs are
highlighted in gray. Vertical double lines indicate Sap9 cleavage site;
numbers 1 and 2 in light chain and 1 to 3 in heavy chain indicate peptides
unique to Trastuzumab.
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product ion tolerance to 0.02 Da. IgG peptides were searched
against the six IgG database and their shuﬄed sequences,
allowing for Cys carbamidomethylation, oxidation of Met,
N-terminal pyroglutamic acid formation from Gln and deami-
dation of Asn as dynamic modiﬁcations. The cleavage speciﬁcity
was set to no-enzyme for Sap9, and to trypsin or GluC allowing
for two missed cleavages for corresponding experiments.
■ RESULTS AND DISCUSSION
Trastuzumab Analysis with Sap9. Trastuzumab IgG was
subjected to a 1 h Sap9 digestion (sample preparation Proce-
dure I). The resultant peptide mixture was then analyzed using
CID LC-MS/MS, Figure 1. Single antibody peptide mapping
resulted in up to 100% sequence coverage for both chains of
Trastuzumab from a single LC-MS/MS experiment. In com-
parison, currently employed digestion protocols for antibody
analysis (digestion with trypsin and/or endoproteinases such as
GluC or LysC)2 reach these values by combining two or more
proteases, long digestion hours, and/or multiple LC runs. More-
over, we identiﬁed peptides unique to Trastuzumab that ensure
almost 50% sequence coverage of the light (peptides 1 and 2,
Figure 1, top panel) and 30% of the heavy chains (peptides 1
and 2, Figure 1, bottom panel). Figure 1 also depicts CID mass
spectra of peptides containing consecutive CDRs for both heavy
and light chains with assigned CID product ion series (b- and
y-ions), additionally conﬁrming the correct peptide identiﬁcation.
CDR3 in a variable domain of a heavy chain (VH) is one of the
hypervariable loops constituting the antigen-binding site of an
antibody that displays high diversity both in sequence and in
length. VH CDR3 can be up to 62 residues long, as recently
reported by Larsen et al.,27 and, interestingly, it is the precise
length of VH CDR3 that was shown to be the crucial speciﬁcity
determining factor in formation of an antigen-speciﬁc binding
site.28 Nowadays, CDR3 grafting is a widely employed technique
for in vitro humanization of antibodies from mammalian
cells. Ergo, unambiguous identiﬁcation and characterization of
complete CDR3 from the antibody of interest is important.
Figure 1, bottom panel, shows a ∼7 kDa long unique peptide,
indicated with number 2, which contains the entire CDR3 of a
heavy chain (Hc) of Trastuzumab. This, along with the extensive
backbone cleavage assignment, oﬀers complete information about
sequence, length, and localization of this loop. This would not be
the case with benchmarked proteases which would cleave in the
middle, beginning, or end of the region, resulting in lost con-
nectivity between diﬀerent parts and, thus, making it less feasible to
get length information and assignment to one antibody.
Peptide indicated by number 3 in light chain (Lc, which is not
to confuse with LC being “liquid chromatography”) of Tra-
stuzumab (Figure 1 top panel) is another long peptide whose
identiﬁcation dramatically augments sequence coverage and,
hence, IgG identiﬁcation. Notably, peptide 3 of the Hc, aside
from increasing sequence coverage, is long enough to be unique
to a class of IgG despite its position deep inside the conserved
region (Figure S1, Supporting Information). Hence, it further
aids in distinguishing between IgG classes in a complex mixture.
Complete sequence coverage for both chains (100%) was also
reached when HCD fragmentation was applied (data not shown).
Moreover, both CID and HCD results attained for a single IgG
analysis are comparable with the ones obtained for Trastuzumab
from the mixture sample, Table 1, taken as an example, vide infra.
The presence of these long peptides reduces the number of
peptide identiﬁcations required per LC-MS/MS run to obtain
full sequence coverage of investigated proteins. Theoretically, it
should also reduce the yield of returned ambiguous hits from a
database search. However, the latter remains to be validated on a
larger data set, as the presence of substantially longer and highly
charged peptides increases spectral complexity in terms of iso-
topically resolved precursor ions and renders product ion charge
state assignments more challenging.
IgG Mixture Analysis with Sap9. We further assessed our
method’s eﬃciency of peptide mapping in an antibody mixture.
An equimolar mixture of six monoclonal antibodies, IgGs, was
subjected to a 1 h proteolytic digestion with Sap9 (sample prepa-
ration Procedure I). Proteolytic peptides were analyzed by LC-
MS/MS. Sap9 proteolysis was repeated three times, exhibiting
high digestion reproducibility as depicted in Figure 2, top panel.
The applied eBUP workﬂow allowed the identiﬁcation of all six
Table 1. Comparison of Sequence Coverage, Average Peptide Length and Charge, Number of Identiﬁed Unique Peptides of Every
IgG in Part, and Number of Total Peptides Obtained from a Single LC-MS/MS Analysis after Single Digestion with Sap9 (1 h),
Trypsin (Overnight), and GluC (Overnight)
*Unique Panitumumab Hc peptide illustrated and discussed in Figure 3 was accounted for in total number of unique peptides for Sap9 CID and
HCD results. **Number of unique peptides for trypsin and GluC is given without/with 2 missed cleavages allowed.30
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IgGs in a single LC-MS/MS run using either of the ion activation
methods applied (CID, HCD, and ETD). The most extensive
protein sequence coverage and the highest number of unique
backbone cleavages was obtained with CID and in part (sequence
coverage) with HCD, whereas the numbers are lower for ETD,
Table 1. Discrepancy between fragmentation eﬃciency in CID
and HCD/ETD could be due to a broad span of charge states
(3+ to 13+) present in the sample. Since HCD and ETD are
charge-dependent activation methods, their successful application
requires further optimization of fragmentation parameters such
as collision energy in HCD, ion/ion reaction time and number of
interacting ions in ETD, or potentially employing the hybrid
method that combines the two, such as EThcD.29
Importantly, peptides containing CDR entities, required for
discrimination between IgGs, were detected for each IgG. Com-
plete and assigned fragmentation maps and companion sequence
coverages (with the exception of ETD due to the yet insuﬃcient
fragmentation) for each IgG are given in Figure S2, Supporting
Information. For comparison, the same IgG mixture was sub-
jected to a digestion with benchmark proteases, trypsin, and
GluC, commonly employed for quality control analysis of re-
combinant IgGs. As expected, both proteases identiﬁed all IgGs,
Figure 2. Extracted LC-MS/MS (CID) base peak chromatogram of IgG peptides obtained after triplicate 1 h digestion with Sap9 (sample preparation
Procedure I). Panels 1−6 show examples of the unique peptides containing the CDRs for three selected IgGs separated by LC: (1) Natalizumab Hc
(IgG4), (2) Rituximab Hc (IgG1), (3) Panitumumab Hc (IgG2), (4) Rituximab Lc, (5) Natalizumab Lc, (6) Panitumumab Lc.
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with average sequence coverage of 69 and 59%, respectively.
Importantly, Sap9-based eBUP analysis resulted in noticeably
higher average sequence coverage (up to 91% for CID, Table 1).
Notably, there is a 1.5-fold increase in average length of Sap9-
produced peptides with respect to those obtained by classical
BUP experiments (3.3 and 2.2 kDa, respectively), Table 1. This,
in turn, increases the likelihood of the presence of two consec-
utive CDRs within one peptide produced by Sap9, which is
generally not observed for shorter proteolytic peptides.
CDRs are parts of the IgG variable domains, which derive from
diﬀerent genes linked during a genetic recombination process. As
a result, diﬀerent IgGs might share one or more CDR regions,
even when targeting diﬀerent antigens. Speciﬁcally, in the mix-
ture used for this study, the CDRs of the light chains of Pani-
tumumab and Bevacizumab demonstrate a shared sequence:
QDISNY. In addition, a CDR belonging to theHc of Trastuzumab
(sequence:GFNIKDTY) is identical to part of the variable domain
of the Hc of Natalizumab (Figure S2, Supporting Information).
Therefore, the presence of peptides containing two CDRs may
lead to more reliable identiﬁcation of each IgG present in a mix-
ture, and it is pertinent to determine connectivity between these
regions. Results from a single LC-MS/MS run of 1 h Sap9 digest
indicate that highly charged long peptides containing consecutive
CDRs for all IgGs in the mixture were successfully generated,
separated, and identiﬁed. Figure 2 illustrates these representative
peptides for each subclass of IgGs with the exception of Pani-
tumumab Hc with their respective CID mass spectra with b- and
y-product ions assignment. For this latter chain, the representative
peptide was present in the chromatographic run, but due to its low
abundance and resulting poor fragmentation, it did not pass the
database search threshold and is not illustrated here. Nevertheless,
Sap9 proteolysis of PanitumumabHc yielded a long peptide with a
single CDR, Figure 2.
Amino Acid Substitution Analysis. The genetic recombi-
nation processes involved in the characteristic hypervariability
of CDRs can eventually lead to single point mutations (i.e.,
substitutions of single bases in the DNA), potentially resulting in
replacements of one amino acid residue with another within the
polypeptidic chain. The Lys-to-Gln substitution can be caused by
this process because the codons encoding for the two amino
acids diﬀer by a single base (Figure S2, Supporting Information).
Figure 3 highlights the ability of the applied LC-MS/MS-based
method to identify and localize a single amino acid substitution
on a long peptide, wherein a Lys residue, typical of IgGs1, is
substituted for Gln in the analyzed IgG2, Panitumumab. This
modiﬁcation produces a net mass change of 36mDa/z, where z is
the charge state of an ion, which is translated into a diﬀerence of
only 7 mTh (or 0.007 m/z) for a 5+ precursor ion. However,
both the b and y product ions (in this case b26 and y17) are
required for the localization of this modiﬁcation. The localization
of the substitution relies on MS/MS, whereas high-resolution
and mass accuracy are required for product ion detection,
considering the very small mass shift. This falls within the lowest
tolerance window for product ion assignment allowed by the
search algorithm (0.02 Da), leading to potential ambiguous
peptide identiﬁcation on product ion level. Note that the
Figure 3. Extracted ion chromatogram of monoisotopic peaks at m/z 969.4727 and 969.4799 (5+) of the peptides DTLMISRTPEVTC-
VVVDVSHEDPEVQFNWYVDGVEVHNAKTK and DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK, corresponding to a
peptide unique to Panitumumab Hc (Q containing), and to a peptide that is shared between IgG1 subclass analyzed herein (K containing), respectively.
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glutamine-modiﬁed peptide from Figure 3 wasmanually assigned
and veriﬁed, as initial automatic assignment via the database
search wrongly identiﬁed the lysine analogue. The manual as-
signment was possible not only due to the high-resolution detec-
tion of both b- and y-ion series, but also because the chro-
matographic elution of the two peptides is baseline separated
under the applied conditions, and the 4:1 ratio between peak
areas of the two corresponds to the presence of four IgGs1
sharing the Lys-containing peptide versus the single IgG2 with
the Gln-peptide.
Deamidation Assessment of Trastuzumab. Trastuzumab
contains two asparagine amino acid residues prone to deami-
dation in its CDRs. One is in the CDR1 of the Lc (Asn30), and
one in the CDR2 (Asn55) of the Hc. Strong cation exchange
chromatography (SCX) is generally employed to obtain a charge
variant proﬁle of IgGs. This proﬁle generally contains a major
peak corresponding to the most abundant proteoform of the
IgG with peaks to its left corresponding to acidic proteoforms,
whereas basic proteoforms elute after this main peak. Basic pro-
teoforms can generally be attributed to the presence of the
C-terminal lysine on one or both heavy chains and C-terminal
proline amidation, whereas acidic charge proteoforms are gen-
erally attributed to Asn or Gln deamidation and N-terminal
glutamine cyclization to form pyroglutamic acid. However, SCX
alone does not allow the attribution and assignment of charged
proteoforms in the IgG sequence. Peptide mapping with bottom-
up LC-MS/MS is a powerful tool to sequence digested peptides
and assess PTMs; however, common enzymes such as trypsin
and GluC require basic pH and prolonged incubation times at
37 °C to achieve eﬃcient digestion. This induces the deami-
dation of Asn rendering impossible the quantitatively accurate
assignment of the endogenous deamidated asparagine amino
acids. As shown in Figure 4, trypsin-digested Trastuzumab shows
high deamidation rates with diﬀerent deamidation products as
conﬁrmed by ETD MS/MS, vide infra. On the other hand, Sap9
digestion is performed at pH 5.5 over only 1 h (sample prepa-
ration Procedure II), which does not induce artifact deami-
dation, Figure 4, top panel. As an example, we can see that for the
peptide-containing Asn30 of Lc, we have two forms, a major
nondeamidated form (92%) and a minor deamidated form
of nearly 8%. The MS quantitation is in accordance with the
results obtained by a more traditional technique (i.e., peak
area calculation using the UV chromatographic trace) by
Harris et al.11
As deamidation can lead to aspartic and isoaspartic acid
formation, we employed ETD MS/MS to determine the isomer
type of deamidated peptides, Figure 5. ETD MS/MS has been
described to yield diagnostic ions diﬀerentiating aspartic and
isoaspartic acids. These ions are a z′−58 Da and a c•+58 Da
species for isoaspartic acid, as previously described by O’Connor
and co-workers.10 We found that with Sap9-based eBUP the
deamidation at Asn30 in the Lc resulted in formation of aspartic
acid and at Asn55 in the Hc in isoaspartic acid, whereas several
deamidated forms for the tryptic peptides containing these
deamidation sites were observed. Figure 5 shows an extracted ion
chromatogram of the tryptic peptide containing Asn55 of Hc.
Although we have observed only one peak corresponding to the
nondeamidated form, four diﬀerent peaks corresponded to the
deamidated forms. ETD-based LC-MS/MS showed that two
of those corresponded to aspartic acid, and two others corre-
sponded to isoaspartic acid. Generally, the deamidation of
asparagine via a succinimide intermediate followed by partial
hydrolysis of the succinimide ring leads to isoaspartate as the
major product and aspartic acid as the minor product.9,10 Alter-
native mechanisms by a nucleophilic attack without the succi-
nimide intermediate leading to aspartic acid have also been
Figure 4. Assessment of Trastuzumab deamidation induced by diﬀerent sample preparation/digestion protocols. Top panel: 1 h Sap9 at pH 5.5
following sample preparation Procedure II (A) Asn55‑Hc, (B) Asn30−Lc; bottom panel: overnight trypsin at pH 7.8 (C) Asn55‑Hc, (D) Asn30-Lc. *
indicates deamidated peptide, corresponding to ∼0.5% deamidation.
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reported.11,12 Here, for the tryptic peptide, we have observed two
isomers eluting at diﬀerent retention times. This is presumably
due to L and D forms of the aspartate/isoaspartate residues.
Finally, we also attempted to assess deamidation of Trastuzumab
when it is present in IgG mixture, and we obtained comparable
results (Figure S3, Supporting Information).
■ CONCLUSIONS
The primary consequence of the increased length of proteolytic
peptides under eBUP conditions is that, with the application of
high-resolution MS, 100% sequence coverage is obtained for
both Hc and Lc in targeted analysis of a single IgG. The analysis
of an IgG mixture (here composed of six IgGs from three
subclasses) returned up to 99 and 100% sequence coverage for
Hc and Lc, respectively. Importantly, these results were achieved
in a single LC-MS/MS run preceded by a quick (1 h) Sap9
proteolysis at slightly acidic pH conditions. Results obtained
using both sample preparation procedures (performed at pH 7.8
or pH 5.5) are comparable in terms of protein identiﬁcation.
Furthermore, it is noteworthy that Sap9 often generates peptides
which include two consecutive CDRs, hence dramatically
increasing the conﬁdence in the IgG identiﬁcation. This aspect
is of particular importance for the analysis of IgG mixtures, such
as a pool of polyclonal antibodies or a cocktail of monoclonal
antibodies,31 as the case of diﬀerent IgGs sharing full sequence of
one CDR domain is not rare, as exempliﬁed here by CDR1 in
light chains of Panitumumab and Bevacizumab. In summary,
we optimized a quick and simple proteomics-grade pipeline that
can be readily implemented in the current state-of-the-art
proteomic setup. It enabled identiﬁcation of modiﬁcations as
small as near-isobaric single point amino acid variation and
assessment of deamidation with results comparable to up to date
ﬁgures of merit.
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Experimental methods details: pooled C4-C18 ZipTip desalting protocol. 
 
Materials 
-? Resin conditioning solution: MeOH 
-? Wash solution: 0.1% TFA in H20 
-? Peptide elution solution: 80% ACN/20% H20/0.1% FA (v/v/v) 
-?  
Procedure (recommended sample volume 10 ?l) 
Start with C4 ZipTip cartridge as follows: 
1.?Condition - Aspirate 10 ?l of conditioning solution and discard to waste; 
                 repeat five times 
   - Aspirate 10 ?l of wash solution and discard to waste; repeat 
             five times 
 
2.?Load - Slowly aspirate 10 ?l of sample and expel the liquid back into the      
          tube; aspirate-expel 15 times in the tube 
 
3.?Wash - Aspirate 10 ?l of wash solution and expel back into the sample      
          tube; repeat 5 times (note: this will increase the final volume in the 
         sample tube, vortex prior to C18 procedure) 
4.?Elute - Aspirate 5 ?l of wash solution and expel into the new tube; 
          aspirate-expel 15 times in the tube  
 
Repeat steps 1-4 with C18 ZipTip cartridge, with step 3 modified as follows:  
3* Aspirate 10 ?l of wash solution and discard to waste; repeat 5 times 
 
Pool fractions together and dilute with 0.1%FA to final 10% ACN  
 
Alternatively: mix with  5% ACN/0.1% FA and inject directly on RP nano C8 
column 
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Figure S1. Sequence alignment of light and heavy chains for a) all IgG1 
present in the mixture, b) IgG1 (Adalimumab), IgG2 (Panitumumab) and 
IgG4 (Natalizumab). Residues are colored according to their physicochemical 
properties. "*" indicates positions which have a single, fully conserved 
residue,  ":" indicates conservation between groups of strongly similar 
properties,  
"." indicates conservation between groups of weakly similar properties. 
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b)  
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Figure S2. Sequence coverage of light (top) and heavy (bottom) chains of a) 
Adalimumab, b) Trastuzumab, c) Bevacizumab, d) Panitumumab, e) 
Natalizumab and f) Retuximab obtained from single LC-MS/MS analysis of 
IgGs mixture. N-terminal b-ions and C-terminal y-ions obtained by CID and 
HCD MS/MS are indicated on the fragmentation map. Fragments of all 
observed charge states were assigned based on the analysis of MS/MS 
spectra for all identified peptides that triggered data-dependent MS/MS 
acquisition. Identified peptides and sequenced regions are indicated in light 
gray (CID) and dark gray (only identified by HCD).  Peptides carrying 
pyroglutamic acid formed from Glutamine (Q) PTMs are shown in red. N/n 
indicates sites where non-deamidated and deamidated asparagine were 
confirmed by manual analysis. 
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Figure S3. Comparison of Trastuzumab deamidation induced in a six IgG 
mixture by different sample preparation/digestion protocols. Top panel: 1 hr 
Sap9 at pH 5.5, sample preparation Procedure II (A) Asn55-Hc, (B) Asn30–Lc; 
middle panel: 1 hr Sap9 at pH 5.5 but sample preparation performed at pH 
7.8 following Procedure I (C) Asn55-Hc, (D) Asn30-Lc; bottom panel: overnight 
trypsin at pH 7.8 (E) Asn55-Hc, (F) Asn30-Lc. 
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Extreme proteome complexity requires development of approaches 
complementary to bottom-up proteomics that analyzes mixtures of proteolytic 
(enzymatic) peptides lighter than 3 kDa and top down proteomics that targets 
intact proteins and protein fragments heavier than 15 kDa. Improvements in 
high resolution mass spectrometry (MS) are currently heading proteomics 
towards application of middle-down (MD) approaches and allow their 
implementation for proteome characterization using heavy, 3-15 kDa, 
proteolytic peptides. So far, MD has been limited by the absence of a highly 
specific protease generating large (>3 kDa) peptides. Chemical reagents may 
be powerful alternatives to enzymes for obtaining heavy (3-7, 7-15 kDa) 
peptides. We therefore considered the use of chemicals historically known in 
biochemistry for cleaving polypeptide chains with elevated amino acid 
specificity. Particularly, we chose to target single and less frequent amino acid 
residues (methionine, cysteine and tryptophane). We sought to optimize 
chemical-based MD proteomics platform at four levels: digestion protocols, by 
reducing duration and maximizing efficiency of proteolysis; peptide 
fractionation, for simplified MS analysis; development of liquid 
chromatography-MS strategies, and search algorithms tailored for large 
peptides with specific cleavage signatures. 
Hereinafter reported considerations are the initial premises later translated 
into sorted results for a targeted application and a research article and 
enclosed at the end of this Chapter: 
?? Chemical-mediated digestion: an alternative realm for middle-down mass 
spectrometry (Paper V) 
 
?
?
?????????????????
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6.1. Paper V: Chemical-mediated digestion: an alternative 
realm for middle-down mass spectrometry 
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Abstract 
 
Recent advances in mass spectrometry (MS) instrumentation provide the 
necessary platform for the application of middle-down (MD) proteomics 
approach and investigation of increasingly longer (>3 kDa) peptides in a high-
throughput manner. Generating longer peptides represents a paramount step 
in launching MD pipeline. In bottom-up proteomics (BUP) approach 
substantial protein degradation targeting lysine and arginine residues yields 
moderately evened distribution of peptides in the investigated mass bin 
(typically 6-30 residues-long resulting peptides) for all major kingdoms as well 
as their subproteome/sub compartment level. Whereas frequent digestion 
works well for BUP mass regime, MD proteolysis requires the exact opposite. 
Increasing the length of resulting peptides greatly depends upon the right 
selection of the targeting residue, which is further contingent on distribution 
of amino acid residues within analyte’s primary sequence, and might 
drastically vary passing from one kingdom to another. Hence, MD presently 
meets its practical limitations in the selection of a cleaving agent that would 
provide the desired peptides of 3-15 kDa. To date, only a couple of attempts 
have been made to propose cleaving strategy for MDP, elucidating potential 
cleaving agent candidates. Our recent bioinformatics study has shown that 
cleavage at rare amino acid residues such as methionine, tryptophan or 
cysteine, and even a combination of these digestion sites would be beneficial 
for MD approach. Chemical cleavage allows targeting of rare amino- acids, for 
which no proteolytic enzymes exist. Herein we have investigated the 
performance of several chemical agents targeting primarily Met, Cys and Trp 
(CNBr, BNPS-Skatole and NTCB, respectively) as potential candidates for MD 
proteolysis. Figures of merit such as digestion reproducibility, peptide size 
distribution and presence of side reactions are discussed. 
?
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Introduction 
 
Proteolysis is considered the main avenue for in-solution and in-gel digestion 
of complex protein mixtures.([1-5] One of the main challenges of both extended 
bottom-up (eBU) ([6, 7] and middle-down (MD) proteomics ([8, 9] is the 
generation of peptides in the defined mass range (3-7 or 7-15 kDa, 
respectively), possibly without creating at the same time peptides that are 
either below or above the targeted size. Recent reports described proteases 
such as LysC, GluC, Sap9 or OmpT [8] as a ‘way to go’ for generating large 
peptides in the mass bin suitable for MD. Claimed advantages of these 
proteases should be, aside from providing the targeted length of yielding 
peptides, their reproducible digestion and robustness. Due to these reasons, 
alongside with their non-toxic nature, proteases are typically favored over 
chemicals in proteomics. Although digestion with chemical agents essentially 
performs the same type of reaction, i.e., hydrolysis of peptide bonds in 
proteins, this alternative approach was exclusively applied in a targeted 
fashion, for cleavage of select proteins, mainly with the purpose of obtaining 
primary sequence information, for protein engineering, and to aid in 
elucidation of protein structure [10] for obtaining primary sequence 
information of selected proteins. With the exception of acid hydrolysis [9, 11-
13], the utility of chemical digestion has not been yet investigated in MD 
proteomic studies. One of the main reasons for this delay might also lay in the 
fact that these small molecules target peptide bonds located on one of the 
termini of less frequent amino acid residues such as methionine, tryptophan 
or cysteine, and the larger peptides they generate could not have been 
investigated in a high-throughput manner until recently, due to technological 
limitations in mass spectrometry (MS). High resolution mass spectrometers, 
such as those equipped with orbitrap or time-of-flight mass analyzers, have 
been adapted for high-throughput characterization of large biomolecules just 
in the last decade. Additionally, until recently, a comprehensive information 
about the average size distribution of peptides obtainable by different chemical 
cleavages was missing. Cleavage of proteins with small molecules, in a 
difference to enzymatic cleavage, entails significant modification to the side 
?????????????????
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chain of the targeted residue. This feature alone changes the input information 
on cleavage rules given to the search algorithm. Nowadays, adequate 
supporting bioinformatics platform, often developed for or also applied to top-
down (TD) proteomics [14-16], can tackle analysis of this type of peptides by 
creating specific databases, properly dealing with complex tandem mass 
spectra obtained by the fragmentation of large polypeptides (similarly to what 
happens with TD MS), and also accounting for eventual unexpected 
modifications [17]. However, there were previous attempts to integrate 
cleavage with chemical agents into routine MS analysis of proteins. For 
instance, cleavage after methionine using cyanogen bromide (CNBr) is one of 
the more commonly used chemical cleavage methods that has limited side 
reactions and has a yield of 90-100% [18]. Vestling et al. reported on cleavage 
at C-terminal side of tryptophan residue using BNPS-skatole [19]. There were 
periodical attempts to utilize cysteine as target cleavage site solution for 
analysis of proteins with particular structure and/or structure adjacent 
problematics. Most of these studies however, were limited to the analysis of a 
single or a couple of proteins, investigation of particular modification 
introduced, such as dehydroalanine formation on cysteines in serum albumin 
[20] or alternatively to optimization of the single step in the reaction or entire 
reaction with the purpose of explaining the underlined mechanism in organic 
chemistry. To our knowledge, the herein described chemical cleavage 
procedures [21] have not been applied to large scale MD studies, nor have 
their cleavage efficiencies been evaluated in comparison with enzymatic 
procedures for the proteolysis of simpler protein mixtures analyzed by MS in 
terms of the effective capability of producing peptides in the desired mass 
range. Nonetheless, our group previously reported a bioinformatics study 
about the potential of all amino acid residues for generating MD-sized peptides 
[22], from where Met, Cys and Trp emerged as viable candidate targets for the 
development of a novel MD platform, with a potential for a future application 
to the whole proteome scale. Here, we first report protocol refinements for the 
chemical cleavage at the three aforementioned amino acid residues, followed 
by the experimental results of the analysis of digestion products of a simple 
seven-protein mixture digested with different chemical agents with a high-
?????????????????
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resolution Orbitrap FTMS, validate those that are suitable for future large 
scale middle-down proteomics applications.  
 
Experimental methods 
 
Sample preparation. An equimolar model mixture (100 μM) consisting of yeast 
enolase 1 and 2, bovine apo-transferrin, serum albumin, pancreatic 
ribonuclease A, chicken egg white lysozyme (all from Sigma Aldrich, St. Louis, 
MO, USA) and bovine carbonic anhydrase 2 (Protea Biosciences, Morgantown, 
WV) was prepared in 6.8 M urea in 100 mM ammonium bicarbonate buffer 
(pH 7.8). An aliquote of the mixture was removed for the digestion with NTCB, 
and the remainder was reduced with DTT (5 mM final concentration) at 50 °C 
for 1 hr, followed by 45 min alkylation at room temperature in dark with 18 
mM final iodoacetamide. Sample was then split into aliquots (each containing 
1 nmol of the protein mixture) dried to pellet in a SpeedVac concentrator 
(Eppendorf) and resuspended in the appropriate buffer for each of the 
chemical digestion procedures. For all procedures in part, digestion was 
carried out on three biological replicates. 
 
Cleavage protocols.? All cleavage procedures employed (N-terminal Cys 
cleavage with NTCB, C- terminal Met cleavage with CNBr, C- terminal Trp 
cleavage with o-iodosobenzoic acid or BNPS Skatole) were based on previously 
tailored protocols [23-24]. 
LC-MS/MS analysis.? All peptides obtained through different chemical 
digestion procedures were subjected to the pooled C4-C18 stage tip cleanup 
with ZipTip cartridges (Millipore, Billerica, MA) as described previously [7] 
prior to LC separation. Approximately 8 pmol of peptide mixture was loaded 
onto C8 (2 cm, 100 Å, 5 um) trap-column for 10 minutes with 0.1% FA at a 
flow rate of 8 uL/min, respectively. Reversed-phase nano LC was performed 
using a Dionex Ultimate 3000 system (Thermo Scientific, Bremen, Germany) 
equipped with C8 column (150 mm, 300 Å, 5 um). Solvent A was composed of 
0.1 % of FA in water and solvent B of 50 % MeOH, 20 % ACN, 10 % TFE, and 
0.1 % FA. The percentage of the organic phase was increased from 5 to 60% 
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over 60 minutes for all performed analyses. For all chemical procedures 
employed, each digestion replicate was analyzed in three consecutive technical 
replicates. 
The outlet of chromatographic column was coupled on-line with a nano 
electrospray ionization (ESI) source (Nanospray Flex ion source, Thermo 
Scientific) equipped with a metallic emitter to which a 2.2 kV potential was 
applied. Mass spectrometric analysis was performed on a hybrid high-field 
LTQ Orbitrap Elite FTMS (Thermo Scientific). Identification of peptides from 
Met, Cys or Trp digestions was carried out on a LC-time scale, with the mass 
spectrometer operating in data-dependent mode. In all the LC-MS/MS runs, 
the survey scan was performed at 60'000 resolution (at 400 m/z) in the 
Orbitrap FTMS with automatic gain control (AGC) set at 1 E6. Dynamic 
exclusion was enabled with 60 s duration.  
Isolated precursor ions were subjected to higher-energy collision induced 
dissociation (HCD), with singly- and doubly-charged precursor ions excluded 
from triggering MS/MS event. The AGC (number of charges) target value for 
MS/MS events was set to 5 E4. HCD was performed in a top-5 mode with 
product ion detection in the Orbitrap FTMS operating at 15'000 resolution (at 
400 m/z) with 3 microscans per each scan. Normalized collision energy (NCE) 
was set at 27% (default charge state: 3+).[25]. Signal to noise (S/N) threshold 
was set to 15'000 throughout all experiments (relative intensity 
units).Additionally, intact  mass measurement of individual proteins selected 
upon first round of data analysis was performed in order to investigate and 
confirm protein N terminal truncation. 
 
Data processing. Theoretical distributions as well as in-silico digestions of the 
non-redundant protein databases of human, yeast, and bacteria were 
performed using an in-house Python-based interface based on pyteomics 
library. The peptide size distributions were determined for currently targeted 
amino-acid cleavage sites for MDP (dibasic, D, Q/E, W, M and C). Obtained 
.raw files for all analysis in part were peak picked using ReadW, centroided 
and converted to mzXML format for deconvolution with SNR threshold set to 
3. 
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Database search.?Data was searched in ‘PTM discovery mode’ by MS Align+ 
against custom database (containing primary sequences of 7 proteins used in 
the experiments). Precursor tolerance was set to 10 ppm, and product ion 
tolerance to 0.1 Da. In all cases except for the Cys-based protocol, 
carbamydometylation of cysteine residue was enabled as a fixed modification. 
?
Data analysis. Manual validation was performed to confirm expected label-
introduced modifications as well as to elucidate potential unexpected 
modifications on the side chains of residues. For that purpose, the search 
algorithm results output was ported to Excel, wherein the mass shifts of all 
the protein species were logged, along with purported mass shift localization 
data. The mass shifts were split into cleavage inducing and non-cleavage 
inducing groups (e.g. +25Da on N terminus, associated with formation of itz-
peptide N-terminal to a cysteine vs. +16Da on methionine associated with 
oxidation of methionine). Next, the mass shifts were evaluated with respect to 
plausibility of occurrence under the expected chemistry for a given chemical 
method. Notably, a significant percentage of mass shifts were, in fact, 
associated with sums of multiple non-localized (due to lack of ion 
assignments) mass shifts within a region of a peptide (e.g. 41 Da = 25 Da + 16 
Da, commonly occurring at the N-terminal end of a peptide with a proximate 
methionine). In such cases, manual ion assignment was carried out on .raw 
data, with aid of Protein Prospector in attempt to localize the individual mass 
shifts, most of the time successfully. Furthermore, the results output was 
subjected to additional treatment in cases where the PrSM with the highest E-
score produced clearly mis-assigned output (i.e. ones containing short peptide 
sequences either side of a truncation with mass shifts of several thousand Da).  
In certain instances, the correct net mass shift was identified by the software, 
but the contributing individual mass shifts were associated with a wrong 
residue, hence matching the peptide with primary sequence which has one 
residue more or less than the true peptide has. In all such cases, the .raw data 
was analyzed in ‘de novo’ fashion to verify the proposed alternative 
assignments. ?
?????????????????
??????????????? ????????????????????
184
Results and Discussion. 
 
Choice of cleaving agent in middle-down (MD) is a key step towards a 
successful pipeline. Several residues were suggested as target for MD so far, 
such as Q, D and dibasic (cleaving agents proposed: Lys-C, formic acid [12, 
13], OmpT [8] Sap9 [6], respectively). Comparing obtainable peptide mass 
distribution from in silico digestion of three proteomes (human, yeast and 
bacterial) shown in Figure S1 for each of these methods with less frequent 
residues (M, C and W), it stands to reason to conclude how latter ones could 
be more suitable or strongly complementary avenue for MD digestion. In terms 
of proteome coverage shown, theoretical survey shows how targeting all three 
residues yields substantial proteome coverage (Figure 1). However, throughout 
kingdoms prevalence of methionine as residue of choice is strongly implied; 
99.85, 99.97 and 99.98 % for human, bacterial and yeast proteome 
respectively. (Figure S2). Reaction mechanism of small molecules employed 
here (Scheme 1) is somewhat different than those of proteases. As depicted in 
Scheme 2, this type of hydrolysis introduces a modification to the side chain 
of the targeted residue upon cleavage. Additionally, a different characteristic 
mass modification to the side chain of a residue is introduced even in the case 
the cleavage is omitted (e.g. -34 Da on Cys from dehydroalanine formation, -
29.99 Da on Met from homoserine formation, +15.99 Da on Trp from 
oxindolyalanine formation). This structurally different way of cleaving 
represents a certain challenge for current data analysis software available for 
treatment of data in proteomics (vide infra). Table 1. shows figures of merit for 
employed chemical cleavage of seven protein mixture. The experimentally 
obtained average molecular weights for the peptides generated by each 
protocols (5.8, 7.8/8.8 and 8.3 kDa for cleavage at C, W and C, respectively) 
are in accordance with theoretical distribution (Figure SI1) and fall in the 
middle of the desired 3-15 kDa mass bin for middle-down. For the iodobenzoic 
acid protocol, the average sequence coverage was 51.4%, with cleavages at W 
detected in 79.4% (27/34) of cases. Notably, several of the identified peptides 
showed cleavage at the N-terminal, rather than C-terminal side to the 
tryptophan. In other cases, a previously unreported mass shift of 31.98 Da 
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was observed (13.98+H2O). Notably, for this particular protein mixture, the 
identified peptides, specifically for the larger proteins tended to be located at 
or very close to the termini of the proteins (e.g., in the case of serotransferrin, 
seroalbumin and enolase). As expected, ribonuclease, for lack of tryptophans, 
and due to its relatively small size (13.6 kDa) was detected as an entire protein 
in MD instrument setup. For the BNPS protocol similar results were obtained: 
overall sequence coverage (excluding ribonuclease) was 47.8% and cleavages 
were observed at 73.5% (25/34) of all tryptophan residues. Finally, some of 
the identified peptides contained cleavages around basic and acidic amino 
acids and not in vicinity of tryptophans. An in-depth analysis of the cleavage 
sites identified for the CNBr protocol revealed that, contrary to the 
chemoselectivity proposed for the reagents, cleavages were equally likely to 
occur at methionine and at tryptophan. In fact, disregarding N-terminal 
methionines, cleavages were identified at 72.5% (37/51) of methionines and 
76.5 % (26/34) of tryptophans – the latter percentage being effectively equal 
to the two observed for the tryptophan-specific protocols, vide supra. A 
mechanism involving halogenation of tryptophan followed by HBr loss and 
hydrolysis has been proposed to explain cleavage at tryptophans, see Scheme 
1 panel b. Finally, it should be noted that multiple instances of protein 
cleavage near aspartic and glutamic acid have also been observed, (likely a 
result of deprotonation of the side chain followed by nucleophilic substitution 
at the carbonyl group of the amide bond). Notably, cleavage at multiple amino 
acids gave rise to significantly higher sequence coverage than in either 
tryptophan cleaving protocols, with 78.8 %. Reproducibility of total ion 
chromatograms depicted in Figure S4 secludes NTCB-based method as the 
most reproducible throughout three digestion replicates. Figure 2. Illustrates 
the comparison of selected NTCB protocol with the benchmarked BUP trypsin 
protocol based on the the number of identifiable proteins as a function of 
peptide length given as a count of residues for human proteome. Considering 
the entire mass range of peptides, trypsin identifies slightly higher number of 
proteins compared to NTCB (19955 vs 19687, respectively). However, if we 
take into account only working regimes for both methods, number of peptides 
and therefore valuable information on proteins ‘lost’  is almost six times higher 
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for trypsin (4061 is in the >30 residues long bin) than it is the case for NTCB 
(721 fall into 0-30 residues long bin). Even though this does not mean how 
protein identification is completely lost by the absence of these peptides (as 
those can be identified with another peptides, or couple of them, in 
appropriate mass bin), significant amount of information on the protein family 
is lost, lowering their unambiguous identification in BUP regime. For MD 
regime this could also mean a loss of PTM information, or connectivity between 
adjacent PTMs, however the ambiguity of identification will not be hindered as 
much, since the probability of having another unique peptide is much higher 
due to their 2-5-fold increased peptide length. Similar trend was found for 
yeast and bacterial kingdoms (Figure S2). In addition, b panels of Figures 2 
and S2 show the number of unique peptides as a function of the peptide length 
for both methods in part. Surprisingly, in 0-30 residues bin, the number of 
unique peptides generated by targeting cysteine is comparable to the one 
obtainable by trypsin, but expectedly significantly higher in respective 30-n 
bin. Another striking information obtained is the number of unique peptides 
that trypsin generates, which only in BUP regime exceeded 500 000 for human 
proteome, while there is still substantial portion of peptides in the MD bin. 
Note how this number does not account for multiple instances of the same 
peptide (various modifications to the peptide primary sequence) and in actual 
experiment it is increased by a minimum of two-fold, overcrowding the LC run 
and therefore challenging their successful elution, ionization and 
fragmentation under LC time constraints. In case of NTCB this number is six 
times reduced (~ 100 000 unique peptides in MD bin).  However, even with the 
reduction of proteolytic pool, intrinsic problem inherent to top-down (TD) – 
high heterogeneity of molecular weights and charges in the same LC run is 
coherent with MD regime as well (Figure 3), challenging their successful 
fragmentation and obtaining the complete sequence coverage, which in turn 
can bias the identification. 
The NTCB protocol was found to be most chemoselective of the four 
protocols under consideration: only a single instance of a cleavage non-
proximate to a cysteine was observed. Notably, this cleavage was observed in 
all four protocols and is thus deemed to be non-reagent specific and likely is 
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a result of local structural effects that render hydrolysis under basic 
conditions particularly efficient. Five additional instances of cleavages within 
three amino acids of a cysteine were observed (Figure 5b). Notably, these 
cleavages are located around specific cysteines in a given protein and in four 
cases serine was present, whilst in three cases either lysine, threonine or/and 
aspartic acid were present – i.e. primary sequence and local secondary 
structure both likely played a role. Cleavages were observed at 62.5% (60/96) 
of cysteines with sequence coverage  
above 80% (excluding carbonic anhydrase, which lacks cysteines, and the two 
enolases which contain one cysteine and would form fragments circa 18.9 kDa 
and 24.8 kDa in mass – unlikely to be detected with a MDP instrumental set-
up). Importantly, as can be seen from Figure 5, the number of missed 
cleavages, as a result of DHA formation or label that did not lead to cleavage, 
was 40 % and 20 % respectively, relative to the number of itz-peptides (note 
that these numbers do not represent a weighted average, but simply the 
number of assigned instances overall thus representing species diversity than 
relative kinetics of the two reactions, i.e. if the most abundant species did not 
contain DHA, and one of the least abundant may contain  two DHA’s – this 
will go as equal number of counts for itz and DHA peptides). It is important to 
stress out how MD data analysis in general, and in this study in particular, is 
circumspect by the lack of appropriate tools for data interpretation. Currently 
available softwares for TD can be used for MD data, however manual 
validation is often required, due to occasional missed assignment of peptide 
N- or C- terminal residue. This might derive from the fact that typical TD 
software accounts for fragmentation pattern, rather than the cleavage rule, 
hence the crucial parameter on peptide’s starting residue (in case of N-
terminal cleavage) or ending residue (in case of C- terminal cleavage) is 
excluded from the defined search guidelines a priori. This in turn means how 
the in-silico database is not constructed (as it is the case in search engines 
designed for proteolytic-based data) and the identification is based on 
matched (or missing) fragmentation ladder and the mass of the investigated 
precursor. The lather can be biased by the various modifications occurring on 
the peptide and lead to an incorrect peptide assignment as exemplified for 
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bovine serotransferrin (UniProt acc. number G3X6N3) in Figure S5. Here an 
additional amino acid (in respect to the expected primary sequence based on 
the cleaving agent specificity) was included at the N-terminus, identifying the 
peptide which starts with serine instead of cysteine. This is likely due to the 
high (>50Da) mass shift associated with expected N-terminal amino acid, and 
the lack of N-terminal fragment ions identified. First fragment ion assigned 
(b448; numerical denotation indicates the position of the bond cleaved in 
respect to the entire protein sequence, as considered by the search algorithm 
employed) identified unknown mass shift which matched theoretical mass of 
a protein portion that corresponds to amino acid sequence starting with serine 
with a loss of -19.03 that is not in the list of known PTMs. Manual assignment 
of product ions from the raw spectra and mass matching to the theoretical list 
of product ions for the peptide starting with cysteine identified b- ion series 
consistent with cyanylation of cysteine (itz-peptide formation; C+ 24.99 Da) as 
well as b- and y-ions localizing carbamylation at lysine (K+43 Da), reported to 
occur in this protocol [26]. It should be noted that due to the basis set of mass 
shifts identified, one could not perform an en masse automated assignment 
because certain mass shift combinations effectively produced sum mass shifts 
of same nominal mass involving different number of cysteines (from zero to 
four). Importantly, of the ~3000 individual entries returned by the software, 
for 9 LC-MS runs for NTCB protocol, over 99 % of mass shifts were rationalized 
and found to be consistent with chemicals reactions occurring during the 
execution of the experimental protocol. For other cleaving methods employed 
~ 10 -15 % of mass shifts (data not shown here) remained unclarified, possibly 
due to the unexplained underlying mechanisms and/or alternative pathways 
of the reactions, which were outside of the scope of this evaluation study. 
 
Conclusions 
 
We found NTCB protocol to be in line with desired characteristics for a MD 
protocol owing to: i) high selectivity towards a target residue, ii) high 
reproducibility, iii) generation of long peptides Thus, it can be proposed for a 
qualitative MD analysis and it shows a promise for development into a 
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quantitatively accurate approach as well. Appearance of unconstrained mass 
modifications in the data analysis revealed that the strategy of changing the 
nature of the base towards reduced basicity with reasonable nucleophilicity 
and low steric hindrance enabled us to affect the branching ratio of competing 
pathways toward proteolysis, rather than formation of dihydroalanine. The 
characteristic mass shifts associated with both major reaction channels, 
coupled to the chemoselectivity of the reactions in question, enable for facile 
data interpretation and manual validation of assignments. Further work will 
include validation of this approach at the large scale, which is currently 
circumspect by the lack of automated search algorithm that accommodates 
requirements of such type of peptides. 
 
Acknowledgments 
Authors would like to thank Grigory Karateev and Dr. Elena Dubikovskaya for 
technical support, and Dr. Luca Fornelli for fruitful discussions. We are 
grateful for financial support through the Swiss National Science Foundation 
(SNF project 200021-125147/1) and the European Research Council (ERC 
Starting Grant 280271). 
?????????????????
??????????????? ????????????????????
190
References 
1. Aebersold, R. and M. Mann, Mass spectrometry-based proteomics. Nature, 
2003. 422(6928): p. 198-207. 
2. Tsiatsiani, L. and A.J. Heck, Proteomics beyond trypsin. FEBS J, 2015. 
282(14): p. 2612-26. 
3. Chait, B.T., Mass spectrometry in the postgenomic era. Annu Rev Biochem, 
2011. 80: p. 239-46. 
4. Chait, B.T., Mass Spectrometry: Bottom-Up or Top-Down? Science, 2006. 
314(5796): p. 65-66. 
5. Zhang, X., Less is More: Membrane Protein Digestion Beyond Urea-Trypsin 
Solution for Next-level Proteomics. Mol Cell Proteomics, 2015. 14(9): p. 2441-
53. 
6. Laskay, U.A., et al., Extended bottom-up proteomics with secreted aspartic 
protease Sap9. J Proteomics, 2014. 110: p. 20-31. 
7. Srzentic, K., et al., Advantages of extended bottom-up proteomics using Sap9 
for analysis of monoclonal antibodies. Anal Chem, 2014. 86(19): p. 9945-53. 
8. Wu, C., et al., A protease for 'middle-down' proteomics. Nat Meth, 2012. 9(8): 
p. 822-824. 
9. Cannon, J., et al., High-throughput middle-down analysis using an orbitrap. 
J Proteome Res, 2010. 9(8): p. 3886-90. 
10. Chapman, E., J.S. Thorson, and P.G. Schultz, Mutational Analysis of 
Backbone Hydrogen Bonds in Staphylococcal Nuclease. Journal of the 
American Chemical Society, 1997. 119(30): p. 7151-7152. 
11. Cannon, J.R., N.J. Edwards, and C. Fenselau, Mass-biased partitioning 
to enhance middle down proteomics analysis. J Mass Spectrom, 2013. 48(3): 
p. 340-3. 
?????????????????
??????????????? ?????????????????????????
191
12. Fenselau, C., O. Laine, and S. Swatkoski, Microwave assisted acid
cleavage for denaturation and proteolysis of intact human adenovirus. Int J
Mass Spectrom, 2011. 301(1-3): p. 7-11.
13. Swatkoski, S., et al., Evaluation of microwave-accelerated residue-specific
acid cleavage for proteomic applications. Journal of Proteome Research, 2008.
7(2): p. 579-586.
14. Liu, X., et al., Protein identification using top-down. Mol Cell Proteomics,
2012. 11(6): p. M111 008524.
15. Liu, X., et al., Deconvolution and database search of complex tandem
mass spectra of intact proteins: a combinatorial approach. Mol Cell Proteomics,
2010. 9(12): p. 2772-82.
16. D. LeDuc, R. and N. L. Kelleher, Using ProSight PTM and Related Tools for
Targeted Protein Identification and Characterization with High Mass Accuracy
Tandem MS Data, in Current Protocols in Bioinformatics. 2002, John Wiley &
Sons, Inc.
17. Ansong, C., et al., Top-down proteomics reveals a unique protein S-
thiolation switch in Salmonella Typhimurium in response to infection-like
conditions. Proceedings of the National Academy of Sciences of the United
States of America, 2013. 110(25): p. 10153-10158.
18. Smith, B.J., Basic Protein and Peptide Protocols, in Methods in Molecular
Biology. 1994, Humana Press, Totowa, NJ. p. 297-309.
19. Vestling, M.M., M.A. Kelly, and C. Fenselau, Optimization by mass
spectrometry of a tryptophan-specific protein cleavage reaction. Rapid Commun
Mass Spectrom, 1994. 8(9): p. 786-90.
20. Bar-Or, R., L.T. Rael, and D. Bar-Or, Dehydroalanine derived from
cysteine is a common post-translational modification in human serum albumin.
Rapid Communications in Mass Spectrometry, 2008. 22(5): p. 711-716.
?? ??????????????
??????????????? ?????????????????????????
192
21. Han, K.-K., C. Richard, and G. Biserte, Current developments in chemical 
cleavage of proteins. International Journal of Biochemistry, 1983. 15(7): p. 
875-884. 
22. Laskay, U.A., et al., Proteome digestion specificity analysis for rational 
design of extended bottom-up and middle-down proteomics experiments. J 
Proteome Res, 2013. 12(12): p. 5558-69. 
23. Degani, Y. and A. Patchornik, Cyanylation of sulfhydryl groups by 2-nitro-
5-thiocyanobenzoic acid. High-yield modification and cleavage of peptides at 
cysteine residues. Biochemistry, 1974. 13(1): p. 1-11. 
24. Crimmins, D.L., S.M. Mische, and N.D. Denslow, Chemical cleavage of 
proteins in solution. Curr Protoc Protein Sci, 2005. Chapter 11: p. Unit 11 4. 
25. Laskay, U.A., et al., Practical considerations for improving the productivity 
of mass spectrometry-based proteomics. Chimia (Aarau), 2013. 67(4): p. 244-
9. 
26. Tang, H.-Y. and D.W. Speicher, Identification of alternative products and 
optimization of 2-nitro-5-thiocyanatobenzoic acid cyanylation and cleavage at 
cysteine residues. Analytical Biochemistry, 2004. 334(1): p. 48-61. 
 
  
?????????????????
??????????????? ?????????????????????????
193
Figure captions. 
Scheme 1. Reaction mechanism for chemical-mediated protein digestion: a) 
cleavage at X-Cys with NTCB, b) cleavage at: Met-X with CNBr (left panel), 
cleavage at Trp-X with CNBr (right panel) c) cleavage at Trp-X with BNPS 
skatole (left panel) and Trp oxidation (right panel). 
Scheme 2. Characteristic mass shifts upon (a) Met-X, (b) X-Cys and (c): Trp-
X cleavages. Top panel indicates mass shifts without miscleavage and bottom 
panels indicate the mas shift yielded by a miscleavage. 
Figure 1. Venn diagram of human proteome coverage with herein proposed 
chemical methods targeting less frequent residues (M,C and W). Percentage of 
non-cleavable proteins is further separated into two categories by mass (MW 
>30 kDa indicated with pink circle; MW <30 kDa indicated with yellow circle).
Figure 2. Histogram representing a) the number of proteins as a function of 
peptide length given as a count of residues for NTCB vs trypsin based cleavage 
in human proteome. For both cleaving agents two mass bin ranges were 
considered (0-n and 30-n residues) Maximum attainable number of 
identifiable proteins in both bins is given. b) Number of unique peptides for 
both NTCB and Trypsin cleavage variant in the respective mas bin defined 
approach (BU (0-30 residues) and MD (30- 150 residues), respectively) 
Figure 3. Evaluation of peptide mass and charge state variation over LC 
gradient obtained with LTQ Orbitrap Elite FTMS. Insets illustrate three 
examples of short (~ 20 residues), moderate (~50 residues) and long (> 60 
residues) peptides.  
Figure 4. Representative example of a single peptide sufficient for 
unambiguous identification of a single protein against Swiss-Prot database. 
Isolated 13+ precursor ion of serotransferrin (Bos Taurus) derived from N-
terminal Cys digestion with NTCB is indicated in the right inset. Assignment 
?? ??????????????
??????????????? ?????????????????????????
194
verification is confirmed by presence of expected chemical label (N-terminal 
cyanylation, Ʀ mass = 24.99 Da) with HCD MS/MS. Identified diagnostic ITZ-
peptide b- ions are highlighted in red. 
 
Figure 5. Statistical analysis of N-terminal Cys cleavage on a model seven 
protein mixture. a) Main panel depicts predominance of the cys cyanylation 
(ITZ peptide formation) reaction channel over the competing ǃ elimination 
(DHA peptide formation). Right inset: Alternative channels and unknown 
modifications are presented as their observed mass shift and indicated with 
threshold (5%) given as the sum of the corresponding peptide entries divided 
by total number of entries returned by  automated MS Align+ search, over 
nine replicas (three digestion replicates repeated in three technical replicates). 
Left inset: miscleavage rate- of 12% of identified peptides resulted in either 
DHA formation (uncleavable product) or peptides that carry a label but the 
cleavage was omitted due to the lack of the base. 
 
b) Cleavage specificity given as the count of cleavage sites at cysteine or at 
other than cysteine residue (averaged throughout nine total replicas), 
resulting from base hydrolysis. Other than cysteine cleavage sites are divided 
into cleavages in the vicinity of cysteine residues (within 3 amino acids) and 
those further away. 
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Table 1. Sequence coverage, number of identified peptides and average 
peptide length for 7 protein mixture digested with chemical methods 
employed. Number of expected vs. experimentally assigned cleavage sites and 
observed secondary cleavages are indicated for each chemical agent. *protein-
specific secondary cleavage; “”protocol independent secondary cleavage, 
observed in all protocols. 
Targeted 
residue 
(cleaving 
agent) 
# prot 
ID 
Avg MW 
(kDa) 
Avg 
charge 
Observed vs 
theoretical 
site 
Primary 
sequence 
mapped, % 
Secondary cleavages 
C (NTCB) 5 4.3 5.8 60/96 82.4 
SCHTGL* DKKSCHT* 
CGDNTRK* SSNYCN* 
TKDRCK QSNSKD“” 
W (BNPS 
skatole) 7* 6.1 7.8 25/34 47.8 D, N 
W (iodosoben. 
acid) 7 6.5 8.8 27/34 51.4 D, N 
M (CNBr) 7 5.7 7.3 37/51 78.8 26/34 of W, D 
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?
?????????????????
??????????????? ?????????????????????????
197
?? ??????????????
??????????????? ?????????????????????????
198
 
?????????????????
??????????????? ?????????????????????????
199
Scheme 2.  
?? ??????????????
??????????????? ?????????????????????????
200
Figure 1. 
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Figure 1S. Bioinformatics survey: In silico digestion of (a) human, (b) yeast 
and (c) bacterial proteome with recently introduced methods for MD MS (Lys-
C, formic acid, OmpT/Sap9) and herein proposed chemical methods targeting 
less frequent residues (M,C and W) 
 
Figure 2S. Venn diagram of (top panel) human, (middle panel) yeast and 
(bottom panel) bacterial proteome coverage with herein proposed chemical 
methods targeting less frequent residues (M, C and W). Percentage of non-
cleavable proteins is further separated into two categories by mass (MW >30 
kDa indicated with pink circle; MW <30 kDa indicated with yellow circle).  
 
Figure 3S. Histograms for a) bacterial and b) yeast proteome. Top panel shows 
the number of proteins as a function of peptide length given as a count of 
residues for NTCB vs trypsin based cleavage (top panel). For both cleaving 
agents two mass bin ranges were considered (0-n and 30-n residues) 
Maximum attainable number of identifiable proteins in both bins is given. 
Bottom panel shows the number of unique peptides for both NTCB and 
Trypsin cleavage variant in the respective mas bin defined approach (BU (0-
30 residues) and MD (30- 150 residues), respectively). 
 
Figure 4S. Extracted base peak chromatogram of peptides obtained by 
triplicate chemical hydrolysis of seven protein mixture with (a) NTCB, (b) CNBr 
and (c) BNPS skatole. Experiments performed with LTQ Orbitrap Elite FTMS. 
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Figure 5S. Example of the incorrect assignment of the cleavage site by the 
search algorithm and correct manual assignment. Product ions that confirm 
modifications and their respective localization are indicated in red. Correct 
delta mass shifts are indicated above respective residue in blue. 
Figure S1. 
(a) 
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(b) 
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Figure S2. 
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Figure S3. 
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Figure S4.  
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Figure S5. 
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6.2. MD with Cysteine-based chemical digestion: targeted analysis of 
Immunoglobulins G 
?
Comprehensive structural analysis of antibodies, specifically of 
immunoglobulins G (IgGs), is indispensable due to their leading role as 
biotherapeutical drugs. The potential of electron transfer dissociation (ETD) 
Orbitrap Fourier transform (FT) mass spectrometry (MS) in characterizing 
IgGs is evaluated as a ‘way to go’ for structural analysis of these large 
biomolecules. Here, we proceed with deeper analysis of the IgG primary 
structure by further developing middle-down (MD) MS on a high-field Orbitrap 
Elite ETD FTMS. 
IgGs became indispensable in treatment of variety of diseases; hence, the 
impetus in drug discovery is to extend the MS approaches for their 
characterization. Hypervariable domain is the fingerprint of an antibody thus, 
its correct assignment and sequence information is necessary for 
distinguishing targeted IgG between variety of sequence homologues, but with 
incomplete sequencing of Complementarity Determining Regions (CDRs), 
which are responsible for the IgG affinity and specificity. Currently employed 
bottom-up (BUP) avenues do not meet this requirement due to the frequent 
digestion, resulting in short peptides and oftentimes even a single CDR is split 
into two or more short peptides. Alternatively, analysis of intact antibodies 
(top-down, TD) is in principle the most adequate approach for structural 
characterization of IgGs. Relatively limited characterization of post-
translational modifications (PTMs), important for modulating or impairing IgG 
biological activity, has been achieved. It is however limited to ~35% (REF 
Marshall, Luca TOF) sequence coverage, where most of the fragments derive 
from the Fc portion of the IgG, complementarity determining regions (CDRs) 
is obscured. 
To address and overcome limitations inherent to BUP, and current technical 
restrictions of TD, we previously optimized extended bottom-up approach 
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employing a non-selective protease (Sap9). Here, we introduce a 
chemoselective cysteine mediated digestion for IgG peptide mapping (Figure 
6.1.).  
Figure 6.1. IgG characterization: proposed MD pipeline for paratope mapping by 
C-digestion.
To test viability of the named method in targeted structural analysis of 
antibodies, we digested therapeutical monoclonal antibody of class 1 (IgG1), 
Trastuzumab with NTCB agent as described in the Paper V in Chapter 5 and 
analysed via RP-LC-MS/MS (vide supra, Chapter 4). Obtained total ion 
chromatogram is shown in Figure 6.2. As expected, we successfully separated 
and identified long (6 kDa on average) peptides for both light and heavy chains 
of IgG.  
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Figure 6.2. Extracted base peak chromatogram of Trastuzumab (IgG1) digested 
with NTCB. Inset: HCD mass spectrum of a 6+ precursor of the peptide 
identifying CDR3 of the light chain. Arrows indicate elution of the peptides 
containing adjacent CDR1 and 2 of the light (light orange) and the heavy chain 
(light green) as well as the peptide containing CDR3 of the heavy chain (light 
green) with their respective backbone fragmentation. 
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Figure 6.3. Sequence coverage of light a) and heavy b) chains of Trastuzumab. 
(b, y) from a light chain and heavy chain identified peptides obtained from a 
NTCB digest and sequenced regions are indicated in light blue. Cysteines of ITZ 
peptide are indicated in orange, cysteines with DHA formation are shown in red. 
Circled residues indicate position of a non-specific cleavage introduced by base 
hydrolysis. 
Due to the position of cysteines within particular IgG structure, generated 
peptides contained adjacent CDRs, revealing the connectivity information. 
Results obtained in this study indicate how employing NTCB-based cleavage 
could in future facilitate paratope discrimination of a single IgG from a mixture 
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of IgGs, while reducing the number of required peptide IDs, and in turn, 
increase the obtainable sequence coverage per LC run. 
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Chapter 7. Towards top-down MS?????MD 

219
Hereinafter reported considerations are the initial premises later translated 
into research articles enclosed at the end of this Chapter: 
? Revealing chain connectivity in monoclonal IgG1 by electron transfer
dissociation Orbitrap FTMS on F(ab) subunits following KGP proteolysis
(Paper VI)
? Middle-down analysis of IgG mixtures using electron transfer dissociation
allows light and heavy chain pairing characterization  (Paper VII)
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7.1. Paper VI: Middle-down analysis of IgG mixtures 
using electron transfer dissociation allows light and 
heavy chain pairing characterization 

223
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Abstract 
Identification of antigen-specific immunoglobulins G, IgGs, from antibody 
repertoire in the serum of immunized animals requires information on pairing 
of light and heavy chains in IgGs. Previously, bottom-up proteomics has been 
employed to guide the IgG identification in these experiments. However, 
digestion of IgGs to small peptides following the bottom-up approach 
scrambles information on the chain pairing. Here, we put forward a middle-
down approach that should provide the required IgG chain pairing information 
with high selectivity and specificity. Briefly, here the IgGs are quickly digested 
above the hinge region with papain into large 50 kDa subunits, Fab and Fc. 
Thus obtained Fab subunits are disulfide bond-bound complexes of a 
complete light chain and the extended N-terminal part, Fd, of a heavy chain. 
Intact Fab subunits are then submitted to gas-phase fragmentation using 
electron transfer dissociation which results in formation of structure-specific 
product ions. Some of these product ions contain parts of both chains still 
bound by an intact S-S bond. Importantly, cleavage sites for some of these 
“pairing-specific” product ions are located in the variable domains of IgGs, 
increasing the confidence of pairing characterization. We validate the 
proposed approach for analysis of a single IgG1, single IgG4, a mixture of three 
IgG1 proteins which provide baseline separation of Fab subunits by liquid 
chromatography, and a mixture of two IgG1 proteins which provide Fab 
subunits co-eluting from liquid chromatography. The reported proof-of-
principle experiments constitute a first step toward the use of the described 
middle-down approach for analysis of significantly more complex antibody 
mixtures with the final goal of improving IgG drug discovery.  
Keywords: top-down mass spectrometry; immunoglobulin G1, IgG1; chain 
pairing; Fourier transform mass spectrometry, FTMS; Orbitrap; transient 
averaging; 
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Introduction 
The development of monoclonal antibody (mAb)-based therapeutics requires 
their thorough and deep characterization due to mAb complexity as bio-
products [1-3]. MAbs and their derivatives, unlike small molecule therapeutics 
are very heterogeneous and present in a large number of variants [1]. For 
safety requirements, these variants need to be thoroughly identified and 
characterized to comply with sanitary authorities guidelines. Mass 
spectrometry (MS)-based techniques are implemented throughout all stages 
of mAbs production and development. It provides valuable information about 
mAb structure, modifications and heterogeneity, ranging from high order 
structure and conformation to sequence and co-/post-translational 
modifications (PTM) mapping. 
Monoclonal antibodies used as therapeutics are from the immunoglobulin G 
(IgG) class. IgGs are tetrameric glycoprotein complexes each composed of two 
~50 kDa heavy chains and two ~25 kDa light chains. Each light chain is linked 
by a disulfide bond to a heavy chain and the heavy chains are linked together 
by two to four disulfide bonds depending on the IgG isotype. Four IgG isotypes 
exist and are defined by their heavy chain amino acid sequence: IgG1, IgG2, 
IgG3 and IgG4. IgG3 are not used as therapeutics due to a rapid clearance (7 
vs 21 days compared to IgG1 in some cases). Disulfide bridges (16 for IgG1 
and IgG4; 18 for IgG2) and non-covalent interactions maintain their three-
dimensional structure (H2L2 homoheterodimers). The heavy and light chains 
are linked by one disulfide bond and the heavy chains by two (for IgG1 and 
IgG4) or three (for IgG2) disulfide bonds located in a short hinge domain (Hi). 
The other 12 cysteine bridges are intramolecular and delimit six different 
globular domains: one variable (VL) and one constant for the light chains (CL) 
and one variable (VH) and three constant for the heavy chains (CH1, CH2, and 
CH3). Antigen binding is mediated by the variable domains, mainly by three 
loops connecting individual ǃ-strands in each domain (CDR). The mass 
measurement of the intact molecule is a basic and fast way to assess a mass 
profile of the whole antibody. It allows the confirmation of the elemental 
amino-acid composition by comparing expected and measured masses. The 
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major glycoforms are also resolved. The resolution and the mass accuracy of 
the mass spectrometer along with the quality of the sample have a direct effect 
on the quality of the mass measurement. The molecular weight measurement 
of intact IgGs gives an overall profile picture of the protein. However, it does 
not provide structural resolution. Reducing the complexity of intact IgGs by 
chopping them into smaller subunits before mass analysis provides more 
resolution for structural heterogeneities. By analogy to bottom-up MS, Zhang 
et al. introduced the term middle-up MS to designate the analysis of large 
subunits of IgGs [4]. This is not to be confused with middle-down MS which 
refers to the MS/MS sequencing and analysis of these large subunits. These 
smaller subunits can be easily obtained by reduction of the disulfide bonds of 
IgGs dissociating them into two 25 kDa LCs and the two 50 kDa HCs. These 
are subsequently analyzed by LC-MS. Over the time, the mass analysis of 
separated light and heavy chains of IgGs has become common in 
biopharmaceutical laboratories. If the reduction is performed in denaturing 
condition, i.e. in the presence of chaotroping agents such as urea or 
guanidine-HCl, all disulfide bonds would be reduced [5-7]. The inter-chain 
disulfide bonds can also be selectively reduced in the absence of denaturing 
conditions leaving the intramolecular bonds intact [8]. Middle-up MS analysis 
can also involve limited proteolysis of the heavy chain, in non-denaturing 
conditions, yielding both two Fab fragments (50 kDa each) and an Fc (50 kDa) 
fragment (in the case of upper hinge cleavage), or a Fab’2 (100 kDa) fragment 
with two half Fc (25 kDa) fragments (in the case of cleavage under the hinge). 
These can be further disulfide bond reduced to obtain three ~25 kDa subunits 
(light chains, half Fc and Fd). Several proteases have been used for these 
middle-up approaches with the most common ones being papain [9], pepsin 
[10], ficin [11] and endoprotease LysC [12]. Papain cleaves IgGs just above the 
hinge region generating from each IgG molecule two fragment antigen binding 
subunits (Fab) and an Fc subunit. The two generated Fabs are identical except 
for the case of bispecific antibodies. Every Fab fragment is constituted of a 
light chain and the N-terminal half of a heavy chain called the Fd domain 
linked together by a disulfide bond. Each of the light chain and the Fd contains 
two intra-chain disulfide bonds. Papain and ficin generate Fab fragments in 
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the presence of cysteine, whereas Fab’2 fragments can also be generated in 
the absence of cysteine. These two proteases have the advantage of cleaving 
IgGs from a broad range of species. In addition, ficin cleaves the Fc into 
multiple small fragments. Pepsin on the other hand generates Fab’2 fragments 
at acidic pH, it does not require cofactors and thiols but suffers from low yield. 
LysC generates generally Fab fragments at pH 8, however, it does not cleave 
all IgG isotypes. IgG2s for example resist digestion under native conditions. 
Limited proteolysis by these enzymes followed by reduction frees the light 
chain and the Fd part from the glycosylation heterogeneity (except in the case 
of Fab glycosylation [13]) and the half Fc fragments bear only one glycosylation 
site. This, conjugated to their smaller size when compared to intact IgGs (and 
even intact heavy chains) renders LC-MS analysis easier and potentially with 
higher mass accuracy giving access to a more straightforward characterization 
of micro-heterogeneities. Recently, a new bacterial cysteine protease, IdeS 
(Immunoglobulin-degrading enzyme of Streptococcus pyogenes), is becoming 
more popular due to its high specificity and yield. It has the advantage of being 
rapid (30 mins for complete cleavage), not requiring any cofactors and for 
cleaving at pHs of formulation buffers therefore limiting artifact introduction 
[13-15].  
Here, we describe a middle-down tandem mass spectrometry approach 
enabling a structural analysis of intact 50 kDa Fab subunits generated by 
papain digestion above the hinge region of single IgG1 and single IgG4 
proteins, as well as simple mixtures of two to three IgG1 proteins. We put a 
particular focus on ETD-derived product ions that contain parts of both light 
and heavy chains of IgG proteins. Thus obtained “chain pairing” information 
is of a potential importance in drug discovery where antigen-specific IgGs need 
to be identified from complex mixtures of antibodies present in serum of 
immunized animals, e.g., rabbits [16].
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Experimental methods 
Reagents. Water, acetonitrile (ACN), trifluoroacetic acid (TFA) and 
isopropanol (IPA) were purchased in LC-MS purity grade. Water and ACN were 
obtained from Fluka Analytical (Buchs, Switzerland), formic acid (FA) from 
Merck (Zug, Switzerland), IPA from Thermo Fisher Scientific (Switzerland), and 
guanidinium chloride (GdnCl) from Carl Roth (Germany). Tris-HCl, EDTA, 
papain and L-cysteine-HCl were purchased from Sigma-Aldrich. Therapeutic 
monoclonal antibodies of the IgG1 class, adalimumab (Humira, Abbot 
Laboratories), trastuzumab (Herceptin, Genentech), palivizumab (Synagis, 
MedImmune), and rituximab (Rituxan, Roche), and IgG4 class, natalizumab 
(Tysabri, Biogen Idec) were the European Medicines Agency approved versions 
and formulations, available commercially to the general public. 
Sample preparation. Samples containing single or mixtures of antibodies are 
prepared using 100 μg of each IgG. Antibodies are first diluted to 1.3 mg/mL 
in digestion buffer: Tris-HCl 100 mM, EDTA 4 mM, L-cysteine-HCl 5.5 mM, 
pH 7.6. Papain digestion performed using an enzyme to substrate ratio of 
1:100 at 37° C for two hours. The mixture is then buffer-exchanged to 
ammonium acetate 50 mM using Zeba 0.5 mL desalting spin columns (Pierce, 
Thermo Fisher Scientific). The solution is then acidified to pH 2-4 using TFA 
and analyzed by LC-MS.  
Liquid chromatography – mass spectrometry. The chromatographic 
separation of IgG proteolytic fragments was performed using an Ultimate 3000 
LC system (Thermo Scientific, Amsterdam, The Netherlands) under UPLC 
conditions. A combination of reversed phase C4 trap-column (Acquity UPLC 
PrST C4 VanGuard pre-column, 2.1x5 mm, particle size 1.7 μm, pore size 300 
Å, Waters) and C4 column (Acquity UPLC PrST C4, 1x150 mm, particle size 
1.7 μm, pore size 300 Å, Waters) was employed to ensure on-line IgG fragment 
desalting and separation. For each injection, 1 μg of digestion product was 
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loaded on the column, heated at 65° C. After initial loading at 5% solution B 
(organic phase), a gradient of solution B from 15 to 45% in 15 minutes was 
used at a flow rate of 100 μl/min. Solution A consisted of 0.1% of FA in water, 
whereas solution B was composed of 39.9% IPA, 60% ACN, and 0.1% FA. The 
LC column outlet was on-line coupled with the electrospray (ESI) source of the 
mass spectrometer. MS experiments were performed on an ETD-enabled 
hybrid linear ion trap high-field Orbitrap FT mass spectrometer (LTQ Orbitrap 
Elite FTMS, Thermo Scientific, Bremen, Germany). Separate LC-MS 
experiments were dedicated to record broadband mass spectra and ETD 
tandem mass spectra. Instrumental parameters were set as follows: S-lens RF 
level was set to 70%, the temperature of heated transfer capillary was 350° C, 
microESI source (IonMax source, Thermo Scientific) was used with a 3.7 kV 
potential, and sheath gas was set to 20 and auxiliary gas to 10 arbitrary units. 
All the mass spectra were acquired using ion detection in the Orbitrap FTMS, 
in the m/z range 200-2000. For broadband and tandem mass spectrometry, 
we both reduced the gas (N2) in the HCD cell to provide “delta pressure” in the 
Orbitrap detector region of about 0.1E-10 torr, and applied “HCD trapping”, 
which is a trapping and a  temporary ion storage in the HCD cell before ion 
transmission to the Orbitrap mass analyzer through the C-trap [17]. 
Broadband mass spectra were recorded with either 15’000 or 120’000 
resolution at 400 m/z, with a target value for the automatic gain control (AGC) 
of 1 million charges in either MS or MS/MS modes. For ETD experiments, 
precursor ions were isolated in the high pressure chamber of the LTQ and 
subsequently subjected to ETD MS/MS. The AGC target value for 
fluoranthene radical anions was set to 7-8E5 charges, with anion maximum 
injection time of 50 ms. ETD duration (i.e., ion-ion interaction time) was 
progressively increased from 3 ms to 9 ms in consecutive experiments. 
Product ion detection in the Orbitrap mass analyzer was performed with 
120’000 resolution at 400 m/z (enhanced FT, eFT, enabled). All Orbitrap FTMS 
scans were recorded averaging 10 microscans to improve the signal-to-noise 
ratio (SNR) via on-board time-domain (transient) averaging prior to eFT signal 
processing. Isolation windows for ETD of IgG fragments included one charge 
state per precursor ion (isolation width: 15 Th) in the case of bevacizumab and 
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trastuzumab, or multiple charge states for adalimumab (isolation width: 100 
Th and wider). 
Data processing and tandem MS analysis. Data were analyzed both as single 
LC-MS/MS runs, and after additional data processing aimed at improving 
SNR of tandem mass spectra. In the latter case, time-domain (transient) 
signals recorded in separate LC-MS/MS experiments were processed as 
previously described for top-down LC-MS/MS of mAbs [18]. Briefly, Orbitrap 
FTMS transient signals were first recorded in MIDAS *.dat format using 
advanced user interface installed on Orbitrap FTMS under a license from 
manufacturer [19]. Thus obtained transients were grouped according to the 
IgG fragment type and duration of ETD MS/MS, averaged, and finally 
subjected to time-to-frequency conversion with the eFT procedure using 
proprietary manufacturer’s tools. The resulting standard Thermo .RAW files 
could be then opened and processed with commercial XCalibur software 
(Thermo Scientific), and were thus ready for the data analysis. For each ETD 
duration, an averaged mass spectrum for each IgG fragment was obtained. In 
addition, a total tandem mass spectrum was built by averaging all the 
transients (i.e., transients derived from different ETD duration experiments) 
available for a single IgG fragment. Data analysis was performed using Xtract 
and ProSightPC 3.0 (Thermo Scientific) [20]. First, Xtract was used for tandem 
mass spectra deconvolution, peak centroiding, and peak picking. Then, 
cleavage sites were assigned with ProSightPC using 15 ppm mass tolerance. 
For disulfide-bridged ETD product ions, the searches were performed using 
an in-house developed algorithm. 
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Results and discussion  
LC-MS analysis of papain digested IgG mixture. In this experiment a mixture 
of three therapeutic monoclonal antibodies was used as a model sample. The 
mixture consisted of three IgG1 class monoclonal antibodies: adalimumab, 
trastuzumab, and palivizumab. After digestion using papain, the IgG mixture 
was directly analyzed by LC-MS. Figure 1 shows the total ion chromatogram 
of the mixture. Expectedly, the Fc subunits of all three IgGs co-eluted as they 
share nearly the same sequences. The Fc subunits contain glycosylation and 
other information that are important for effector functions, interaction with Fc 
receptors and stability, but they provide no information about Lc and Hc 
pairing as they originate solely from the heavy chains. In the context of Fab 
analysis, Fc subunits can be removed from the sample using protein A or 
protein G capture to simplify the analysis. The three Fab subunits originating 
from the three IgGs were near baseline separated by liquid chromatography. 
Maintaining the LC column at a constant temperature (65 °C) ensured the 
high elution reproducibility necessary for subsequent LC-time scheduled ETD 
fragmentation. The mass spectra of the three Fabs subunits show charge state 
distributions stretching mainly from m/z 1000 to 2500 and centered around 
charge states 33-35+, Figure 1 insets. The measured molecular masses 
(47’637 Da, 47’681 Da, and 47’528.5 Da) are consistent with the theoretical 
masses calculated from the sequences of trastuzumab, adalimumab and 
palivizumab, respectively. For palivizumab, the heavy chain’s N-terminal 
glutamine is cyclized into a pyroglutamic acid, a common post-translational 
modification in IgGs with N-terminal glutamines.  
 
ETD LC-MS/MS analysis of papain generated IgG1 Fab subunits mixture. The 
ETD settings were first optimized to maximize sequence coverage. Namely, like 
previously reported by Fornelli et al. for 25 kDa IgG subunits [15], high m/z 
product ion transmission was improved by reducing the nitrogen gas pressure 
in the HCD cell to obtain a “delta pressure” in the Orbitrap detector of 0.1x10-
10 Torr and by applying HCD trapping.  HCD trapping consists of temporarily 
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storing the ions in the HCD cell before their transmission to the Orbitrap mass 
analyzer via the C-trap. Several ETD reaction times ranging from 3 to 25 ms 
were tested. The 10 and 15 ms reaction times we found to be the most effective 
to maximize sequence coverage and provide complementary product ions. The 
high reproducibility of the Fab subunits chromatographic elution allowed for 
setting the instrument to perform ETD MS/MS in a time-scheduled fashion, 
i.e. only during selected time windows corresponding to the elution times of
the different Fab IgG subunits. Isolation windows of 200 Th to include ~5
charge states of precursor ions were used to increase ETD efficiency, Figure 1
insets. The transients from 15 LC-MS/MS runs using 10 ms reaction time and
15 LC-MS/MS runs using 15 ms reaction time were summed together for each
Fab elution peak. The resulting ETD mass spectra were searched using
ProSight PC to assign the peaks. The searches were performed independently
for the light chain and the Fd subunit considering that the disulfide bond
linking the two chains is cleaved upon ETD fragmentation.
As expected, sequence coverages were between 21 and 30 % for the 
different chains of the different Fabs subunits. This is comparable to results 
obtained on intact IgGs which, like Fab subunits, retain highly structured 
areas mainly in correspondence to the immunoglobulin domain and disulfide 
bond protected areas [18, 21]. Higher sequence coverage can be obtained if 
the disulfide bonds were reduced as shown in a previous paper using IdeS 
digestion followed by DTT reduction to produce 25 kDa IgG subunits [15]. 
Unlike in bottom-up approaches where the sequence coverage is calculated 
based on the identified peptides without regards to the cleavage sites assigned 
upon MS/MS, in top-down and middle-down experiments the sequence 
coverage is calculated as the ratio of assigned cleavage sites to the total 
number of possible cleavage sites, Figure 2. The fragmentation map of 
adalimumab is presented in Figure 2 top panel. The CDR 3 of the light and 
heavy chains are covered with cleavage sites corresponding to the 
complementary c and z ions. CDR 3 is the part of the sequence that is clone-
specific to the IgG and is therefore crucial for clone identity determination. 
CDR 1 and 2 of both chains are also covered by at least one fragment.  
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Disulfide bonds are known to be cleaved using ETD as demonstrated by 
the 23.9 % and 25.7 % sequence coverage obtained for adalimumab’s light 
chain and half heavy chain respectively. However, the propensity of ETD to 
cleave disulfide bonds in IgG is not known and, presumably, is less than 
100%. Therefore, in the case of two independent polypeptide chains linked 
together by a disulfide bond, ETD may generate product ions from each chain 
that are linked together by a preserved disulfide bond. We believe this is the 
case for IgGs and their Fab subunits. According to our hypothesis, these 
product ions can provide light and heavy chain pairing information in the case 
of IgG mixtures. Nevertheless, these product ions bound by disulfide bridges 
are not accounted for by classical top-down MS or proteomics search 
algorithm. Furthermore, they would have a high mass and present in high 
charge states which would further complicate the challenge of assigning them. 
Therefore, we in-house developed a dedicated algorithm that would i) calculate 
the masses of all possible disulfide bond-bridged product ions based on the 
sequences of the light and heavy chains; and ii) compare them to the product 
ions from the experimental ETD MS/MS spectra within a certain mass error. 
The assignments of the product ions are then manually controlled and the 
ambiguous matches are discarded, namely masses that would match several 
possible product ions. Figure 3 shows an example of such ions with expanded 
views on simple ions and disulfide bond-bridged ions. It is important here to 
highlight the high resolution of the employed mass spectrometer that allows 
isotopic resolution of these large product ions and the benefits of the improved 
sensitivity brought by transient averaging over multiple LC-MS/MS runs. The 
fragmentation map obtained is presented in Figure 2 bottom panel. When 
considering only product ions that consist of a light chain fragment and an Fd 
fragment linked together by a disulfide bond, the sequence coverage is nearly 
16 % for both chains. All ions containing inter-chain disulfide bonds are 
logically z-type ions since in IgG1s, the two chains, Lc and Fd are linked by 
their C-termini: namely the C-terminal cysteine of the Lc and the cysteine of 
the Fd which is the fifth C-terminal residue. Many of the ETD cleavage sites 
identified using these disulfide bond-bridged product ions have already been 
observed in the first search using ProSight PC, most of them are 
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complementary z-type ions. The fact that the most simple ions identified are 
c-type ions and the number of complementary z type ions identified contains
an intra-chain disulfide bond might indicate that in many cases, upon ETD
backbone cleavage, the inter-chain disulfide bond is conserved. When
accounting for the new cleavage sites corresponding to these newly assigned
ions, the sequence coverage reaches 26.8 % for the Lc and 31 % of the Fd.
While this increase in sequence coverage is not high, identifying several ions
sharing the same ETD cleavage sites does strengthen the confidence in the
assignments. More interestingly, the CDR 3 domains of the Lc and the Fd are
also well covered by several cleavage sites assigned from simple and disulfide
bond-bridged product ions. This would confirm the IgG clone identity and,
with the intact masses measured allows access to the Lc and Hc pairing
information.
ETD LC-MS/MS analysis of papain generated IgG4 Fab subunit. After 
achieving the proof of concept for IgG1, the compatibility of the approach for 
other IgG subclasses was evaluated. The disulfide bond linkage is one of the 
main differences between the four IgG subclasses. IgG1s and IgG4s contain 
two disulfide bridges in the hinge region linking the two heavy chains. More 
related to Fab subunits is the linkage between the light chain and the heavy 
chain. In IgG1s, the disulfide bond linking the Lc to the Hc is between the fifth 
and last cysteine of the light chain and the fifth cysteine of the Fd, whereas in 
IgG2 and IgG4 the link is between the fifth cysteine of the light chain and the 
third cysteine of the heavy chain, Figure 4. Natalizumab was used here as an 
IgG4 benchmark to test the method. ETD was performed exactly the same way 
as for the IgG1 Fab mixture. Figure 5 presents the fragmentation map 
obtained with the Prosight PC search, i.e. accounting only for product ions 
with the disulfide bond between the two chains cleaved. The sequence 
coverage achieved is near 30 % for both chains with both CDR 3 domains well 
covered. When running the search for product ions with an inter-chain 
disulfide bond, the sequence coverage increases to nearly 35 % and 36 % for 
the Lc and Fd respectively. Note that for IgG4s like natalizumab, unlike for 
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IgG1s, not all the disulfide linked ions are z ions: z ions from the light chain 
can be linked with z ions from the Fd for cleavage before cysteine 96 (form the 
N-terminus) or with c ions for cleavages to after cysteine 96. These results 
demonstrate that the approach can work for all isotypes as IgG2, IgG3 and 
IgG4 share the same type of Fab disulfide linkage. 
 
ETD LC-MS/MS of co-eluting papain generated Fab subunit. In the first papain 
digested IgG mixture, all Fab subunits where separated by chromatography. 
This allows for the use of broad isolation windows to maximize ETD efficiency 
and sequence coverage as the generated product ions will correspond to one 
Fab subunit specie. However, separating different Fab subunits in a mixture 
using chromatography is not always trivial and co-elution of different Fab 
molecules is very common. For highly complex mixtures, other separation and 
fractionation techniques such as ion exchange chromatography or off-gel 
isoelectrofocusing can be used prior to reverse phase LC-MS analysis. 
Nevertheless, co-elution can still occur for molecules sharing close pI and 
hydrophobicity factors. In that case, one can use narrow isolation windows for 
one charge state from each co-eluting IgG and obtain MS/MS spectra that 
correspond to only one Fab subunit. However, this will translate in less 
product ions and reduced signal to noise ratio. Another alternative is to isolate 
for each molecule several charge states and fragment them independently and 
then sum the transients for each Fab all together. This on an LC-MS peak 
elution profile is very challenging as only a few transients can be acquired 
which renders increasing the number of runs necessary. A mixture of 
trastuzumab and rituximab, two IgGs that provide co-eluting Fab subunits in 
the LC-MS setting used were analyzed using a broad isolation window of 230 
Th to test if the quality of the Fab sequencing would be affected and if it would 
still be possible to identify ions connected by an inter-chain disulfide bond, 
Figure 6. 
The sequence coverage for trastuzumab was 23 and 26 % for the Lc and 
Fd respectively when not considering intra-chain disulfide bond linked ions. 
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For rituximab 22 and 24 % sequence coverage for the Lc and the Fd were 
obtained, respectively. When considering only inter-chain disulfide bond 
linked z-ions, about 17 % sequence coverage was obtained for both Lc and Fd 
for both rituximab and trastuzumab. In all cases CDR-3 domains were covered 
with several product ions. Rituximab presents cyclized glutamine to 
pyroglutamic acid on both chain. These results show that this co-isolation of 
several charge states from both IgGs did not affect the outcome of the 
sequence coverage in either search (with and without disulfide linked ions). 
This proves that the sequencing and light chain and heavy chain pairing 
determination is possible even in the case of co-elution proving the validity of 
the middle-down approach at the Fab level for such IgG mixtures. 
Conclusions 
Middle-down ETD-MS/MS at the Fab level constitutes an interesting 
approach for the characterization of monoclonal antibodies. Importantly, Fab 
subunit conserves the pairing information of light and heavy chain, which is 
otherwise lost in analysis of reduced or further digested IgG. The method 
achieves sequence coverages similar to those reported in intact IgG top-down 
characterization studies. Additionally, the reduced, 50 kDa, Fab subunit size 
compared to the 150 kDa intact IgG is more readily analyzed with high-
resolution MS and MS/MS. The complementarity determining regions (CDR) 
3 of both the light and the heavy chains are well sequenced. Furthermore, 
searching for disulfide bond-bridged ions allows for increasing sequence 
coverage and along with the intact Fab molecular mass and CDR-3 identity 
can constitute a valuable tool to determine light and heavy chain pairing in 
mixtures of antibodies. The latter information is practically unachievable with 
top-down MS of intact IgGs, and even more so from the mixtures of intact 
IgGs. The results show a strong proof of principle and that the approach can 
be applied to all IgG subclasses and even in the case of co-eluted and co-
isolated IgGs. The long-term goal here is to apply this approach to complex 
mixtures of serum antibodies and search the mass spectra against a reference 
B cell genome-derived database [16]. 
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Figure captions. 
 
Figure 1. Extracted total ion chromatogram of separated 50 kDa Fab 
subunits of three monoclonal IgG1s from a mixture digested with papain. 
Numbered panels show broadband FTMS mass spectra of the charge state 
envelopes of 1) trastuzumab, 2) adalimumab and 3) palivizumab. The red 
rectangle shows the isolation windows (200 Th and wider) used for subsequent 
ETD fragmentation, centered around 34-36+, 33-35+ and 35-37+ charge 
states for trastuzumab, adalimumab and palivizumab, respectively. 
 
Figure 2. Fragmentation map of Fab subunit of adalimumab. Top panel: ETD 
product ions (c- and z- type) assigned using ProSight PC, excluding those ions 
linked by intermolecular disulfide bond. Bottom panel: linked ions (z+z) 
assigned using an in-house developed tool. CDRs of each chain are highlighted 
in orange. Obtained sequence coverage is indicated below each chain in each 
panel. 
?
Figure 3. Expanded view of ETD mass spectrum (m/z 1500-1640 range) of 
Fab subunit of trastuzumab. Indicated are c- ions and disulfide bond linked 
z+z ions. Insets show expanded views of isotopically resolved product ions: 
linked ion interchain disulfide bond z104-z118 (13+) (left) and the c103 (7+) 
classical ion (right). 
 
Figure 4. Cartoon representation of linkage of Fab subunits by 
intermolecular disulfide bond for IgG1s (left) and IgG2s, IgG3s and IgG4s 
(right). Both inter- and intramolecular disulfide bonds are shown in red. 
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Figure 5. Fragmentation map of Fab subunit of natalizumab. Top panel: ETD 
product ions (c- and z- type) assigned using ProSight PC, excluding those ions 
linked by intermolecular disulfide bond. Bottom panel: linked ions (z+z) 
assigned using an in-house developed tool. CDRs of each chain are highlighted 
in orange. Obtained sequence coverage is indicated below each chain in each 
panel. 
Figure 6. Broadband FTMS mass spectrum (top) and ETD tandem mass 
spectrum (bottom) of co-eluting trastuzumab and rituximab Fab subunits. 
Respective charge state envelopes are color coded. The red rectangle shows 
the isolation window of 230 Th used for ETD fragmentation. The isolation 
window contains five to six charge states of each Fab subunit. 
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Abstract 
Pairing light and heavy chains in monoclonal antibodies using top-down 
mass spectrometry may complement chain sequence information provided by 
high-throughput genomics sequencing for rational selection of drug 
candidates. The 50 kDa F(ab) subunit of monoclonal antibodies is the smallest 
structural unit that contains the required information on pairing and can be 
enzymatically produced with high specificity. Here we develop and 
characterize the associated top-down workflow comprising the following steps: 
i) enzymatic digestion with single cleavage site specificity using GingisKHAN
protease for production of F(ab) subunits; ii) multiple liquid chromatography
(LC)  – Orbitrap Fourier transform mass spectrometry (FTMS) runs with intact
F(ab) fragmentation in the gas phase using electron transfer dissociation
tandem mass spectrometry (MS/MS); iii) spectral averaging of tandem mass
spectra across multiple LC-MS/MS runs acquired in reduced or full profile
mode; iv) transient averaging across multiple LC-MS/MS runs followed by
enhanced FT or absorption mode FT signal processing; and v) comprehensive
automated and manual data analysis using ProSight Light and MASH Suite
top-down software. We first benchmark the described workflow using
myoglobin as a target protein and then apply thus validated method for the
analysis of F(ab) subunit of trastuzumab. Obtained results confirm the
envisioned benefits in terms of increased sensitivity from averaging of multiple
LC-MS/MS runs for top-down protein analysis for both spectral and transient
averaging, both of which are now accessible for general users.
Keywords: top-down mass spectrometry; immunoglobulin G1, IgG1; chain 
pairing; Fourier transform mass spectrometry, FTMS; Orbitrap; transient 
averaging; spectral averaging; absorption mode FT
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Introduction 
Monoclonal antibodies in general and immunoglobulins G1 (IgG1) in 
particular constitute an important class of biotherapeutics with demonstrated 
success for treatment of life-threatening diseases, including [1-3]. For 
example, trastuzumab IgG1, commercially known as herceptin, is widely used 
to treat breast cancer [4]. Therefore, the development of improved analytical 
methods and techniques addressing in-depth structural analysis of IgGs is 
important not only for accompanying targeted IgG development and 
production, but also for the discovery of new IgG-based drugs. Regarding the 
latter, bottom-up mass spectrometry (MS), in combination with high-
throughput genomic sequencing, has been used for the identification of 
organism-produced IgGs present as complex biomolecular mixtures in body 
tissues or fluids like blood. Genomics-derived data enables the creation of 
databases containing sequence information on separately light and heavy 
chains of IgGs present in these mixtures [5]. Mass spectrometry data thus 
needs to pair the two antibody chains. Thorough protein degradation resulting 
from frequent digestion in bottom-up proteomics hinges the chain-pairing 
information and therefore the list of potential IgG lead candidates produced 
with bottom-up proteomics is not specific and contains false positive 
suggestions.    
To overcome the limitations of bottom-up proteomics in providing pairing 
information on IgGs, we previously reported on the use of top-down (TD) mass 
spectrometry applied to the characterization of ~50 kDa F(ab) subunits of 
monoclonal IgGs. To obtain F(ab) fragments, we employed papain for IgG 
cleavage in the hinge region, whereas to increase the sensitivity of the TD 
approach we performed transient averaging followed by enhanced Fourier 
transform (eFT) signal processing (a commercial solution to improve resolution 
in Orbitrap Fourier transform mass spectrometry (FTMS) returning absorption 
mode [6]) at the manufacturer’s site (Thermo Scientific, Bremen, Germany). 
The reported data validated such method for the analysis of up to three 
different IgGs simultaneously present in a mixture. The limitations of the 
developed approach are both in sample preparation, as the relatively low 
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specificity of papain can potentially result in multiple digestion sites, and at 
the MS data processing level, given the restricted access to eFT for the general 
users.  
In regard to the latter aspect, some consideration can be made with specific 
reference to top-down mass spectrometry. In general, sensitivity is a major 
bottleneck of TD MS. While in survey mass spectra the signal of an 
electrosprayed protein is detected as a complex charge state envelope, 
reducing the signal-to-noise ratio (SNR) of each single charge state, in tandem 
MS (MS/MS) selected precursor ions are dissociated in the gas phase, with 
the incoming total ion charge being split between many – hundreds or even 
thousands – of product ion channels. Therefore, signal amplitude of product 
ions in each single tandem mass spectrum (or microscan, in Orbitrap FTMS) 
can be very low. As a result, to construct a sufficiently accurate and abundant 
isotopic envelope of a product ion for unambiguous product ion assignment, 
averaging of a large number of microscans is required. Effectively, according 
to the fundamentals of signal processing in FTMS [7], the most sensitive and 
accurate approach to analysis data from a set of microscans is to first perform 
averaging of the time-domain data (transients) and then Fourier transform the 
final averaged transient to yield frequency spectrum, which can be further 
calibrated into a mass spectrum. The expected increase in signal-to-noise ratio 
(SNR) for ions in this case would scale as ??, where N is the number of 
averaged microscans. However, the number of available microscans is limited 
by the total time allocated for selected precursor ion analysis. In the case of 
LC-MS experiments, this analysis time is determined by the elution time of a 
precursor protein from the LC column and by the complexity of the sample – 
dictating the need to perform MS/MS on different co-eluting precursors, as in 
the case of proteomics studies.  
For targeted TD experiment a total of 10-40 microscans are acquired per 
precursor protein ion elution peak within a single LC-MS/MS run [8-10]. 
However, to reach the spectral SNR level required to identify low-abundant 
product ions in convoluted MS spectra, the total number of acquired 
microscans is to be significantly, preferably more than 10 fold, increased. This 
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result can be achieved either using off-line protein fractionation and 
subsequent MS/MS experiment from direct infusion of purified proteins, or 
performing multiple consecutive on-line LC-MS/MS experiments. The latter 
approach has the benefits of a better separation of co-eluting proteins, 
improved ionization efficiency, and a wider range of applications, including 
analysis of simple protein mixtures. Similarly to the above described 
microscan-averaging approach, time-domain transients of MS/MS data from 
multiple LC-MS/MS runs can be averaged altogether off-line. The benefits of 
time-domain averaging from multiple LC-MS/MS runs for improved top-down 
mass spectrometry have already been demonstrated for the above mentioned 
F(ab) subunit as well as for the analysis of intact, 150 kDa, IgG1 proteins [8], 
and of their 25 kDa [10] fragments. However, the reported examples were 
based on proprietary signal processing by Thermo Scientific, not available for 
general public. As a result, the use of the described approach for TD MS and 
TD proteomics has been so far limited. An alternative route to increase SNR is 
to first Fourier transform each of the single microscans (i.e., transients), and 
then perform spectral averaging of the resulting mass spectra. Traditionally, 
the disadvantage of this approach, which is believed to be less sensitive, 
include the possibility to introduce artifacts for analysis of peaks with low SNR 
values, and the fact that it is normally impossible, when using proprietary 
software for visualizing mass spectra, to average together MS scans stored in 
separate files.  
Here, we first describe a new workflow for improving top-down MS analysis 
developed in the attempt of taking advantage of data recorded in separate LC-
MS/MS runs and of applying both time-domain and spectral averaging 
overcoming the above mentioned restrictions. Specifically, we propose two 
user-accessible approaches: i) a python-based software for spectral averaging 
capable of using spectra from distinct LC-MS/MS data files; and ii) transient 
averaging followed by in-house calculated absorption mode FT allowing to 
reproduce from the averaged transient the resolution provided by eFT signal 
processing on commercial instruments.  
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To benchmark this top-down platform, we applied it to the analysis of ~50 
kDa F(ab) subunits obtained using the recently commercialized GingisKHAN 
protease, which is characterized by superior cleavage specificity than papaine, 
addressing also the other limitation of our original work. Our methodology 
shows final level of spectral SNR that allow the identification of low abundant 
product ions, including those that can lead to the confirmation of the cysteines 
involved in inter-molecular disulfide bridges. This information is fundamental 
to prove light and heavy chain pairing, and therefore the here presented 
methodology can be used as a template for future drug-discovery research 
studies requiring the identification of selected IgGs from complex antibody 
mixtures derived from natural sources. 
Experimental methods 
Chemicals.?Water, acetonitrile (ACN), formic acid (FA) and trifluoroethanol 
(TFE) were obtained in LC-MS purity grade. Water and ACN were purchased 
from Fluka Analytical (Buchs, Switzerland). FA was obtained from Merck (Zug, 
Switzerland) and TFE from Acros Organics (Geel, Belgium). 
Samples. Horse myoglobin was obtained from Sigma Aldrich, therapeutic 
monoclonal antibody of the IgG1 class, trastuzumab (Herceptin, Genentech) 
was obtained as the European Medicines Agency approved version and 
formulation, available commercially to the general public.  
GingisKHAN digestion. GingisKHAN (Genovis, Lund, Sweden) digestion of 
IgG1 was performed in formulation buffer. Two units of GingisKHAN (Tris-HCl) 
were added to each Ǎg of IgG and left to react for 1 hr at 37 °C in presence of 
2 mM Cys solution. The reaction was quenched by acidifying the solution to 1 
% TFA. For analysis, samples were diluted with 0.1 % FA in water to a final 
concentration of 1 Ǎg/Ǎl. 
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Liquid chromatography – mass spectrometry. The chromatographic 
separation of IgG proteolytic fragments was performed using an Ultimate 3000 
LC ystem (Thermo Scientific, Amsterdam, The Netherlands) under UPLC 
conditions. A combination of reversed phase C4 guard-column (Acquity UPLC 
PrST C4 VanGuard pre-column, 2.1 x 5 mm, particle size 1.7 Ǎm, pore size 
300 Å, Waters, Baden-Dättwil, Switzerland) and C4 analytical column (Acquity 
UPLC PrST C4, 1 x 150 mm, particle size 1.7 Ǎm, pore size 300 Å, Waters) was 
employed to ensure on-line IgG fragment desalting and separation. For each 
injection, 1 Ǎg of digestion product was loaded on the column, heated at 60 
°C. After initial loading at 5 % solution B (organic phase), a gradient of solution 
B from 10 to 45 % in 15 minutes was applied at a flow rate of 100 Ǎl/min. 
Solution A consisted of 0.1 % of FA in water, whereas solution B was composed 
of 99,9 % ACN and 0.1 % FA. The LC column outlet was on-line coupled with 
the electrospray ionization (ESI) source of the mass spectrometer. MS 
experiments were performed on an ETD-enabled hybrid linear ion trap high-
field Orbitrap FT mass spectrometer (LTQ Orbitrap Elite FTMS, Thermo 
Scientific, Bremen, Germany). Separate LC-MS experiments were dedicated to 
record broadband mass spectra and ETD tandem mass spectra. All mass 
spectra were acquired using ion detection in the Orbitrap FTMS, in the m/z 
range 400-2800 and 200-2000 for broadband and tandem mass spectra, 
respectively. All mass spectrometry aquisitions were performed in 'protein 
mode': N2 gas pressure in the HCD cell was reduced to reach a pressure in the 
Orbitrap mass analyzer region that is approximately of 0.15E-10 torr higher 
than the „base pressure“ measured in the same region (obtained with the N2 
flux completely shut down) [10]. Additionally, ions were captured and 
temporarily stored in the HCD cell before ion transmission to the Orbitrap 
[11]. Broadband mass spectra were recorded with 15’000 resolution at 400 
m/z, with a target value for the automatic gain control (AGC) of one million 
charges in either MS or MS/MS modes. For ETD experiments, AGC target 
value for fluoranthene radical anions was set to 7E5 charges, with anion 
maximum injection time of 100 ms. ETD ion-ion interaction time was set to 
10 ms. Product ion detection in the Orbitrap mass analyzer was performed 
with 120’000 resolution at 400 m/z. All Orbitrap FTMS scans were recorded 
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averaging 10 microscans. Isolation windows for ETD of IgG fragments included 
multiple charge states per precursor protein (isolation width: 200 Th).  
Data acqusition and signal processing. All experimental data were acquired 
using standard built-in data acquistion system, DAQ, (Thermo Scientific, 
Xcalibur). The mass spectra (*.raw) were obtained in either full or reduced 
profile mode in the separate data sets via standard software interface (Thermo 
Scientific). In parallel to mass spectra acquisition for both data sets, the 
transients in MIDAS format (*.dat) were acquired using the advanced software 
interface (Thermo Scientific). Further, the given number of mass spectra were 
averaged within each single LC-MS/MS run via standard data analysis 
software (Xcalibur, Thermo Scientific). The averaged mass spectra from 
multiple separate LC-MS/MS runs were produced using MS File Reader 
(Thermo Scientific) and the pyFTMS data analysis framework (Spectroswiss, 
Lausanne, Switzerland). The averaging of the corresponding transients in the 
time-domain followed by the absorption mode Fourier transform (aFT) signal 
processing were performed using pyFTMS data analysis framework and 
Autophaser Professional, correspondingly (Spectroswiss) [David P. A. Kilgour, 
Konstantin O. Nagornov, Anton N. Kozhinov, Konstantin O. Zhurov, Yury O. 
Tsybin.: Producing absorption mode Fourier transform ion cyclotron 
resonance mass spectra with non-quadratic phase correction functions. 
RCMS, 1087-1093, 29/11 (2015)]. The averaged mass spectra were converted 
into mzXML format for further data analysis. Additionally, transients were 
averaged via proprietary protocols and processed using enhanced Fourier 
transform (eFT) to yield mass spectra in *.raw format directly at Thermo 
Scientific [8].  
Data analysis. Peak picking and deconvolution was performed using MASH 
Suite sofftware with following parameters: for myoglobin SNR threshold was 
set to 5 for transient and spectral averaged runs acquired in full profile mode 
and 0.2 for spectral averaged runs of reduced profile mode. For IgGthe values 
were set to 5, 0.6 and 0.2 for transient averaged full profile mode, spectral 
averaged full profile mode and spectral averaged reduced profile mode, 
respectively. For both myoglobin and IgG matching against their custom 
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databases (containing primary sequence of protein in question) the minimum 
score between theoretical and experimental peak cluster was set to 80 %.  
In case of the branched ions (zHC + zLC) list of theoretical fragments (neutral 
mass) was calculated using in-house Python script based on pyteomics library 
[12]. The internal disulfide bonds as well as the interchain disulfide bond were 
considered preserved. All probable pairs of heavy and light chains were 
considered; fragmentation N-terminal to proline or inside the cysteine loops 
was excluded from the calculations. Maximum of one cleavage site in each 
chain was allowed. 
Results and discussion 
Due to the aforementioned reasons, we tailored a pipeline for structural 
analysis of IgGs presented in Figure 1. This procedure entails the use of a 
novel KGP protease (commercially available as GingisKHAN, Genovis, Sweden) 
selective towards IgG1 class, and more importantly, highly specific and 
reproducible (showing primary structure specificity to the motif XXK-TXX 
above the hinge region). Total ion chromatogram of baseline separated Fc and 
F(ab) of Trastuzumab, and their subsequent intact mass measurements upon 
deconvolution with Protein Deconvolution software (Thermo Scientific) 
returned a molecular weight of 48,xxx Da which is in accordance with ones 
calculated based on the primary sequence within 10 ppm window. After a 
rapid digestion step, we performed ten consecutive LC-MS/MS runs followed 
by data averaging step. The novelty of the proposed pipeline lies in the 
procedures employed for the averaging. Obtained time-domain data 
(transients) were processed with enhanced Fourier transform (eFT) within a 
single LC-MS/MS .RAW file, with resulting single-file spectra further subjected 
to spectral averaging using an in-house Python script. Alternatively, 
transients collected from all the LC-MS/MS runs were averaged and converted 
to mass spectra applying either absorption mode FT (aFT) or the commercial 
eFT signal processing, as shown in the bottom part of the Figure 1.  
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LC-MS/MS analysis of model protein and IgG1. The proposed pipeline was 
tested on intact ~17 kDa myoglobin. Firstly, the LC settings were tested to 
assure that the elution reproducibility is maintained with respect to the time 
window set for triggering MS/MS event. This was important to ensure that the 
variation in number of recorded transients (or related mass spectra in the case 
of spectral averaging procedure) for each individual LC run is minimized. 
Figure 2a shows broadband mass spectrum of intact myoglobin from a single 
LC run recorded in Orbitrap analyzer to verify transmission efficiency under 
particular instrument setup in terms of pressure (so-called ‘protein mode’) and 
temporal storage of ions in HCD trap (also known as ‘extended trapping’). ETD 
was optimized by testing different ion-ion interaction time spanning from 3 ms 
to 15 ms. Based on the intensity of the remaining precursor ion we establish 
the optimal value for fragmentation efficiency to be 7 ms. For subsequent ETD 
MS/MS a ‘narrow’ isolation window of 80 Th was centered around 848 m/z, 
comprising two charge states (20+ and 21+) shown in the inset. At resolution 
of 120 000 (at m/z 400), the charge state envelope of myoglobin is baseline 
isotopically resolved as seen in a zoom-in of 21+ charge state (Figure 2a, inset). 
In case of F(ab) subunits of trastuzumab, a wider isolation window of 200 Th 
was centered at charge state 38+ and it comprised six isotopically unresolved 
charge states of Fab) subjected to MS/MS as depicted in Figure 2b. Optimal 
ion-ion interaction time was found to be 10 ms. In case of Fc peak eluting 
prior to F(ab) an ETD event was not triggered, as Fc portion of antibody does 
not carry information on chain connectivity, and as such was beyond the 
scope of this study. Usually Fc subunit can be removed using Protein A so it 
does not interfere with separation or co-elutes with another F(ab) in mixtures 
analysis, however here it was kept to monitor LC separation and performance, 
as well as the one of MS. Its broadband mass spectrum and an expanded view 
of its portion containing the distribution of the glycoforms in 33-35+ charge 
states is shown in Figure 2c.  
Method validation. Acquired data for myoglobin was further utilized for 
testing of different averaging procedures on single and multiple LC runs. As 
previously described, in FTMS the improvement in SNR ratio upon averaging 
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should increase with square root of number of time-domain transients (or 
microscans) that are averaged. For spectral averaging, similar dependence was 
observed. However, it is to be noted how in this procedure increment will follow 
named dependence  will be contigent on provided mass accuracy of peaks from 
the preceding peak picking procedure as well as the accuracy of averaging 
itself. Figure 3. top panel portrays a comparison between spectral intensities 
for myoglobin tandem mass spectra after absorption mode FT of a transient 
data from a single and 10 LC-MS/MS runs. It is obvious how the SNR of 
product ions increases and experimental distributions of peak intensities 
approach the theoretical ones by increased number of averaged runs. To 
further investigate viability of novel averaging methods, we addressed another 
figure of merit, the protein sequence coverage obtained by matching ETD 
product ions. For that purpose, all acquired and averaged data was subjected 
to deconvolution and product ion assignment against custom data base 
(contained only myoglobin sequence, or later trastuzumab one, vide infra). 
Results of the searches were used to construct the fragmentation maps 
presented in Figure 4. This data set represents the initial proving ground for 
assessment of viability of the herein proposed workflow, with particular 
emphasis on data averaging procedure for product ion assignment of TD and 
MD MS data sets, applied to IgG1 subunits analysis (vide infra). 
ETD product ions (c- and z- type) vary in distribution throughout all the 
maps, however their variety does not change drastically the number of bond 
cleavages they assign. We observe how passing from single to multiple LC run, 
and from spectral to transient averaging of the same dataset, there is a twofold 
increase in difference of obtainable sequence coverage (2 % in case of single 
runs, and 4 % in case of ten LC runs). Increasing sequence coverage trend 
seems to favor transient averaging.  
The ~ 50kDa F(ab) subunit represents a challenge for ETD fragmentation 
as it is composed by two chains of about 25 kDa each, with a total of five 
disulfide bridges (4 intra-molecular and 1 inter-molecular). As a consequence, 
each chain seems to retain high order structure even in the gas phase, as 
demonstrated by previous works were the fragmentation was localized 
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primarily on the disulfide-free loops of each chain (in the region comprised 
between the second and third Cys residue). At the same time, the total number 
of potential fragmentation channels is particularly high, even by counting only 
the canonical N- and C-terminal-containing product ions. As depicted in 
Supplementary Figure S1, the fragmentation maps obtained from mass 
spectra resulting from spectral or time-domain transient averaging are very 
similar when only single LC-MS/MS run is considered. The 9-10 % sequence 
coverage for each chain seem to indicate that the spectral SNR has to be 
increased by additional averaging. Furthermore, most of the matched ions in 
the maps are c-type ions. A possible explanation for this phenomenon is given 
by the fact that the inter-molecular disulfide bridge linking light and heavy 
chains is located at the C-terminus of each chain (more precisely, it involves 
the last residue of the light chain and the third lo last residue of the heavy 
chain fragment, or Fd). 
To improve the sequence coverage, we tested both in-house developed 
methods, spectral averaging and transient averaging with aFT signal 
processing, on the mass spectra/time-domain transients collected within 10 
LC-MS/MS experiments. Figure 5 shows the results of spectral averaging 
when starting from reduced profile (Figure 5a) or full profile mode spectra 
(Figure 5b). In both cases the increase in sequence coverage is substantial, 
reaching almost 19 and 30 % for light and heavy chain, respectively, in the 
case of full profile mode. The signal apodization and noise cutoff method 
commercially implemented obviously reduces the possibility to observe in the 
average mass spectrum the very low abundant product ions as they are 
oftentimes cut in the first place in the single spectra used for the averaging 
procedure; this slightly affects the final sequence coverage which is about 10-
15% lower than that obtained using full profile mode spectra. Importantly, the 
averaged spectra were also used for matching a list of potential branched ions, 
i.e., product ions which include a portion of the heavy and of the light chain,
linked by the above mentioned inter-molecular disulfide bond. Remarkably,
we calculated a total theoretical number of zHC+zLC ions (c-type ions are
excluded for reason already explained) equal to about 7500. Although an
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unambiguous assignment based solely on MS2 is not possible for all these 
ions, as about 40 % of them share the molecular formula and hence the exact 
mass with at least a second ion, our attempt, shown on the right panels of 
Figure 5, to match these ions with the light and heavy chain sequences 
demonstrated the fact that ETD is actually forming z-type ions, but they are 
not of the traditional type but rather have a branched nature; most of matched 
branched ions are located in those portions of the sequences of each chain 
that seem poorly covered when looking at the fragmentation maps including 
only c- and z-type ions, such as the C-terminus of both light and heavy chain. 
Notably, some very large product ions (>15 kDa) were also matched. It has to 
be considered, finally, that although this assignment strategy is more 
sophisticated that the traditional one that simply accounts for non-branched 
fragments, it still does not include the assignment of internal fragment. A 
recent paper has demonstrated that, at least in beam-style collisional 
dissociation, the number of internal fragments generated when fragmenting 
large protein such as carbonic anhydrase is dramatically high. A similar study 
for ETD or any similar radical-driven fragmentation technique, however, is 
currently missing. 
As a concluding remark, it has to be mentioned that the mass spectrum 
obtained by transient averaging produced a slightly higher sequence coverage 
for the F(ab) subunit (Supplementary Figure S2). Considering the minimal 
difference between the two averaging methods for what concerns the canonical 
c- and z-type ions, we can conclude that the spectral method works well.
However, if we assume that product ions formed by two cleavage on two
different chains, the branched zHC+zLC ions, are less likely to be produced by
ETD and, hence, are generally characterized by a lower abundance than
traditional c- and z ions, the transient averaging method exibits an advantage
in increasing the final SNR of tandem mass spectra, as it allows to increase
the sequence coverage from branched ions from the 8-9 % obtained by spectral
averaging to about 12 %.
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Conclusions 
The developed workflow for top-down FT mass spectrometry has 
demonstrated the envisioned advantages for targeted protein analysis when 
data from consecutive LC-MS/MS experiments can be analyzed together. 
Increase in sensitivity, or SNR values, scales comparably for spectral and 
transient averaging as a function of a number of scans. Performance of the 
described top-down mass spectrometry was first evaluated on myoglobin 
analysis and then applied to analysis of monoclonal antibodies. For the latter, 
a novel enzyme, with a commercial name GingisKHAN, has been employed to 
produce 50 kDa F(ab) subunits of IgG1 with a single-cleavage site specificity. 
Top-down analysis of F(ab) subunits allowed rendering pairing of light and 
heavy chains in IgG. Data analysis confirmed that the most accurate and 
extensive protein sequence coverage is obtained with transient averaging, 
followed by spectral averaging of mass spectra acquired in the full profile mode 
and then by spectral averaging of mass spectra acquired in the reduced profile 
mode. 
Both spectral and transient averaging capabilities are now readily available 
for the general users. Importantly, absorption mode FT signal processing has 
been successfully applied here for the first time on transients acquired from 
Orbitrap FTMS, allowing reaching the performance of commercial mass 
spectra produced via enhanced FT (eFT) signal processing. Further 2-4 fold 
increase in sensitivity is expected from the improvements in high-performance 
data acquisition electronics and on-line signal processing on high-throughput 
FPGA chips. The accumulated developments should enable transition of top-
down mass spectrometry from targeted protein analysis from multiple LC-
MS/MS runs to large-scale top-down proteomics from a single LC-MS/MS 
run. 
?? ??????????????
????????????????? ?????? ?????????????
26?
Acknowledgements 
We express our gratitude to Thermo Fisher Scientific Inc. for providing access 
under license to LTQ Orbitrap Elite FTMS transient signals and related 
functionality enabled by the developers’ kit. We are grateful for financial 
support through the European Research Council (ERC Starting Grant 280271 
to YOT).  
?? ??????????????
????????????????? ?????? ?????????????
26?
References 
1. Leavy, O., Therapeutic antibodies: past, present and future. Nat Rev
Immunol, 2010. 10(5): p. 297-297.
2. Kirkpatrick, P., J. Graham, and M. Muhsin, Cetuximab. Nat Rev Drug
Discov, 2004. 3(7): p. 549-550.
3. Smith, M.R., Rituximab (monoclonal anti-CD20 antibody): mechanisms
of action and resistance. Oncogene, 0000. 22(47): p. 7359-7368.
4. Breast cancer: Trastuzumab therapy for small, HER2-positive breast
tumours. Nat Rev Clin Oncol, 2015. 12(3): p. 126-126.
5. Wine, Y., et al., Molecular deconvolution of the monoclonal antibodies
that comprise the polyclonal serum response. Proc Natl Acad Sci U S A,
2013. 110(8): p. 2993-8.
6. Lange, O., et al., Enhanced Fourier transform for Orbitrap mass
spectrometry. International Journal of Mass Spectrometry, 2014. 369:
p. 16-22.
7. Marshall, A.G., Theoretical signal-to-noise ratio and mass resolution in
Fourier transform ion cyclotron resonance mass spectrometry.
Analytical Chemistry, 1979. 51(11): p. 1710-1714.
8. Fornelli, L., et al., Analysis of intact monoclonal antibody IgG1 by
electron transfer dissociation Orbitrap FTMS. Mol Cell Proteomics,
2012. 11(12): p. 1758-67.
9. Tsybin, Y.O., et al., Structural analysis of intact monoclonal antibodies
by electron transfer dissociation mass spectrometry. Anal Chem, 2011.
83(23): p. 8919-27.
?? ??????????????
????????????????? ?????? ?????????????
26?
10. Fornelli, L., et al., Middle-down analysis of monoclonal antibodies with
electron transfer dissociation orbitrap fourier transform mass
spectrometry. Anal Chem, 2014. 86(6): p. 3005-12.
11. Rosati, S., et al., Exploring an orbitrap analyzer for the characterization
of intact antibodies by native mass spectrometry. Angew Chem Int Ed
Engl, 2012. 51(52): p. 12992-6.
12. Goloborodko, A., et al., Pyteomics—a Python Framework for Exploratory
Data Analysis and Rapid Software Prototyping in Proteomics. Journal of
The American Society for Mass Spectrometry, 2013. 24(2): p. 301-304.
13. Fellers, R.T., et al., ProSight Lite: graphical software to analyze top-down
mass spectrometry data. Proteomics, 2015. 15(7): p. 1235-8.
14. Cai, W., et al., MASH Suite Pro: A Comprehensive Software Tool for Top-
down Proteomics. Molecular & Cellular Proteomics, 2015.
?? ??????????????
????????????????? ?????? ?????????????
26?
Figure captions. 
Figure 1. Schematics of the proposed middle-down workflow for structural 
analysis of IgGs. Sample preparation entails rapid (one hour) digestion of IgG 
with a novel IgG1 selective and …K-T… sequence motif specific KP protease 
(REF Genovis poster) followed by multiple consecutive LC-MS/MS runs. 
Obtained time-domain data (transients) are: either processed with enhanced 
Fourier transform (eFT), with resulting mass spectra that are first averaged 
within a single .RAW file and from there subjected to spectral averaging 
through the pyFTMS platform; or alternatively collected and averaged prior to 
in-house absorption mode FT signal processing. The final mass spectrum, 
obtained either via spectral or transient averaging, is analyzed with ProSight 
Lite [13] and MASH suite [14] to yield protein sequence coverage maps. 
Figure 2. Intact protein and protein subunits mass measurements with - 
Orbitrap Elite FTMS and precursor ion isolation for subsequent ETD MS/MS. 
a) Broadband mass spectrum of myoglobin. Inset shows a mass spectrum of
its isolated precursor ions (charge states 21+ and 20+, an isolation window of
80 Th centered at m/z 848) and baseline-resolved isotopic envelope of charge
state 21+. b) Broadband mass spectrum of F(ab) subunit of monoclonal IgG1
trastuzumab. Inset shows a mass spectrum of isolated precursor ions around
charge state 38+ obtained using an isolation window of 200 m/z centered at
m/z 1248; and c) Broadband mass spectrum of Fc subunit of monoclonal IgG1
trastuzumab. Inset shows an expanded view of a broadband mass spectrum
containing the distribution of the glycoforms in 33-35+ charge states.
Figure 3. Tandem mass spectra (normalized to the base peak) of myoglobin 
(top panel) and F(ab) subunit of trastuzumab (middle panel) after absorption 
mode FT of an averaged transient obtained from a single LC-MS/MS run 
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(black lines) or from 10 LC-MS/MS runs (red lines). Insets show representative 
examples of product ion assignment. The SNR of product ions increases and 
experimental distributions of peak intensities approach the theoretical ones 
(shown with green circles) passing from single to multiple LC-MS/MS runs. 
(Bottom panel) shows an expanded view of a tandem mass spectrum of F(ab) 
containing assigned c- and branched zLC+zHC- product ions after absorption 
mode FT of an averaged transient from 10 LC-MS/MS runs. The equidistant 
polymeric peaks visible in mass spectrum originate from sample preparation 
and do not belong to IgG.  
Figure 4. Sequence coverage of myoglobin obtained using LC-MS/MS 
workflow presented in Figure 1. ETD at 7 ms ion-ion interaction time was 
employed for MS/MS. Data was acquired with an Orbitrap Elite and recorded 
in full profile mode. Fragmentation maps shown are obtained from a) a single 
LC-MS/MS run after conventional spectral averaging (Qual Browser), b) a 
single LC-MS/MS run after in-house transient averaging, c) ten consecutive 
LC-MS/MS runs after in-house spectral averaging, and d) ten consecutive LC-
MS/MS runs after in-house transient averaging. ETD product ions (c- and z- 
type) are color coded. Obtained sequence coverage is indicated below each 
chain in each panel. For single LC-MS/MS runs xxxx scans were averaged, 
whereas for ten consecutive LC-MS/MS runs xxx scans were averaged.  
Figure 5. Application of workflow described in Figure 1 to IgG analysis using 
Orbitrap Elite FTMS. Shown are ETD MS/MS fragmentation maps of F(ab) 
subunit of trastuzumab produced by GingisKHAN digestion,obtained after in-
house spectral averaging of a) 10 LC-MS/MS runs recorded in reduced profile 
mode and b) 10 LC-MS/MS runs recorded in full profile mode. Fragmentation 
maps are shown for both when the intramolecular disulfide bridge between 
the light and heavy chains of IgG is preserved (left panel) or cleaved (right 
panel). ETD product ions (c- and z- type as well as branched zLC+zHC ions) are 
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represented according to the color coding. Cysteines forming intramolecular 
disulfide bond are highlighted in orange, and those participating in 
intermolecular bond in red. CDRs are highlighted in grey. Resulting sequence 
coverage is indicated below each chain in each panel. 
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Supporting Information. 
Revealing chain connectivity in monoclonal IgG1 using 
GingisKHAN proteolysis and top-down electron transfer 
dissociation Orbitrap FTMS  
Kristina Srzentiþ, Konstantin O. Nagornov, Anna A. Lobas, Daniel Ayoub, 
Luca Fornelli, Mikhail V. Gorskhov, Konstantin Ayzikov and Yury O. Tsybin 
Figure S1. Fragmentation maps of F(ab) subunit of trastuzumab following 
GingisKHAN digestion and 15 ms ETD MS/MS from a single LC-MS/MS run 
obtained using (left panel) in-house spectral averaging and (right panel) in-
house transient averaging. ETD product ions (c- and z- type) are indicated in 
black. Obtained sequence coverage is indicated below each chain in each 
panel. All LC-MS/MS runs were recorded in full profile mode. 
Figure S2. Fragmentation maps of F(ab) subunit of trastuzumab following 
GingisKHAN digestion obtained from transient averaging (performed with 
assistance of Thermo Scientific) of 10 LC-MS/MS runs recorded in full profile 
mode. Panels show fragmentation maps obtained when intramolecular 
disulfide bridge is cleaved (left) or preserved (right). ETD product ions (c- and 
z- type as well as branched zLC+zHC ions) are represented according to the color
coding. CDRs are highlighted in grey. Obtained sequence coverage is indicated
below each chain in each panel.
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Figure S3. Normalized to the base peak tandem mass spectra of F(ab) 
subunit of IgG1 trastuzumab (top panel) after transient averaging (black line), 
and after averaging of mass spectra acquired in the full profile mode (red line) 
and in the reduced profile mode (blue line) of 10 LC-MS/MS runs. Panels A, B 
and C show expanded views of the mass spectra with 
assigned c- and z- product ions of light chain (left column) and of heavy chain 
(right column) of trastuzumab. The colored star symbol indicates that the 
experimental mass and abundance of a peak of the corresponding mass 
spectrum was matched with theoretical values in a certain accuracy range and 
assigned. Unassigned isotopic peaks can reduce the confidence in product ion 
assignment. Data show reduction in peak assignment efficiency of spectral 
averaging in the reduced profile compared to both full profile mode and 
transient averaging. The transient averaging provides better identification of 
product ions isotopic peaks compared to spectral averaging in both the full 
and reduced profile modes. 
Figure S4. Mass accuracy distributions (in parts-per-million, ppm) after 
spectral averaging (left) and transient averaging (right) of myoglobin (top) and 
F(ab) (bottom). Tandem mass spectra acquired with LTQ Orbitrap FTMS using 
ETD. Data averaging is performed over 10 LC-MS/MS runs. 
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Chapter 8. Conclusions 
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8.1. Summary of the results. 
The experimental studies presented in this Thesis are a comprehensive 
account of contemporary considerations including: i) validated or disproved 
‘educated guesses’, ii) development of both practical and instrumental 
methods that aim at inception and further advancement of the middle-down 
(MD) mass spectrometry (MS)-based approach to proteomics for in-depth
proteome analysis. In tailoring this novel domain, steered by mid-size range
peptide analysis, throughout all studies presented herein, special attention to
details of each step was given, from theoretical bioinformatics calculations,
sample preparation and wet lab protocol optimization to data acquisition,
processing and analysis.
With advancement of the field, analytical characteristics, such as increased 
mass resolution and mass accuracy, became accessible in many laboratories 
across the world. Hence, initial proof-of-principle experiments that attest the 
viability and importance of the MDP commenced, and the field of proteomics 
has already defined a set of proteases capable of cleaving proteins with 
different specificities. However, there are very few proteases that were 
suggested for MD [117, 153].This may be because, from an evolutionary point 
of view, a biologically efficient protease can accomplish protein degradation 
readily. Only in a few cases is the degradation process aimed at targeting rare 
amino acids or amino acid sequences; oftentimes the final biological function 
of a protease is simply facilitating protein turnover within a cell or, in the case 
of a secreted protease, degrading proteins present in the environment into 
smaller peptides. For both of these tasks, the specificity of the protease should 
be either very limited or directed towards non-rare amino acids. Choice of the 
agent for MD that would produce peptides in a desired way with respect to the 
selected mass bin requires a thorough theoretical cross-kingdoms study to 
reveal a good target residue, or a combination of good target residues.  
 In particular, we considered that it is of fundamental importance to tackle 
selecting the best theoretical targets for protein cleavage in MD from two 
different points of view. The first is the frequency of occurrence of each of the 
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20 amino acids in all proteomes. Paper I of this Thesis focuses on 
bioinformatics studies in order to define the set of residues to target for 
performing middle-down experiments. This bioinformatics survey was crucial 
for understanding: which residue(s) would be a good target for obtaining long 
peptides, if that residue comes as a first candidate across all kingdoms, and 
finally, how much of a proteome (expressed as a percentage of the total 
number of proteins within) we can map with these peptides. The latter one is 
particularly interesting, as it is not obvious how if one yields a pool of peptides 
with an average mass which fits the selected mass bin, this will not necessarily 
mean that all of the peptide masses are equally partitioned or that the 
distribution of masses is uniform. This means that not all peptides will be 
successfully analyzed and lead to an identification in MD experimental setup. 
Interestingly, the survey revealed how there is no single residue, or any 
combination of residues that we could target to obtain 100 % proteome 
coverage in any proteolytic-based working regime (BUP, the newly-defined 
eBUP and MDP). However, results indicated that targeting dibasic and rare 
amino acids such as methionine, tryptophan or cysteine would identify up to 
90 % of the proteome with a drastic reduction in the number of yielded 
peptides (five-fold compared to BUP). Reduction in eluting peptides per LC run 
is a desirable characteristic that our approach could provide, and, from there, 
we wanted to evaluate how these peptides ionize and how their terminal 
residues can aid in obtaining a successful fragmentation ladder upon different 
ion activation and dissociation techniques, particularly the charge-dependent 
ones such as ETD and HCD. 
Hence, the second consideration we made for selection of MD cleavage site 
was the position of specific amino acid residues, such as the basic ones, within 
the sequence of the obtained peptide. The mentioned aspect, in combination 
with the average size of obtained polypeptides, is important as it might 
potentially affect the peptide fragmentation, defining which ion activation 
technique is more suitable for this category of proteolytic peptides. Paper II 
discusses the effect of specific positioning of basic residues (namely lysines) 
on the fragmentation of large (>20 amino acids) synthetic peptides. 
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Specifically, we investigated the result of different cleavages at dibasic 
sites (before the site, in-between the basic residues, and after the 
dibasic pair), to observe the effect produced by charge location on the 
radical-mediated (ETD) and energy threshold-based (HCD) fragmentation. 
The study also aimed at determining optimal HCD and ETD parameters for 
fragmentation of middle-down range peptides. Interestingly, for both HCD and 
ETD, we found a direct correlation between precursor charge state and 
obtained sequence coverage, regardless of the position of the basic residues 
belonging to the dibasic site. The analysis of the observed product ions 
revealed that in HCD the distal positioning of the two fixed charges is 
detrimental for the cleavage of peptide bonds in the middle of the peptide 
sequence, even at the collision energies where virtually no precursor ion 
remains. Conversely, in the same condition in ETD, we observed a charge 
reduction phenomenon at the N-terminal basic amino acid, as demonstrated 
by the absence of light c-ions (up to c6). Final results showed how optimal 
ETD ion-ion interaction time changes from 10-15 ms for the longest peptides 
to around 50 ms for 2 kDa peptides. The optimal NCE value we identified for 
HCD for MD was 27 %, which is the value used in all subsequent 
experimental studies conducted.  
Next, we found agents, developed and proposed workflows for each of the 
identified targets (dibasic, M, W, and C). The first study characterized a novel 
protease that targets basic/dibasic residue at scissile bond. Results of Paper 
III present a detailed assessment of such a candidate: a secreted aspartic 
protease Sap9. Biochemical properties and activity of Sap9 are better than of 
other proteases in the acidic pH, but Sap9 was found in our studies to be not 
highly specific without engineering. The generated peptides are almost equally 
distributed in 3-7 kDa; hence, even though it was not the original aim of the 
research, the study of Paper IV describes the result of a specific application of 
Sap9 for the structural analysis of immunoglobulins G. The study 
describes the experimental results of a novel Sap9-based eBUP approach 
aiming to further improve in-depth structural analysis of monoclonal 
antibodies and their mixtures. Key features of Sap9-based eBUP IgG 
analysis include extensive antibody sequence coverage with up to 100% for 
light chain and up to 99-
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100% for heavy chain in a single LC-MS/MS run, sequence information on 
connectivity of complementarity determining regions (CDRs) and, importantly, 
reduced artifact introduction (e.g., deamidation) during proteolysis with Sap9 
compared to conventional bottom-up proteomics workflows, e.g., with trypsin. 
This allowed us to investigate endogenous deamidation in CDR regions in 
therapeutic IgG1, trastuzumab. Importantly, this was the first attempt of a 
proteolytic MS-based quantitation, and we obtained comparable results to 
other orthogonal methods. Since the publication of this paper, a particularly 
strong interest was given to Sap9-based IgG analysis from both academic and 
industrial (pharmaceutical) groups, with a number of them now using Sap9 
for IgG analysis in their drug development workflows.  
In the following, we developed new protocols and workflows for chemical-
mediated middle-down mass spectrometry and proteomics, which could offer 
similarly successful results to those related to Sap9, but potentially more 
specific and able to be used for quantitative and qualitative proteomics. Paper 
V describes a thorough evaluation of different protocols targeting rare amino 
acids and elucidates cysteine cleavage as the novel selective MD avenue. 
During this study, we successfully defined novel cleavage rules and strategy 
for tailoring a dedicated MD search engine, which is to date still not available. 
This methodology was of particular interest when applied to IgG, as it allowed 
confident paratope ID with significant reduction in the number of peptides 
whilst their average size was true MD range (5-7 kDa). Additionally, one of the 
important variable domains (CDR3) would with this approach always be 
located on the N-terminus of the protein (starting with chemically-tagged 
cysteine) and would therefore be more susceptible to complete sequencing. 
These considerations encompass two novel methods for MD we proposed: 
primary-sequence dependent enzymatic proteolysis with Sap 9 and chemical-
mediated hydrolysis N-terminal to cysteine. 
Finally, papers VI and VII bring a structure-dependent MD approach 
integrated with TD-like MS settings we developed for characterization of 
antibodies. The main objective of this work was improving IgG drug discovery 
pipeline via matching the pairs of light and heavy chains. The applied MD 
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proteolysis is based on a single structure-specific cleavage either with papain 
(Paper VI) or a novel protease GinigisKHAN (Paper VII) and analyzed with ETD 
MS/MS in TD fashion. Both of these approaches were developed and applied 
to overcome the intact IgG sequence coverage limit of TD (33 %) while 
obtaining important chain pairing information. These methods are 
first attempts for a novel workflow that assesses pairing information on  50 
kDa subunits. Additionally, these studies were focused on data acquisition 
and subsequent analysis, and they represent the first time evaluation of 
spectral full and reduced profile mode and transient averaging for protein 
analysis using Orbitrap FTMS. This pipeline was successfully tested on IgG 
(up to 34 % and 41 % sequence coverage for LC and HC respectively), and 
we believe that these tests could be considered proof-of-principle for future 
application in TD analysis of large proteins. Overall, these developments 
complete the triad of methods for structural analysis of antibodies 
introduced by our group: top-down, middle-down, and extended 
bottom-up, allowing for their comprehensive structural analysis. 
8.2. Concluding remarks and future perspectives. 
Advancing a new field is always a challenging task which requires a lot of 
considerations that ultimately can be proven wrong. Oftentimes it happens 
that a series of time-consuming and expensive experiments does not offer 
expected results, and, less often, those lead to positive experimental results 
that are conclusive and definite. Middle-down proteomics has the potential for 
proposing new avenues in digestion-based shotgun studies. The peculiar 
feature of MD is the size of the generated peptides. The research project 
presented in this Thesis as Paper IV clearly illustrates that, at least for selected 
applications, the unambiguous identification of a certain protein is not 
possible using single (or even multiple, in specific cases) short peptides like 
tryptic ones. Conversely, MD-sized peptides can allow confident 
identification which, passing from a targeted to a large-scale type of 
experiment, could translate into the possibility of including in the 
identification additional 
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information, (i.e., about splicing variants or isoforms, which is 
generally lost in BUP). Effectively, the Human Proteome Project 
Organization (HUPO) is proposing progressively more stringent criteria for 
the validation of BUP data. Particularly, the guidelines for the 2015 version 
of the Project propose the need not only to apply a 1% false discovery rate 
threshold at the protein level to filter the data, but also to include in the 
list of identified proteins only those described by two uniquely mapping 
identified peptides of at least nine amino acid long [154]. In this context, MD 
could be seen as a means to create a level of high-throughput analysis of the 
human (and others) proteomes similar to the level currently reached by 
shotgun BUP [155, 156], but with the possibility of confidently identifying a 
protein using one long peptide only. Although the effectiveness of MD in 
research projects focused on extremely complex proteomes such as the 
eukaryotic ones is not fully demonstrated, some pioneering studies suggest 
that MDP is applicable to large-scale studies [117]. However, the utility of 
developing a new proteomic pipeline with a novel set of specific rules exceeds 
the simple practical result of having, at the end of the process, a new tool for 
the investigation of protein mixtures. Establishing new paradigms, in fact, 
might help also to put into discussion old ones, so that eventually  already 
established technology can be further optimized and refined. For instance, 
the widely accepted opinion is that for proteomics we should need one 
protease for all organisms and one method for all biological problems to 
investigate. Although the attention of scientists in the world is currently 
focused on increasing the number of protein identifications and accuracy of 
protein quantification, considering as an example the human proteome and 
its sophisticated organization, it is probable how we need to address each 
biological question as an individual one, and not try to apply a default 
patch to all, with the result that when that does not work for all 
problems, it is discarded as insufficient. Not a single MDP approach for all, 
but rather a myriad of approaches for particular targeted protein 
analysis. The work presented in this Thesis not only puts forward the 
equation “larger peptides=more information” and advocates for it, but also 
introduces different methods, targeting different amino acid residues 
(including some, like cysteines, that have rarely or never been used in 
proteomics) so that it could 
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be potentially possible to obtain MD-sized peptides for specific sub-proteomes. 
Effectively this approach is already applied to histones, which include a large 
number of basic amino acids and can be thus better treated with proteases 
specific for acid residues (such as Glu-C) for generating peptides bigger than 
5 kDa [157]. Major bottleneck in validation of MDP data analysis is the 
limitation in the currently available workflow for top-down mass spectrometry. 
This Thesis showed clear potential of MD and contributed to its further 
advancement towards a well-defined stand-alone approach. In particular, we 
clarified in detail how to generate longer-size peptides, proposed analyte-
dependent proteolysis, offered novel pipelines and proposed a set of general 
guidelines: residues to target, methods and agents to use, ion activation 
techniques and their optimal parameters, all the way to data analysis and 
software requirements. We showed experimentally the potential, robustness, 
efficiency and real-life applicability of proposed methodologies in a targeted 
proteomics survey on a presently very important class of proteins (IgGs). 
Besides some practical aspects to improve, in parallel with 
instrumentation, method development and data analysis tools, it is easy to 
envision MD as a mature approach in the near future. The position of MD 
alongside BUP and TD with respect to the scientific awareness and 
feasibility will fluctuate with time. Today MDP could be benchmarked for 
targeted analysis of limited sample pool such as sequence verification of IgG 
candidates for drug delivery, mapping of mutually dependent adjacent 
modifications and their subsequent quantitation (e.g., ‘cross-talk’ 
analysis of histones), detection of single point mutations from low-
abundant proteins, such as those present in biological, clinically relevant 
samples due to the potential for a complete or close to complete 
sequence coverage from a single proteomic experiment. Considering the 
variety of mutations that may be present on a single protein, identification of 
the position of the mutation may be critical for the correct diagnosis, for 
determining the outcome of the disease and for finding the most suitable 
treatment. 
In my opinion, optimizing current shortcomings (i.e., increased spectral 
complexity despite the sample pool reduction), optimizing front-
end separations and tweaking the proteolysis to the analyte characteristics, 
?? ??????????????
Conclusions
292
is a challenging initiative and a ‘must do’ task that will prove to be very  
important for the future MD applications. While TD remains the only approach 
that can provide identification of proteoforms, contribution of proteolysis-
based approaches is still very important, and I envision in the future 
integration of BUP, MD and TD approaches, where MD will have a significant 
complementary contribution in large–scale characterization of protein 
families and extended PTM studies.?
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